<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Gas Res</journal-id><journal-id journal-id-type="iso-abbrev">Med Gas Res</journal-id><journal-id journal-id-type="pmc-domain-id">1622</journal-id><journal-id journal-id-type="pmc-domain">mgr</journal-id><journal-id journal-id-type="publisher-id">MGR</journal-id><journal-id journal-id-type="publisher-id">Med Gas Res</journal-id><journal-title-group><journal-title>Medical Gas Research</journal-title></journal-title-group><issn pub-type="epub">2045-9912</issn><publisher><publisher-name>Wolters Kluwer -- Medknow Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11918480</article-id><article-id pub-id-type="pmcid-ver">PMC11918480.1</article-id><article-id pub-id-type="pmcaid">11918480</article-id><article-id pub-id-type="pmcaiid">11918480</article-id><article-id pub-id-type="pmid">39812023</article-id><article-id pub-id-type="doi">10.4103/mgr.MEDGASRES-D-24-00063</article-id><article-id pub-id-type="publisher-id">MGR-15-234</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Xenon gas as a potential treatment for opioid use disorder, alcohol use disorder, and related disorders</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4383-1264</contrib-id><name name-style="western"><surname>Kaufman</surname><given-names initials="MJ">Marc J.</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5739-6956</contrib-id><name name-style="western"><surname>Meloni</surname><given-names initials="EG">Edward G.</given-names></name><xref rid="aff1" ref-type="aff"/></contrib></contrib-group><aff id="aff1">McLean Hospital, Harvard Medical School, Belmont, MA, USA</aff><author-notes><corresp id="cor1"><label>*</label><bold>Correspondence to:</bold> Marc J. Kaufman, PhD, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="kaufman@mclean.harvard.edu">kaufman@mclean.harvard.edu</email>.</corresp><p><bold><italic toggle="yes">Funding:</italic></bold>
<italic toggle="yes">This work was supported in part by National Institute on Drug Abuse (NIDA) grants R01DA055568 and R41DA055403 and by a NIDA &#8220;Start a SUD Startup 2020&#8221; Challenge Award.</italic></p><fn fn-type="con"><p><bold>Author contributions:</bold>
<italic toggle="yes">MJK and EGM conceptualized the approach for this review. MJK drafted the manuscript, EGM edited the manuscript, and both approved the final version.</italic></p></fn></author-notes><pub-date pub-type="collection"><season>Apr-Jun</season><year>2025</year></pub-date><pub-date pub-type="epub"><day>13</day><month>1</month><year>2025</year></pub-date><volume>15</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">484662</issue-id><fpage>234</fpage><lpage>253</lpage><history><date date-type="received"><day>02</day><month>8</month><year>2024</year></date><date date-type="rev-recd"><day>23</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>19</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-19 16:25:46.323"><day>19</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright: &#169; 2025 Medical Gas Research</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="MGR-15-234.pdf"/><abstract><p>Xenon gas is considered to be a safe anesthetic and imaging agent. Research on its other potentially beneficial effects suggests that xenon may have broad efficacy for treating health disorders. A number of reviews on xenon applications have been published, but none have focused on substance use disorders. Accordingly, we review xenon effects and targets relevant to the treatment of substance use disorders, with a focus on opioid use disorder and alcohol use disorder. We report that xenon inhaled at subsedative concentrations inhibits conditioned memory reconsolidation and opioid withdrawal symptoms. We review work by others reporting on the antidepressant, anxiolytic, and analgesic properties of xenon, which could diminish negative affective states and pain. We discuss research supporting the possibility that xenon could prevent analgesic- or stress-induced opioid tolerance and, by so doing could reduce the risk of developing opioid use disorder. The rapid kinetics, favorable safety and side effect profiles, and multitargeting capability of xenon suggest that it could be used as an ambulatory on-demand treatment to rapidly attenuate maladaptive memory, physical and affective withdrawal symptoms, and pain drivers of substance use disorders when they occur. Xenon may also have human immunodeficiency virus and oncology applications because its effects relevant to substance use disorders could be exploited to target human immunodeficiency virus reservoirs, human immunodeficiency virus protein-induced abnormalities, and cancers. Although xenon is expensive, low concentrations exert beneficial effects, and gas separation, recovery, and recycling advancements will lower xenon costs, increasing the economic feasibility of its therapeutic use. More research is needed to better understand the remarkable repertoire of effects of xenon and its potential therapeutic applications.</p></abstract><kwd-group><kwd>alcohol use disorder</kwd><kwd>glioblastoma</kwd><kwd>glycogen synthase kinase 3</kwd><kwd>HIV</kwd><kwd>hyperkatifeia</kwd><kwd>memory reconsolidation</kwd><kwd>opioid use disorder</kwd><kwd>posttraumatic stress disorder</kwd><kwd>withdrawal symptoms</kwd><kwd>xenon</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>Xenon is a rare noble gas best known in the medical field as an inhaled anesthetic and imaging agent, applications in which it is considered to have good safety and side effect profiles, even in critical care patients.<xref rid="R1" ref-type="bibr">1</xref><xref rid="R2" ref-type="bibr">2</xref><xref rid="R3" ref-type="bibr">3</xref><xref rid="R4" ref-type="bibr">4</xref><xref rid="R5" ref-type="bibr">5</xref><xref rid="R6" ref-type="bibr">6</xref> Reviews on the effects of xenon, including its use as an anesthetic<xref rid="R3" ref-type="bibr">3</xref><xref rid="R7" ref-type="bibr">7</xref><xref rid="R8" ref-type="bibr">8</xref> and imaging agent,<xref rid="R1" ref-type="bibr">1</xref><xref rid="R4" ref-type="bibr">4</xref><xref rid="R5" ref-type="bibr">5</xref><xref rid="R9" ref-type="bibr">9</xref> organoprotective,<xref rid="R10" ref-type="bibr">10</xref><xref rid="R11" ref-type="bibr">11</xref> neuroprotective,<xref rid="R7" ref-type="bibr">7</xref><xref rid="R11" ref-type="bibr">11</xref><xref rid="R12" ref-type="bibr">12</xref><xref rid="R13" ref-type="bibr">13</xref><xref rid="R14" ref-type="bibr">14</xref><xref rid="R15" ref-type="bibr">15</xref><xref rid="R16" ref-type="bibr">16</xref><xref rid="R17" ref-type="bibr">17</xref> and analgesic<xref rid="R18" ref-type="bibr">18</xref> effects, potentially beneficial effects in people with posttraumatic stress disorder,<xref rid="R19" ref-type="bibr">19</xref> and pleiotropic biological and molecular effects,<xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref><xref rid="R23" ref-type="bibr">23</xref> have been published. The utility of xenon for treating substance use disorders (SUDs) was hypothesized in 2006 on the basis of a study reporting that xenon blocked both amphetamine-induced dopamine release and locomotor sensitization.<xref rid="R24" ref-type="bibr">24</xref> However, in the interim, only a handful of additional studies evaluating the effects of xenon directly relevant to SUDs have been published,<xref rid="R25" ref-type="bibr">25</xref><xref rid="R26" ref-type="bibr">26</xref><xref rid="R27" ref-type="bibr">27</xref><xref rid="R28" ref-type="bibr">28</xref> all of which support the possibility that xenon could be an effective SUD treatment. To our knowledge, no comprehensive review on xenon&#8217;s potential for treating SUDs exists.</p><p>Accordingly, this review outlines xenon&#8217;s effects and known targets relevant to SUDs, in particular, opioid use disorder (OUD) and alcohol use disorder (AUD). Together, these SUDs account for large mortality, public health, and economic burdens in the United States.<xref rid="R29" ref-type="bibr">29</xref> The multitarget effects of xenon could be especially beneficial in people living with comorbid SUDs and psychiatric disorders, which are prevalent and difficult to treat.<xref rid="R30" ref-type="bibr">30</xref><xref rid="R31" ref-type="bibr">31</xref><xref rid="R32" ref-type="bibr">32</xref><xref rid="R33" ref-type="bibr">33</xref><xref rid="R34" ref-type="bibr">34</xref><xref rid="R35" ref-type="bibr">35</xref></p><p>We discovered two potentially beneficial effects of subsedative xenon administration relevant to SUDs: the inhibition of conditioned memory reconsolidation (MR)<xref rid="R36" ref-type="bibr">36</xref> and the inhibition of physical opioid withdrawal (abstinence) symptoms.<xref rid="R27" ref-type="bibr">27</xref> Others have reported that xenon reduces anxiety, depression, and pain symptoms, which emerge in people living with SUDs when their preferred substances are unavailable, a dysfunctional state termed hyperkatifeia.<xref rid="R29" ref-type="bibr">29</xref> Maladaptive memories, physical withdrawal symptoms, and hyperkatifeia perpetuate SUDs by preventing people from initiating or maintaining SUD treatment,<xref rid="R29" ref-type="bibr">29</xref><xref rid="R37" ref-type="bibr">37</xref><xref rid="R38" ref-type="bibr">38</xref><xref rid="R39" ref-type="bibr">39</xref> which leads to inferior outcomes. Our working hypothesis is that xenon could help attenuate these effects and improve SUD treatment outcomes. We used several databases to identify relevant literature, including PubMed (National Library of Medicine), Web of Science (Clarivate), and Google Search. We also searched bibliographies of relevant manuscripts to identify additional pertinent literature. All publication years were eligible for inclusion. We used manuscript keywords as key search terms.</p></sec><sec id="sec1-2"><title>The Physical Properties of Xenon Make It a Multitargeting Agent</title><p>Xenon has numerous beneficial effects because it acts as a multitarget agent. The molecular targets of xenon have been identified in the biological and physiological studies described in several reviews.<xref rid="R11" ref-type="bibr">11</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R23" ref-type="bibr">23</xref> The xenon &#8220;interactome&#8221; was further expanded by analytical studies using X-ray crystallography, nuclear magnetic resonance, in silico screening, and protein oxidation or proteolysis detection to reveal dozens of additional possible targets.<xref rid="R20" ref-type="bibr">20</xref><xref rid="R22" ref-type="bibr">22</xref><xref rid="R40" ref-type="bibr">40</xref><xref rid="R41" ref-type="bibr">41</xref><xref rid="R42" ref-type="bibr">42</xref> Potential SUD-relevant targets, e.g., &#945;1-adrenergic receptors, have been identified via the use of pressurized xenon to force it into protein fissures and gaps.<xref rid="R42" ref-type="bibr">42</xref></p><p>Xenon interacts with many targets because it is relatively small in volume, has high lipid solubility, and is highly polarizable, enabling it to behave like a solvent that occupies and disrupts the external and internal protein cavity and lipid domains, thereby constraining molecular fluctuations and functions.<xref rid="R41" ref-type="bibr">41</xref><xref rid="R43" ref-type="bibr">43</xref><xref rid="R44" ref-type="bibr">44</xref><xref rid="R45" ref-type="bibr">45</xref> The xenon targets we consider most likely to have therapeutic potential for treating or preventing SUDs include ionotropic neurotransmitter receptors, kinases, potassium and calcium channels, monoamine transporters, and lipid rafts, which often act in tandem in bidirectional mutually reinforcing ways. By disrupting these interactions, xenon may be especially well suited for treating SUDs. In the following sections, we review xenon&#8217;s effects on SUDs, including its ability to inhibit conditioned MR, physical withdrawal (abstinence) symptoms, and hyperkatifeia symptoms.</p><sec id="sec2-1"><title>Memory reconsolidation</title><p>SUDs have long been considered learning and memory disorders in which these normally adaptive cognitive processes are &#8220;hijacked,&#8221; causing individuals to compulsively seek rewarding or relieving effects of psychoactive substances, despite adverse consequences.<xref rid="R46" ref-type="bibr">46</xref> MR is critically involved in these processes because memory directs future attention and behavior. MR occurs after a memory is reactivated by exposure to an environment (e.g., location) or cue (e.g., sight, sound, smell, or internal/interoceptive stimulus) previously associated with the memory. Environments or cues associated with pleasant (feeling good, high, or relaxed) or unpleasant (opposite effects, including aversive drug withdrawal symptoms or with the emergence of affective or tactile pain) feelings reactivate salient yet maladaptive memories that trigger substance use. Upon reactivation of a memory, its molecular structure becomes labile and susceptible to updating by strengthening (if the current experience induces an expected effect) or weakening (if no or a different effect occurs). Reconsolidation is adaptive because it enables memories to be updated so that behavior is either sustained, intensified, or changed the next time a particular environment or cue predicting reward or aversion is encountered.<xref rid="R37" ref-type="bibr">37</xref><xref rid="R47" ref-type="bibr">47</xref><xref rid="R48" ref-type="bibr">48</xref><xref rid="R49" ref-type="bibr">49</xref> Reward and aversion memories are important because they direct our attention toward salient stimuli, and when these stimuli are encountered in future, they are more likely to trigger substance use or relapse.<xref rid="R37" ref-type="bibr">37</xref><xref rid="R50" ref-type="bibr">50</xref></p><p>We discovered that inhaled subsedative xenon inhibited fear MR in rats that had been conditioned to form an aversive memory.<xref rid="R36" ref-type="bibr">36</xref> The rats were conditioned in an experimental chamber (environment) with a brief aversive (but not harmful) electric foot shock paired with an audible tone (cue). One day later, the rats were returned to the conditioning environment for 2 minutes, and the tone was played for 1 minute, but no shock was delivered. Exposure to the environment and tone reactivated memory and caused the rats to remain motionless (freeze), the standard rodent response to a fearful stimulus. Freeze time after memory reactivation (~80% of the total time; <bold><xref rid="mgr.MEDGASRES-D-24-00063-F1" ref-type="fig">Figure 1</xref></bold>) reflects the extent of fear associated with the memory, with shorter times indicating less fear. Immediately after memory reactivation, separate groups of rats were placed into a closed-circuit gas exposure chamber that maintained the target xenon, oxygen, and nitrogen concentrations where for 1 hour, the rats inhaled either subsedative xenon (25%/21% oxygen/54% nitrogen) or, in the same exposure chamber (to replicate exposure chamber sensations), 21% oxygen/79% nitrogen. A separate control group was exposed to normal room air. The rats were then returned to their home cages and retested with the same memory reactivation procedures to assess fear responses 2, 4, and 18 days later. Full descriptions of these experiments are found in our report.<xref rid="R36" ref-type="bibr">36</xref></p><fig position="float" id="mgr.MEDGASRES-D-24-00063-F1" orientation="portrait"><label>Figure 1</label><caption><p>Xenon (Xe) inhibits conditioned aversive memory reconsolidation.</p><p>(A) Xe (25%) inhalation (gray bars) for 1 hour given immediately after conditioned aversive memory reactivation durably and substantially inhibited conditioning environment-induced fear (% freezing time) in rats. (B) One hour of Xe treatment without memory reactivation or (C) 1 hour of Xe treatment given 2 hours after memory reactivation did not reduce freezing time. The data are expressed as the means &#177; SEMs (<italic toggle="yes">n</italic> = 7&#8211;11). *<italic toggle="yes">P</italic> &lt; 0.05, **<italic toggle="yes">P</italic> &lt; 0.005, <italic toggle="yes">vs</italic>. air controls. These data are adapted from our previous report.<xref rid="R36" ref-type="bibr">36</xref></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="MGR-15-234-g001.jpg"/></fig><p>Xenon substantially and durably reduced conditioning environment-induced freezing times for up to 18 days (<bold><xref rid="mgr.MEDGASRES-D-24-00063-F1" ref-type="fig">Figure 1A</xref></bold>) and induced similar effects in response to the tone cue.<xref rid="R36" ref-type="bibr">36</xref> The results of these experiments revealed that xenon, in the absence of memory reactivation (<bold><xref rid="mgr.MEDGASRES-D-24-00063-F1" ref-type="fig">Figure 1B</xref></bold>), or xenon administered more than 2 hours after memory reactivation (<bold><xref rid="mgr.MEDGASRES-D-24-00063-F1" ref-type="fig">Figure 1C</xref></bold>), did not affect freezing time. In mouse experiments conducted by others using a similar aversive memory conditioning protocol, an anesthetic xenon dose (70%) given without reactivating the conditioned memory did not modify MR,<xref rid="R51" ref-type="bibr">51</xref> further illustrating that xenon inhibits memory only when given after a conditioned memory is reactivated. The period during which reactivated memory is labile and can be updated is known as the reconsolidation window.<xref rid="R52" ref-type="bibr">52</xref><xref rid="R53" ref-type="bibr">53</xref> It remains to be determined whether the effects of xenon in animals translate to humans, although this seems likely for several reasons. First, MR mechanisms are evolutionarily conserved.<xref rid="R54" ref-type="bibr">54</xref> Second, MR can be disrupted in humans,<xref rid="R37" ref-type="bibr">37</xref> as discussed further below. Third, our case report study of a woman meeting the clinical criteria for posttraumatic stress disorder (PTSD) revealed that, after undergoing multiple therapeutic trauma memory reactivation sessions (e.g., exposure therapy) immediately followed by subsedative (15&#8211;25%) xenon inhalation, PTSD symptoms declined by nearly 80%.<xref rid="R19" ref-type="bibr">19</xref> Aversive memories are also common in people living with OUD or AUD, including memories of physical withdrawal and hyperkatifeia symptoms, which lead to substance seeking and taking for symptom relief, thereby perpetuating SUDs. Accordingly, xenon, by inhibiting MR, may be able to treat maladaptive aversive memory disorders, including PTSD and SUDs.</p><p>Because aversive and appetitive (reward) MR are inhibited by glutamatergic N-methyl-D-aspartate (NMDA) receptor antagonists,<xref rid="R48" ref-type="bibr">48</xref> xenon inhibition of NMDA receptors<xref rid="R24" ref-type="bibr">24</xref><xref rid="R55" ref-type="bibr">55</xref><xref rid="R56" ref-type="bibr">56</xref><xref rid="R57" ref-type="bibr">57</xref><xref rid="R58" ref-type="bibr">58</xref><xref rid="R59" ref-type="bibr">59</xref><xref rid="R60" ref-type="bibr">60</xref><xref rid="R61" ref-type="bibr">61</xref><xref rid="R62" ref-type="bibr">62</xref><xref rid="R63" ref-type="bibr">63</xref><xref rid="R64" ref-type="bibr">64</xref><xref rid="R65" ref-type="bibr">65</xref><xref rid="R66" ref-type="bibr">66</xref><xref rid="R67" ref-type="bibr">67</xref><xref rid="R68" ref-type="bibr">68</xref><xref rid="R69" ref-type="bibr">69</xref><xref rid="R70" ref-type="bibr">70</xref><xref rid="R71" ref-type="bibr">71</xref><xref rid="R72" ref-type="bibr">72</xref> likely enables the attenuation of both MR types. Human studies are consistent with this idea by showing that the NMDA receptor antagonist ketamine or nitrous oxide administered once, after reactivation of alcohol reward memory, inhibit appetitive MR and reduce future drinking.<xref rid="R73" ref-type="bibr">73</xref><xref rid="R74" ref-type="bibr">74</xref> Methadone, a first-line opioid receptor agonist treatment for OUD,<xref rid="R75" ref-type="bibr">75</xref> when used to reactivate heroin reward memories prior to an MR updating procedure, attenuated heroin reward MR and more effectively sustained heroin abstinence than methadone treatment as usual without MR manipulation.<xref rid="R76" ref-type="bibr">76</xref> Other techniques also weaken maladaptive MR, including disgust-based counterconditioning, which reduces alcohol reward MR and problematic drinking,<xref rid="R77" ref-type="bibr">77</xref> or extinction training, which persistently suppresses heroin craving.<xref rid="R78" ref-type="bibr">78</xref> Notably, in these studies, higher blood ketamine concentrations after memory reactivation during the reconsolidation window predicted less future drinking in people at high risk for AUD,<xref rid="R73" ref-type="bibr">73</xref> and in the methadone study, memory updating outside of the reconsolidation window was ineffective at enhancing heroin abstinence.<xref rid="R76" ref-type="bibr">76</xref> These findings support our theory that xenon administration soon after reactivating maladaptive memory, within the reconsolidation window, could disrupt aversive or appetitive MR in humans with OUD, AUD, or other SUDs.</p><p>By inhibiting NMDA receptors, xenon is also expected to attenuate extinction learning,<xref rid="R79" ref-type="bibr">79</xref><xref rid="R80" ref-type="bibr">80</xref><xref rid="R81" ref-type="bibr">81</xref> a process involving new competing learning after a memory is reactivated, but the expected stimulus (e.g., alcohol or drug reward or aversive symptom relief) does not occur. Because extinction learning opposes MR, thereby weakening the effects of an existing maladaptive memory, selectively inhibiting MR while sparing extinction learning may be desirable. Xenon&#8217;s fast systemic kinetics<xref rid="R82" ref-type="bibr">82</xref><xref rid="R83" ref-type="bibr">83</xref><xref rid="R84" ref-type="bibr">84</xref><xref rid="R85" ref-type="bibr">85</xref><xref rid="R86" ref-type="bibr">86</xref> combined with the fact that it exerts effects almost immediately upon reaching its targets,<xref rid="R58" ref-type="bibr">58</xref><xref rid="R59" ref-type="bibr">59</xref><xref rid="R61" ref-type="bibr">61</xref><xref rid="R62" ref-type="bibr">62</xref><xref rid="R63" ref-type="bibr">63</xref><xref rid="R64" ref-type="bibr">64</xref><xref rid="R65" ref-type="bibr">65</xref><xref rid="R67" ref-type="bibr">67</xref><xref rid="R69" ref-type="bibr">69</xref><xref rid="R70" ref-type="bibr">70</xref><xref rid="R87" ref-type="bibr">87</xref><xref rid="R88" ref-type="bibr">88</xref><xref rid="R89" ref-type="bibr">89</xref><xref rid="R90" ref-type="bibr">90</xref> could support its administration briefly, right after maladaptive memory reactivation, to inhibit targets that mediate MR while sparing xenon-sensitive extinction learning targets. Additionally, xenon&#8217;s capacity to increase phosphatidylinositol-dependent kinase 1 (PDK-1)<xref rid="R91" ref-type="bibr">91</xref> could weaken the effects of conditioned maladaptive MR by increasing protein kinase Mzeta (PKM&#950;) activity, which facilitates memory updating.<xref rid="R92" ref-type="bibr">92</xref><xref rid="R93" ref-type="bibr">93</xref> Thus, xenon could be administered in ways that leverage the MR/extinction/updating balance to favor memory extinction/updating over maladaptive MR. On the basis of findings from prior studies, we propose that the following xenon targets individually or convergently mediate its inhibitory effects on MR, although not all effects may occur in all cell types or brain areas.</p><sec id="sec3-1"><title>Ionotropic receptors</title><p>Xenon inhibits NMDA receptors, including those in the amygdala, prefrontal cortex, and hippocampus, key brain areas involved in memory-related processes, by blocking the NMDA receptor coagonist (strychnine-insensitive &#8220;glycineB&#8221;) binding site.<xref rid="R24" ref-type="bibr">24</xref><xref rid="R55" ref-type="bibr">55</xref><xref rid="R56" ref-type="bibr">56</xref><xref rid="R57" ref-type="bibr">57</xref><xref rid="R59" ref-type="bibr">59</xref><xref rid="R60" ref-type="bibr">60</xref><xref rid="R61" ref-type="bibr">61</xref><xref rid="R62" ref-type="bibr">62</xref><xref rid="R63" ref-type="bibr">63</xref><xref rid="R64" ref-type="bibr">64</xref><xref rid="R65" ref-type="bibr">65</xref><xref rid="R66" ref-type="bibr">66</xref><xref rid="R67" ref-type="bibr">67</xref><xref rid="R68" ref-type="bibr">68</xref><xref rid="R69" ref-type="bibr">69</xref><xref rid="R70" ref-type="bibr">70</xref><xref rid="R71" ref-type="bibr">71</xref><xref rid="R72" ref-type="bibr">72</xref><xref rid="R94" ref-type="bibr">94</xref><xref rid="R95" ref-type="bibr">95</xref> This binding site is activated <italic toggle="yes">in vivo</italic> primarily by D-serine, which, like glycine, supports MR.<xref rid="R96" ref-type="bibr">96</xref><xref rid="R97" ref-type="bibr">97</xref> Xenon also inhibits &#945;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic (AMPA) receptors, including calcium-permeable AMPA GluA1-containing (also known as GluR1) receptors<xref rid="R59" ref-type="bibr">59</xref><xref rid="R61" ref-type="bibr">61</xref><xref rid="R62" ref-type="bibr">62</xref><xref rid="R63" ref-type="bibr">63</xref><xref rid="R64" ref-type="bibr">64</xref><xref rid="R67" ref-type="bibr">67</xref><xref rid="R71" ref-type="bibr">71</xref><xref rid="R98" ref-type="bibr">98</xref> and kainate receptors.<xref rid="R58" ref-type="bibr">58</xref><xref rid="R59" ref-type="bibr">59</xref><xref rid="R67" ref-type="bibr">67</xref> Since NMDA and AMPA receptor antagonists attenuate MR,<xref rid="R52" ref-type="bibr">52</xref><xref rid="R73" ref-type="bibr">73</xref><xref rid="R74" ref-type="bibr">74</xref><xref rid="R99" ref-type="bibr">99</xref> a form of synaptic plasticity regulated by a dynamic interplay between NMDA and AMPA receptor trafficking and function,<xref rid="R99" ref-type="bibr">99</xref><xref rid="R100" ref-type="bibr">100</xref><xref rid="R101" ref-type="bibr">101</xref><xref rid="R102" ref-type="bibr">102</xref><xref rid="R103" ref-type="bibr">103</xref><xref rid="R104" ref-type="bibr">104</xref> xenon inhibition of both receptor types likely contributes to its ability to strongly inhibit MR.<xref rid="R36" ref-type="bibr">36</xref> Xenon reportedly reduced cue-induced alcohol seeking in a rat alcohol relapse model, but because xenon was administered outside of the reconsolidation window in that study,<xref rid="R26" ref-type="bibr">26</xref> it seems unlikely that MR inhibition mediated this effect. We found no reports implicating kainate receptor involvement in MR.</p><p>Xenon activates inhibitory (strychnine-sensitive) glycine receptors<xref rid="R56" ref-type="bibr">56</xref><xref rid="R105" ref-type="bibr">105</xref> to induce membrane hyperpolarization, an effect that could oppose excitatory NMDA or AMPA receptor-mediated membrane depolarization to inhibit MR.<xref rid="R106" ref-type="bibr">106</xref> Xenon also activates inhibitory &#947;-aminobutyric acid receptor (GABA<sub>A</sub>) receptors,<xref rid="R56" ref-type="bibr">56</xref><xref rid="R89" ref-type="bibr">89</xref> which can disrupt MR.<xref rid="R107" ref-type="bibr">107</xref> Xenon blocks nicotinic cholinergic &#945;4&#946;2, &#945;4&#946;4<xref rid="R56" ref-type="bibr">56</xref> and &#945;7<xref rid="R88" ref-type="bibr">88</xref> receptors, the latter of which are linked to MR attenuation.<xref rid="R108" ref-type="bibr">108</xref><xref rid="R109" ref-type="bibr">109</xref><xref rid="R110" ref-type="bibr">110</xref><xref rid="R111" ref-type="bibr">111</xref> Serotonin (5-hydroxytryptamine, 5-HT)<sub>3</sub> receptors that support methamphetamine-related MR<xref rid="R112" ref-type="bibr">112</xref> are also inhibited by xenon.<xref rid="R56" ref-type="bibr">56</xref><xref rid="R87" ref-type="bibr">87</xref>
<bold><xref rid="mgr.MEDGASRES-D-24-00063-F2" ref-type="fig">Figure 2</xref></bold> summarizes xenon&#8217;s multitarget ionotropic receptor-mediated effects that could inhibit MR, perhaps convergently, resulting in stronger MR inhibition than more selective treatments that target individual proteins.</p><fig position="float" id="mgr.MEDGASRES-D-24-00063-F2" orientation="portrait"><label>Figure 2</label><caption><p>Xenon (Xe)-targeted ionotropic receptor effects that could mediate the inhibition of memory reconsolidation (MR).</p><p>(A) Xe inhibits and activates multiple receptors (thick arrows) shown by others (thin arrows) to enhance and inhibit MR. The known targets of xenon have yet to be confirmed as mediators of MR inhibition. Not all effects may occur in all cell types. *N-methyl-D-aspartate (NMDA) glutamate receptor, strychnine-insensitive D-serine/glycine coagonist binding site. **Strychnine-sensitive glycine receptor binding site. Green and red lines denote activating and inhibiting effects, respectively. Absent lines reflect either no effect or current knowledge gaps. (B) Citations reporting Xe effects on receptor targets and citations reporting that these targets regulate MR. 5-HT<sub>3</sub>: 5-Hydroxytryptamine 3 subtype receptor; AMPA: &#945;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic receptor; GABA<sub>A</sub>: &#947;-aminobutyric acid subtype A receptor; Nic: nicotinic cholinergic receptor subtypes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="MGR-15-234-g002.jpg"/></fig></sec><sec id="sec3-2"><title>Protein kinases</title><p>Xenon regulates a number of kinases, including protein kinases A,<xref rid="R113" ref-type="bibr">113</xref> B (also known as Akt),<xref rid="R114" ref-type="bibr">114</xref><xref rid="R115" ref-type="bibr">115</xref><xref rid="R116" ref-type="bibr">116</xref><xref rid="R117" ref-type="bibr">117</xref><xref rid="R118" ref-type="bibr">118</xref><xref rid="R119" ref-type="bibr">119</xref><xref rid="R120" ref-type="bibr">120</xref> C,<xref rid="R120" ref-type="bibr">120</xref><xref rid="R121" ref-type="bibr">121</xref><xref rid="R122" ref-type="bibr">122</xref> and G,<xref rid="R123" ref-type="bibr">123</xref> calcium calmodulin kinase,<xref rid="R124" ref-type="bibr">124</xref> p38 mitogen-activated protein kinase,<xref rid="R121" ref-type="bibr">121</xref> phosphatidylinositol 3-kinases,<xref rid="R91" ref-type="bibr">91</xref><xref rid="R114" ref-type="bibr">114</xref><xref rid="R119" ref-type="bibr">119</xref> PDK-1,<xref rid="R91" ref-type="bibr">91</xref> extracellular signal-regulated kinases,<xref rid="R117" ref-type="bibr">117</xref><xref rid="R119" ref-type="bibr">119</xref><xref rid="R122" ref-type="bibr">122</xref> mammalian target of rapamycin,<xref rid="R120" ref-type="bibr">120</xref><xref rid="R125" ref-type="bibr">125</xref><xref rid="R126" ref-type="bibr">126</xref> and glycogen synthase kinase 3 (GSK3)<xref rid="R114" ref-type="bibr">114</xref><xref rid="R127" ref-type="bibr">127</xref> (<bold><xref rid="mgr.MEDGASRES-D-24-00063-F3" ref-type="fig">Figure 3</xref></bold>). As noted above, xenon activation of PDK-1<xref rid="R91" ref-type="bibr">91</xref> may increase PKM&#950; activity to facilitate memory updating.<xref rid="R93" ref-type="bibr">93</xref> Although several kinases play important and interactive roles in memory, including in the reconsolidation of drug-related memories,<xref rid="R128" ref-type="bibr">128</xref><xref rid="R129" ref-type="bibr">129</xref><xref rid="R130" ref-type="bibr">130</xref><xref rid="R131" ref-type="bibr">131</xref><xref rid="R132" ref-type="bibr">132</xref> for the remainder of this review, we focus on GSK3 for several reasons: GSK3 is inhibited, perhaps convergently, by most kinases xenon activates (<bold><xref rid="mgr.MEDGASRES-D-24-00063-F3" ref-type="fig">Figure 3</xref></bold>), and GSK3 expression and activity are increased by opioids<xref rid="R133" ref-type="bibr">133</xref><xref rid="R134" ref-type="bibr">134</xref><xref rid="R135" ref-type="bibr">135</xref><xref rid="R136" ref-type="bibr">136</xref> and possibly by alcohol.<xref rid="R137" ref-type="bibr">137</xref> GSK3 overexpression increases alcohol consumption,<xref rid="R138" ref-type="bibr">138</xref> and a synthetic GSK3&#946; inhibitor disrupts heroin MR and reduces heroin relapse.<xref rid="R139" ref-type="bibr">139</xref> GSK3 regulates physical withdrawal symptoms, hyperkatifeia, opioid tolerance, and other effects, as discussed below. GSK3, like xenon, is multitargeting, and its inhibition could amplify xenon&#8217;s multitargeting capability.</p><fig position="float" id="mgr.MEDGASRES-D-24-00063-F3" orientation="portrait"><label>Figure 3</label><caption><p>Xenon (Xe)-targeted kinases that may mediate the inhibition of memory reconsolidation (MR).</p><p>(A) Xe activates (green) multiple protein kinases (thick arrows) known to inhibit (red lines) GSK3. Xe-targeted kinases have yet to be confirmed as mediators (thin arrows) of its ability to inhibit MR. The dotted/dashed line denotes the possibility that Xe sterically inhibits the GSK3 ATP binding site.<xref rid="R156" ref-type="bibr">156</xref> Not all kinases or kinase interactions are shown. Not all effects may occur in all cell types. **GSK3&#945; may also be targeted by these effects. (B) Citations reporting Xe kinase targets and citations reporting that these targets regulate GSK3. ATP: Adenosine triphosphate; CaMKII: calcium calmodulin kinase II; ERK1/2: extracellular signal-related kinases; mTOR: mammalian target of rapamycin; p38 MAPK: p38 mitogen-activated protein kinase; PI3K: phosphatidylinositol 3-kinases; PDK-1: phosphatidylinositol-dependent kinase 1; PK: protein kinase; PKB: protein kinase B, also known as Akt; PKM&#950;: protein kinase M-zeta.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="MGR-15-234-g003.jpg"/></fig><p>The amplification of xenon&#8217;s effects by GSK3 is plausible because GSK3 is a constitutively active multitargeting serine/threonine kinase involved in numerous key biological processes, including glycogen synthesis/glucose availability, mitochondrial function, and glutamate receptor expression and localization.<xref rid="R140" ref-type="bibr">140</xref><xref rid="R141" ref-type="bibr">141</xref> GSK3 exists as &#945; and &#946; paralogs that are widely distributed throughout the brain<xref rid="R142" ref-type="bibr">142</xref><xref rid="R143" ref-type="bibr">143</xref> and that share some but not all regulatory mechanisms and functions.<xref rid="R140" ref-type="bibr">140</xref><xref rid="R144" ref-type="bibr">144</xref><xref rid="R145" ref-type="bibr">145</xref><xref rid="R146" ref-type="bibr">146</xref><xref rid="R147" ref-type="bibr">147</xref><xref rid="R148" ref-type="bibr">148</xref> Most SUD-relevant research to date has focused on GSK3&#946;, but GSK3&#945; may also contribute to SUD-relevant effects; thus, in most of the following mentions, we use the term GSK3 if a paralog-selective effect is not specified. Xenon inhibits GSK3 via multiple mechanisms (<bold><xref rid="mgr.MEDGASRES-D-24-00063-F3" ref-type="fig">Figure 3</xref></bold>), the most well documented of which involves increasing protein kinase B (Akt) excitatory phosphorylation and activity. In turn, activated Akt inhibits GSK3<xref rid="R114" ref-type="bibr">114</xref><xref rid="R127" ref-type="bibr">127</xref> by increasing GSK3&#946; serine 9 (or GSK3&#945; serine 21) phosphorylation,<xref rid="R140" ref-type="bibr">140</xref> and xenon also increases p38 mitogen-activated protein kinase activity,<xref rid="R121" ref-type="bibr">121</xref> an effect that could independently inhibit GSK3&#946; (but not GSK3&#945;) by increasing GSK3&#946; serine 389 (mouse) or threonine 390 (human) phosphorylation.<xref rid="R149" ref-type="bibr">149</xref><xref rid="R150" ref-type="bibr">150</xref><xref rid="R151" ref-type="bibr">151</xref> Transgenic mice lacking the GSK3&#946; serine 389 phosphorylation site exhibit GSK3&#946; hyperactivity and exaggerated and prolonged fear conditioning responses.<xref rid="R151" ref-type="bibr">151</xref> These mice constitute a translationally relevant model of GSK3&#946; hyperactivity, exhibiting phenotypes comparable to those reported in people with a prevalent GSK3&#946; single nucleotide polymorphism (rs6438552) associated with Parkinson&#8217;s disease, anxiety, and major depression.<xref rid="R152" ref-type="bibr">152</xref><xref rid="R153" ref-type="bibr">153</xref><xref rid="R154" ref-type="bibr">154</xref> Parkinson&#8217;s disease has been associated with stimulant use,<xref rid="R155" ref-type="bibr">155</xref> and anxiety and major depression are common in people living with SUDs (see below). Xenon may also directly inhibit GSK3 activity by obstructing its adenosine triphosphate (ATP)-binding site,<xref rid="R156" ref-type="bibr">156</xref> a target of synthetic ATP-competitive GSK3 inhibitors developed to treat other disorders.<xref rid="R145" ref-type="bibr">145</xref><xref rid="R146" ref-type="bibr">146</xref><xref rid="R157" ref-type="bibr">157</xref> A proteomics study supported this possibility by indicating that the xenon interactome is enriched in ATP-regulated targets.<xref rid="R20" ref-type="bibr">20</xref> Interestingly, concurrent GSK3 serine 9 and GSK3&#946; serine 389 inhibitory phosphorylation exerts additive protective effects in the heart,<xref rid="R158" ref-type="bibr">158</xref> suggesting that the capacity of xenon to regulate both GSK3 inhibitory phosphorylation sites could amplify its effects.</p><p>GSK3 inhibition is likely relevant to xenon&#8217;s MR-inhibitory effects because GSK3 plays multiple key MR roles. During MR, GSK3&#946; is activated by serine 9 dephosphorylation,<xref rid="R159" ref-type="bibr">159</xref> which in turn inhibits glycogen synthase, thereby increasing the concentrations of glucose needed to optimally support synaptic plasticity.<xref rid="R160" ref-type="bibr">160</xref> GSK3 inhibition also stimulates mitochondria<xref rid="R161" ref-type="bibr">161</xref> to support other energy demands. Activated GSK3&#946; regulates neuroplasticity by transiently increasing the synaptic expression of high-calcium conducting glutamate GluR1 (also known as GluA1) receptors,<xref rid="R102" ref-type="bibr">102</xref><xref rid="R103" ref-type="bibr">103</xref><xref rid="R162" ref-type="bibr">162</xref> and GSK3&#946; stabilizes NMDA receptor synaptic expression,<xref rid="R163" ref-type="bibr">163</xref> effects that regulate the balance between long-term potentiation and long-term depression.<xref rid="R164" ref-type="bibr">164</xref> Critically, serine 9 (or GSK3&#945; serine 21) dephosphorylation enables GSK3 to enter lipid rafts<xref rid="R165" ref-type="bibr">165</xref>&#8212;membrane domains enriched in specialized lipids, receptors, and scaffolding proteins, including NMDA and AMPA receptors,<xref rid="R166" ref-type="bibr">166</xref> that mediate signaling events and neuroplasticity. Xenon thus physically separates GSK3 from the lipid raft interactome that supports neuroplasticity, including MR. Xenon itself destabilizes artificial lipid raft preparations, an effect thought to contribute to its anesthetic effects at high concentrations,<xref rid="R43" ref-type="bibr">43</xref><xref rid="R44" ref-type="bibr">44</xref><xref rid="R45" ref-type="bibr">45</xref> raising the possibility that nonspecific lipid raft disordering also contributes to xenon&#8217;s ability to inhibit MR. Notably, xenon&#8217;s lipid raft effects are also relevant to the neurodegenerative memory disorder in Alzheimer&#8217;s disease because GSK3, amyloid-&#946;, and Tau proteins are lipid raft interactome elements that enable Alzheimer&#8217;s disease progression.<xref rid="R167" ref-type="bibr">167</xref><xref rid="R168" ref-type="bibr">168</xref> These findings support the possibility that xenon could be developed to treat Alzheimer&#8217;s disease.<xref rid="R169" ref-type="bibr">169</xref><xref rid="R170" ref-type="bibr">170</xref> GSK3 also regulates other potentially relevant targets, including neurotransmitter transporters and brain-derived neurotropic factor expression, as discussed below.</p></sec><sec id="sec3-3"><title>Neurotransmitter transporters</title><p>Activated GSK3 increases dopamine transporter (DAT) membrane expression and DA uptake capacity.<xref rid="R171" ref-type="bibr">171</xref> Because dopamine receptor activation is required for memory destabilization<xref rid="R49" ref-type="bibr">49</xref> and updating,<xref rid="R172" ref-type="bibr">172</xref> xenon inhibition of GSK3 could reduce DAT expression, increase synaptic DA concentrations, and enhance memory destabilization and updating. However, xenon reportedly does not increase nucleus accumbens microdialysate DA concentration,<xref rid="R25" ref-type="bibr">25</xref> so changes in DAT expression resulting in increases in extracellular DA may not be required for xenon to inhibit MR. Xenon activation of PDK-1<xref rid="R91" ref-type="bibr">91</xref> and its downstream memory-updating kinase PKM&#950;<xref rid="R92" ref-type="bibr">92</xref><xref rid="R93" ref-type="bibr">93</xref> could support MR inhibition by enhancing memory updating, instead of or along with xenon-induced changes in synaptic DA signaling.</p><p>Xenon increases brain<xref rid="R173" ref-type="bibr">173</xref><xref rid="R174" ref-type="bibr">174</xref> and systemic norepinephrine (NE) concentrations,<xref rid="R175" ref-type="bibr">175</xref> effects that may result from downregulated NE transporter membrane expression and activity secondary to Akt activation and GSK3 inhibition.<xref rid="R176" ref-type="bibr">176</xref> While NE activates &#946;-adrenergic receptors that support opioid<xref rid="R177" ref-type="bibr">177</xref><xref rid="R178" ref-type="bibr">178</xref><xref rid="R179" ref-type="bibr">179</xref> or alcohol MR,<xref rid="R180" ref-type="bibr">180</xref><xref rid="R181" ref-type="bibr">181</xref> if xenon, under conditions that can be administered to humans, also inhibits &#946;1-adrenergic receptors,<xref rid="R42" ref-type="bibr">42</xref> NE-mediated &#946;1AR enhancement of maladaptive MR may be limited,<xref rid="R182" ref-type="bibr">182</xref> including MR of aversive opioid withdrawal-like symptoms.<xref rid="R183" ref-type="bibr">183</xref><xref rid="R184" ref-type="bibr">184</xref></p><p>By inhibiting GSK3 activity, xenon may also increase serotonin transporter membrane expression and activity<xref rid="R185" ref-type="bibr">185</xref><xref rid="R186" ref-type="bibr">186</xref> and, in turn, decrease extracellular and synaptic 5-HT concentrations. Since no studies have reported on xenon-induced 5-HT changes, it remains to be determined whether xenon alters synaptic or extracellular 5-HT concentrations. If xenon-induced serotonin transporter upregulation reduces synaptic 5-HT concentrations, this could augment xenon&#8217;s inhibition of 5-HT<sub>3</sub> receptors<xref rid="R56" ref-type="bibr">56</xref><xref rid="R87" ref-type="bibr">87</xref> that contribute to MR<xref rid="R112" ref-type="bibr">112</xref> and could inhibit MR mediated by other serotonin receptor subtypes.<xref rid="R49" ref-type="bibr">49</xref></p></sec><sec id="sec3-4"><title>Other targets</title><p>Xenon inhibits P-type membrane calcium ATPases (PMCAs), resulting in increased intracellular calcium concentrations.<xref rid="R187" ref-type="bibr">187</xref><xref rid="R188" ref-type="bibr">188</xref><xref rid="R189" ref-type="bibr">189</xref><xref rid="R190" ref-type="bibr">190</xref> Although no studies to date have implicated PMCAs in MR, by increasing intracellular calcium concentrations, xenon could reduce the effect sizes of glutamate receptor-mediated calcium transients, the antagonism of which inhibits MR.<xref rid="R58" ref-type="bibr">58</xref><xref rid="R59" ref-type="bibr">59</xref><xref rid="R61" ref-type="bibr">61</xref><xref rid="R62" ref-type="bibr">62</xref><xref rid="R63" ref-type="bibr">63</xref><xref rid="R64" ref-type="bibr">64</xref><xref rid="R67" ref-type="bibr">67</xref> Additionally, lipid raft PMCAs activate glycine transporter 2 (GlyT2) transporters,<xref rid="R191" ref-type="bibr">191</xref> which are potential targets for treating pain and possibly SUDs, depressive disorders, anxiety, or seizure disorders.<xref rid="R192" ref-type="bibr">192</xref> Thus, xenon&#8217;s PMCA-inhibitory effects could inhibit glycine uptake, increase synaptic glycine concentrations, and activate inhibitory glycine receptors to attenuate MR.<xref rid="R106" ref-type="bibr">106</xref> This effect could confer other potential benefits mediated by glycine inhibitory transmission, as discussed below.</p><p>Xenon inhibits and increases, respectively, expression of the apoptosis protein Bax<xref rid="R193" ref-type="bibr">193</xref><xref rid="R194" ref-type="bibr">194</xref><xref rid="R195" ref-type="bibr">195</xref> and the prosurvival protein Bcl-2.<xref rid="R193" ref-type="bibr">193</xref><xref rid="R194" ref-type="bibr">194</xref><xref rid="R195" ref-type="bibr">195</xref><xref rid="R196" ref-type="bibr">196</xref><xref rid="R197" ref-type="bibr">197</xref> The resulting increase in the Bcl-2/Bax ratio could exert MR-inhibitory effects similar to those of prazosin, which blunts aversive MR.<xref rid="R198" ref-type="bibr">198</xref> Xenon increases cyclic AMP response element binding protein (CREB) phosphorylation<xref rid="R196" ref-type="bibr">196</xref><xref rid="R199" ref-type="bibr">199</xref> and brain-derived neurotrophic factor (BDNF) concentrations,<xref rid="R117" ref-type="bibr">117</xref><xref rid="R120" ref-type="bibr">120</xref><xref rid="R196" ref-type="bibr">196</xref> possibly by inhibiting GSK3&#946;<xref rid="R200" ref-type="bibr">200</xref><xref rid="R201" ref-type="bibr">201</xref><xref rid="R202" ref-type="bibr">202</xref> A xenon-induced BDNF increase could be important because BDNF increases PKM&#950; expression and memory updating.<xref rid="R203" ref-type="bibr">203</xref> In contrast, CREB transcription factor activity is required for MR,<xref rid="R204" ref-type="bibr">204</xref><xref rid="R205" ref-type="bibr">205</xref> so xenon&#8217;s CREB-enhancing effect could support MR. That being said, xenon may also increase the expression of a CREB feedback inhibitor, inducible cyclic AMP early repressor protein, which limits CREB&#8217;s duration of action.<xref rid="R206" ref-type="bibr">206</xref> This lithium-sensitive effect<xref rid="R207" ref-type="bibr">207</xref> could be mediated by GSK3 inhibition<xref rid="R140" ref-type="bibr">140</xref> and thus also by xenon. Furthermore, by increasing PKA and PKC activities and BDNF concentrations, xenon could increase inducible cyclic AMP early repressor protein expression,<xref rid="R206" ref-type="bibr">206</xref> thereby countering CREB-induced MR-enhancing effects. Xenon desensitization of acid-sensing ion channels<xref rid="R208" ref-type="bibr">208</xref> could decrease the lability of reactivated conditioned memory by altering AMPA receptor dynamics,<xref rid="R209" ref-type="bibr">209</xref> possibly countering xenon&#8217;s MR-inhibitory effects.</p><p>We did not find reports linking the following xenon targets to MR, although several may mediate other SUD-relevant effects discussed below. Xenon activates TREK-1 potassium channels<xref rid="R66" ref-type="bibr">66</xref><xref rid="R210" ref-type="bibr">210</xref> and ATP-dependent potassium (Kir 6.2) channels<xref rid="R211" ref-type="bibr">211</xref><xref rid="R212" ref-type="bibr">212</xref><xref rid="R213" ref-type="bibr">213</xref> and increases hypoxia inducible factor-1&#945;<xref rid="R115" ref-type="bibr">115</xref> and microRNA-21 (miR-21) expression.<xref rid="R118" ref-type="bibr">118</xref><xref rid="R214" ref-type="bibr">214</xref><xref rid="R215" ref-type="bibr">215</xref> Xenon inhibits hyperpolarization-activated cyclic nucleotide-gated channels,<xref rid="R90" ref-type="bibr">90</xref><xref rid="R216" ref-type="bibr">216</xref> transient receptor potential vanilloid (TRPV1) receptors,<xref rid="R217" ref-type="bibr">217</xref> Caspase 3,<xref rid="R194" ref-type="bibr">194</xref><xref rid="R195" ref-type="bibr">195</xref><xref rid="R197" ref-type="bibr">197</xref><xref rid="R218" ref-type="bibr">218</xref> and tissue plasminogen activator and plasmin,<xref rid="R219" ref-type="bibr">219</xref> although the latter effect has been challenged.<xref rid="R220" ref-type="bibr">220</xref><xref rid="R221" ref-type="bibr">221</xref></p><p>To summarize, most xenon targets have the capacity to inhibit MR or enhance memory updating, which is consistent with our findings.<xref rid="R19" ref-type="bibr">19</xref><xref rid="R36" ref-type="bibr">36</xref> Targeting MR as an approach to treat maladaptive memory disorders has been critiqued because some studies have reported minimal or modest effects.<xref rid="R37" ref-type="bibr">37</xref> Importantly, the degree of memory reactivation required for effective MR attenuation is determined in part by a particular memory&#8217;s strength and age.<xref rid="R48" ref-type="bibr">48</xref><xref rid="R49" ref-type="bibr">49</xref><xref rid="R79" ref-type="bibr">79</xref> Thus, the use of artificial or weak memory reactivating stimuli presented in artificial (research laboratory or clinic) environments may insufficiently reactivate some memories, thereby limiting the capacity to inhibit MR. Our theory is that administering (or self-administering) xenon briefly in the real world, immediately after highly salient maladaptive memories are reactivated&#8212;perhaps multiple times each day when such memories are triggered by real-world stimuli<xref rid="R222" ref-type="bibr">222</xref>&#8212;will be more effective at inhibiting MR than what can be achieved by laboratory or clinic MR-attenuation conditions.<xref rid="R49" ref-type="bibr">49</xref> The next section reviews xenon&#8217;s ability to inhibit physical withdrawal (abstinence) symptoms, which are potent negative reinforcers that trigger substance use for symptom relief.</p></sec></sec><sec id="sec2-2"><title>Physical withdrawal (abstinence) syndrome</title><p>Physical dependence develops after prolonged heavy opioid or alcohol use, during which highly aversive withdrawal (abstinence) symptoms emerge when blood opioid or alcohol concentrations decline. Opioid withdrawal symptoms (OWS) and alcohol withdrawal symptoms (AWS), which include diarrhea, nausea, vomiting, and cramps,<xref rid="R38" ref-type="bibr">38</xref><xref rid="R223" ref-type="bibr">223</xref><xref rid="R224" ref-type="bibr">224</xref> are potent negative reinforcers; they or interoceptive cues predicting their onset trigger withdrawal fears and substance use to avert or relieve symptoms. Withdrawal fears prevent many people with SUDs from initiating treatment, and for those in treatment, they prompt unprescribed substance use,<xref rid="R225" ref-type="bibr">225</xref> which in turn leads to relapse.<xref rid="R29" ref-type="bibr">29</xref><xref rid="R38" ref-type="bibr">38</xref><xref rid="R39" ref-type="bibr">39</xref><xref rid="R75" ref-type="bibr">75</xref><xref rid="R224" ref-type="bibr">224</xref><xref rid="R226" ref-type="bibr">226</xref><xref rid="R227" ref-type="bibr">227</xref> Accordingly, withdrawal symptom management is considered critical for optimizing OUD or AUD outcomes.<xref rid="R29" ref-type="bibr">29</xref><xref rid="R38" ref-type="bibr">38</xref><xref rid="R39" ref-type="bibr">39</xref><xref rid="R227" ref-type="bibr">227</xref> OWS and AWS are caused in part by opioid- or alcohol-induced gut leakiness (dysbiosis), which enables inflammatory mediators to enter and spread through the systemic circulation, effectively causing a low level of sepsis.<xref rid="R228" ref-type="bibr">228</xref><xref rid="R229" ref-type="bibr">229</xref><xref rid="R230" ref-type="bibr">230</xref><xref rid="R231" ref-type="bibr">231</xref> The resulting systemic inflammation enhances sympathetic nervous system (SNS) activity<xref rid="R232" ref-type="bibr">232</xref> and increases withdrawal symptom severity.<xref rid="R29" ref-type="bibr">29</xref><xref rid="R38" ref-type="bibr">38</xref><xref rid="R39" ref-type="bibr">39</xref><xref rid="R223" ref-type="bibr">223</xref><xref rid="R227" ref-type="bibr">227</xref><xref rid="R231" ref-type="bibr">231</xref></p><p>We tested whether xenon could blunt opioid receptor antagonist (naltrexone)-precipitated OWS in morphine-dependent mice. After naltrexone administration, the mice were placed into a closed-circuit gas exposure chamber containing either 21% oxygen/balance nitrogen (controls) or 21% oxygen/30% xenon/balance nitrogen. After 10 minutes, the mice were moved to a normal air chamber and videorecorded for 45 minutes for behavioral scoring by a rater blinded to the treatment conditions. Our primary measure of OWS severity was the number of naltrexone-precipitated jumps. Detailed descriptions of these experiments can be found in our previous report.<xref rid="R27" ref-type="bibr">27</xref> Xenon substantially reduced jumping, and its effect was rapid, apparent within the first 10-minute observation period (<bold><xref rid="mgr.MEDGASRES-D-24-00063-F4" ref-type="fig">Figure 4</xref></bold>). These effects are consistent with those in a human study reporting that exposure to higher (sedative) xenon concentrations reduced OWS or AWS and reduced the subsequent need for therapeutic opioid or benzodiazepine use.<xref rid="R28" ref-type="bibr">28</xref></p><fig position="float" id="mgr.MEDGASRES-D-24-00063-F4" orientation="portrait"><label>Figure 4</label><caption><p>Xenon (Xe) inhibits naltrexone-precipitated jumping counts in morphine-dependent mice.</p><p>These data are adapted from our previous report.<xref rid="R27" ref-type="bibr">27</xref> No sex differences were detected, so the mice were grouped together. Xe inhalation for 10 minutes starting immediately after naltrexone injection substantially reduced jumping at all time points (*<italic toggle="yes">P</italic> &lt; 0.002, two-way (treatment, time) analysis of variance). Tukey multiple comparisons <italic toggle="yes">post hoc</italic> analysis revealed rapid onset of the Xe effect, which was significant in the first 10-minute window (&#8224;<italic toggle="yes">P</italic> &lt; 0.02). Periods 1&#8211;3 are consecutive 10-minute intervals, and period 4 is a 15-minute interval. No jumps were detected in Xe-treated mice during period 4. The data are expressed as the means &#177; SEMs (<italic toggle="yes">n</italic> = 15&#8211;26). GraphPad Prism version 10.3 was used to produce the figures and analyze the data.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="MGR-15-234-g004.jpg"/></fig><p>The effects of xenon on OWS may be attributable to its ability to attenuate inflammation<xref rid="R118" ref-type="bibr">118</xref><xref rid="R125" ref-type="bibr">125</xref><xref rid="R233" ref-type="bibr">233</xref><xref rid="R234" ref-type="bibr">234</xref><xref rid="R235" ref-type="bibr">235</xref><xref rid="R236" ref-type="bibr">236</xref><xref rid="R237" ref-type="bibr">237</xref><xref rid="R238" ref-type="bibr">238</xref> and SNS activity.<xref rid="R239" ref-type="bibr">239</xref><xref rid="R240" ref-type="bibr">240</xref><xref rid="R241" ref-type="bibr">241</xref><xref rid="R242" ref-type="bibr">242</xref> Intriguingly, recent work indicates that it is possible to rapidly phase in naltrexone treatment for OUD, which is significant because naltrexone, by blocking opioid receptors, is one of the most effective but most aversive and least tolerated treatments for OUD.<xref rid="R243" ref-type="bibr">243</xref> By attenuating OWS, xenon could be used in combination with naltrexone to increase its tolerability and perhaps accelerate its introduction. Given that OWS and AWS are driven by comparable mechanisms, including gut dysbiosis, inflammation, and SNS hyperactivity,<xref rid="R231" ref-type="bibr">231</xref> and that xenon reduces AWS in humans,<xref rid="R28" ref-type="bibr">28</xref> we predict that xenon could also be used to attenuate AWS. The following xenon targets may mediate its effects on physical withdrawal symptoms.</p><sec id="sec3-5"><title>Ionotropic receptors</title><p>Xenon inhibition of NMDA, AMPA, and 5HT<sub>3</sub> receptors and activation of GABA<sub>A</sub> receptors support the possibility that these targets contribute to xenon attenuation of OWS and possibly AWS. In this regard, NMDA and AMPA receptor antagonists reduce OWS and/or AWS symptoms.<xref rid="R244" ref-type="bibr">244</xref><xref rid="R245" ref-type="bibr">245</xref><xref rid="R246" ref-type="bibr">246</xref><xref rid="R247" ref-type="bibr">247</xref><xref rid="R248" ref-type="bibr">248</xref><xref rid="R249" ref-type="bibr">249</xref><xref rid="R250" ref-type="bibr">250</xref><xref rid="R251" ref-type="bibr">251</xref><xref rid="R252" ref-type="bibr">252</xref> Serotonin 5-HT<sub>3</sub> receptor inhibition reduces OWS in animals<xref rid="R253" ref-type="bibr">253</xref><xref rid="R254" ref-type="bibr">254</xref><xref rid="R255" ref-type="bibr">255</xref> and is moderately effective at inhibiting OWS in human neonates<xref rid="R256" ref-type="bibr">256</xref> but not in adults with OUD.<xref rid="R257" ref-type="bibr">257</xref> GABA<sub>A</sub> receptor activation attenuates AWS.<xref rid="R258" ref-type="bibr">258</xref></p></sec><sec id="sec3-6"><title>Kinases</title><p>GSK3 may mediate xenon&#8217;s effects on OWS and AWS because GSK3 positively regulates SNS activity<xref rid="R259" ref-type="bibr">259</xref><xref rid="R260" ref-type="bibr">260</xref><xref rid="R261" ref-type="bibr">261</xref><xref rid="R262" ref-type="bibr">262</xref> and inflammation.<xref rid="R263" ref-type="bibr">263</xref><xref rid="R264" ref-type="bibr">264</xref> Furthermore, opioids increase GSK3 expression and activity,<xref rid="R133" ref-type="bibr">133</xref><xref rid="R134" ref-type="bibr">134</xref><xref rid="R135" ref-type="bibr">135</xref><xref rid="R136" ref-type="bibr">136</xref> as may alcohol,<xref rid="R137" ref-type="bibr">137</xref> potentially enhancing OWS or AWS severity by increasing SNS activity and inflammation. GSK3 inhibitors of several different chemical classes, including lithium, insulin, and synthetics, attenuate OWS,<xref rid="R265" ref-type="bibr">265</xref><xref rid="R266" ref-type="bibr">266</xref><xref rid="R267" ref-type="bibr">267</xref> and the GSK3 inhibitor lithium reduces AWS severity.<xref rid="R268" ref-type="bibr">268</xref></p></sec><sec id="sec3-7"><title>Transporters</title><p>Xenon-induced increases in brain extracellular and systemic NE concentrations,<xref rid="R173" ref-type="bibr">173</xref><xref rid="R174" ref-type="bibr">174</xref><xref rid="R175" ref-type="bibr">175</xref> possibly resulting from NE transporter downregulation,<xref rid="R176" ref-type="bibr">176</xref> could activate &#945;<sub>2</sub> adrenergic receptors and, like the &#945;<sub>2</sub> adrenergic receptor agonists clonidine and lofexidine used to treat AWS and OWS,<xref rid="R231" ref-type="bibr">231</xref> attenuate OWS or AWS.</p></sec><sec id="sec3-8"><title>Other targets</title><p>Chronic opioid exposure downregulates ATP-dependent potassium channels,<xref rid="R269" ref-type="bibr">269</xref><xref rid="R270" ref-type="bibr">270</xref><xref rid="R271" ref-type="bibr">271</xref><xref rid="R272" ref-type="bibr">272</xref> whereas TRPV1 activity is increased during opioid withdrawal,<xref rid="R273" ref-type="bibr">273</xref> and TRPV1 receptor inhibition reduces OWS in mice.<xref rid="R274" ref-type="bibr">274</xref> Accordingly, xenon activation of ATP-dependent (Kir 6.2) potassium channels<xref rid="R211" ref-type="bibr">211</xref><xref rid="R212" ref-type="bibr">212</xref><xref rid="R213" ref-type="bibr">213</xref> and/or inhibition of TRPV1 receptors<xref rid="R217" ref-type="bibr">217</xref> could attenuate OWS or AWS. The probiotic activity of xenon could favorably impact the gut microbiome<xref rid="R275" ref-type="bibr">275</xref> and counter opioid- or alcohol-induced gut dysbiosis, leakage, and the systemic inflammation that drive SNS hyperactivity and AWS or OWS.<xref rid="R231" ref-type="bibr">231</xref></p><p>In summary, most xenon effects predict its ability to attenuate OWS or AWS (<bold><xref rid="mgr.MEDGASRES-D-24-00063-F5" ref-type="fig">Figure 5</xref></bold>). If xenon is administered as withdrawal symptoms emerge, it may dually blunt withdrawal symptoms and aversive MR of those symptoms, perhaps exerting additive effects that reduce present and future motivation to seek withdrawal symptom relief via substance use.</p><fig position="float" id="mgr.MEDGASRES-D-24-00063-F5" orientation="portrait"><label>Figure 5</label><caption><p>Xenon (Xe) targets that could mediate its inhibition of withdrawal symptoms or seizures.</p><p>Xe inhibits (thick red arrows) physical opioid withdrawal symptoms (OWS)<xref rid="R27" ref-type="bibr">27</xref><xref rid="R28" ref-type="bibr">28</xref> and seizures<xref rid="R276" ref-type="bibr">276</xref><xref rid="R277" ref-type="bibr">277</xref><xref rid="R278" ref-type="bibr">278</xref><xref rid="R279" ref-type="bibr">279</xref><xref rid="R280" ref-type="bibr">280</xref><xref rid="R281" ref-type="bibr">281</xref><xref rid="R282" ref-type="bibr">282</xref> and may inhibit alcohol withdrawal symptoms (AWS). (A) Xe inhibits (thick red arrows) and activates (thick green arrows) several targets/effects that have yet to be confirmed as mediators (thin arrows) of its ability to inhibit withdrawal symptoms or seizures. Not all effects or interactions are shown. Not all effects may occur in all cell types. Absent lines indicate either no effect or current knowledge gaps. (B) Citations reporting Xe targets and citations reporting that these targets regulate withdrawal symptoms or seizures. *Effects in animals and human neonates but not adults. 5-HT<sub>3</sub>: 5-Hydroxytryptamine 3 subtype receptor; AMPA: &#945;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic receptor; K<sub>ATP</sub> (6.2): ATP-dependent potassium (6.2) channels; AWS: alcohol withdrawal symptoms; GABA<sub>A</sub>: &#947;-aminobutyric acid subtype A receptor; GSK3: glycogen synthase kinase-3; NE: norepinephrine; OWS: opioid withdrawal symptoms; TRPV1: transient receptor potential vanilloid-1 receptor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="MGR-15-234-g005.jpg"/></fig></sec></sec><sec id="sec2-3"><title>Alcohol withdrawal seizures</title><p>One of the most serious withdrawal symptoms that can occur after prolonged heavy alcohol use is the development of seizures.<xref rid="R223" ref-type="bibr">223</xref> Xenon&#8217;s anticonvulsant effects<xref rid="R276" ref-type="bibr">276</xref><xref rid="R277" ref-type="bibr">277</xref><xref rid="R278" ref-type="bibr">278</xref><xref rid="R279" ref-type="bibr">279</xref><xref rid="R280" ref-type="bibr">280</xref><xref rid="R281" ref-type="bibr">281</xref><xref rid="R282" ref-type="bibr">282</xref> could be employed to reduce seizures. Xenon inhibition of excitatory NMDA and AMPA glutamate receptors and activation of inhibitory GABA<sub>A</sub> or glycine receptors or K<sub>ATP</sub> (6.2) channels predict its antiseizure activity.<xref rid="R223" ref-type="bibr">223</xref><xref rid="R277" ref-type="bibr">277</xref><xref rid="R278" ref-type="bibr">278</xref><xref rid="R280" ref-type="bibr">280</xref><xref rid="R282" ref-type="bibr">282</xref><xref rid="R283" ref-type="bibr">283</xref><xref rid="R284" ref-type="bibr">284</xref><xref rid="R285" ref-type="bibr">285</xref><xref rid="R286" ref-type="bibr">286</xref><xref rid="R287" ref-type="bibr">287</xref><xref rid="R288" ref-type="bibr">288</xref><xref rid="R289" ref-type="bibr">289</xref> The next section discusses the negative emotional state of hyperkatifeia, a substance withdrawal phenomenon that also catalyzes relief seeking via substance abuse.</p></sec></sec><sec id="sec1-3"><title>Hyperkatifeia: Negative Emotional States That Emerge During Drug Unavailability</title><p>People who use opioids, alcohol, and other substances, including anabolic steroids, cannabis, cocaine, MDMA, methamphetamine, and nicotine experience affective symptoms, including anxiety, depression and dysphoria, as well as pain symptoms, when their substance is unavailable.<xref rid="R290" ref-type="bibr">290</xref> This leads to the emergence of a negative emotional state called hyperkatifeia.<xref rid="R29" ref-type="bibr">29</xref> Although milder than physical withdrawal symptoms, hyperkatifeia similarly prompts relief seeking through continued or renewed substance abuse. Hyperkatifeia tends to occur early in the course of SUDs, as neural systems adapt to the presence of alcohol or drugs, a process called tolerance (discussed below), during which escalation of opioid, alcohol, or other substance use is required either to experience rewarding effects or to relieve aversive effects.<xref rid="R29" ref-type="bibr">29</xref> Reward or relief become more difficult to achieve as tolerance increases, and ultimately, aversive symptom relief becomes a primary goal of substance use.<xref rid="R29" ref-type="bibr">29</xref></p><p>Xenon reduces hyperkatifeia symptoms, including anxiety,<xref rid="R19" ref-type="bibr">19</xref><xref rid="R36" ref-type="bibr">36</xref><xref rid="R236" ref-type="bibr">236</xref><xref rid="R241" ref-type="bibr">241</xref><xref rid="R242" ref-type="bibr">242</xref><xref rid="R275" ref-type="bibr">275</xref><xref rid="R291" ref-type="bibr">291</xref> depression/dysphoria,<xref rid="R120" ref-type="bibr">120</xref><xref rid="R236" ref-type="bibr">236</xref><xref rid="R275" ref-type="bibr">275</xref><xref rid="R292" ref-type="bibr">292</xref><xref rid="R293" ref-type="bibr">293</xref> and pain and its sensitization.<xref rid="R18" ref-type="bibr">18</xref><xref rid="R71" ref-type="bibr">71</xref><xref rid="R82" ref-type="bibr">82</xref><xref rid="R84" ref-type="bibr">84</xref><xref rid="R233" ref-type="bibr">233</xref><xref rid="R272" ref-type="bibr">272</xref><xref rid="R294" ref-type="bibr">294</xref><xref rid="R295" ref-type="bibr">295</xref><xref rid="R296" ref-type="bibr">296</xref><xref rid="R297" ref-type="bibr">297</xref><xref rid="R298" ref-type="bibr">298</xref><xref rid="R299" ref-type="bibr">299</xref><xref rid="R300" ref-type="bibr">300</xref> Accordingly, xenon administered as hyperkatifeia symptoms emerge could provide relief that otherwise would be attained through substance use. Xenon targets that could mediate its antihyperkatifeia effects are described below.</p><sec id="sec2-4"><title>Ionotropic receptors and ion channels</title><p>Xenon modulation of ionotropic receptors and ion channels predict its ability to attenuate hyperkatifeia symptoms. In this regard, NMDA receptor antagonists reduce anxiety,<xref rid="R96" ref-type="bibr">96</xref><xref rid="R301" ref-type="bibr">301</xref> depression,<xref rid="R302" ref-type="bibr">302</xref><xref rid="R303" ref-type="bibr">303</xref><xref rid="R304" ref-type="bibr">304</xref> and pain.<xref rid="R18" ref-type="bibr">18</xref><xref rid="R305" ref-type="bibr">305</xref><xref rid="R306" ref-type="bibr">306</xref><xref rid="R307" ref-type="bibr">307</xref> AMPA receptor antagonists exert anxiolytic effects,<xref rid="R308" ref-type="bibr">308</xref> enhance depression symptoms,<xref rid="R308" ref-type="bibr">308</xref><xref rid="R309" ref-type="bibr">309</xref><xref rid="R310" ref-type="bibr">310</xref> and inhibit pain and pain sensitization.<xref rid="R18" ref-type="bibr">18</xref><xref rid="R306" ref-type="bibr">306</xref> Kainate receptor antagonists reduce depression symptoms<xref rid="R311" ref-type="bibr">311</xref><xref rid="R312" ref-type="bibr">312</xref> and pain<xref rid="R311" ref-type="bibr">311</xref> but increase anxiety.<xref rid="R312" ref-type="bibr">312</xref><xref rid="R313" ref-type="bibr">313</xref> Glycine receptor activation reduces anxiety and depression symptoms, including those associated with alcohol withdrawal,<xref rid="R314" ref-type="bibr">314</xref> and reduces pain.<xref rid="R315" ref-type="bibr">315</xref> TPRV1 antagonists attenuate depression, anxiety, pain, and hyperalgesia, including in alcohol-withdrawn rats.<xref rid="R18" ref-type="bibr">18</xref><xref rid="R273" ref-type="bibr">273</xref><xref rid="R306" ref-type="bibr">306</xref><xref rid="R316" ref-type="bibr">316</xref><xref rid="R317" ref-type="bibr">317</xref> Hyperpolarization-activated cyclic nucleotide-gated channel inhibition reduces pain,<xref rid="R18" ref-type="bibr">18</xref><xref rid="R318" ref-type="bibr">318</xref> and ASIC antagonists attenuate depression-like behaviors,<xref rid="R319" ref-type="bibr">319</xref> anxiety,<xref rid="R320" ref-type="bibr">320</xref> and pain.<xref rid="R306" ref-type="bibr">306</xref><xref rid="R320" ref-type="bibr">320</xref> PMCA inhibitors, by inhibiting glycine transporter (GlyT2) uptake,<xref rid="R191" ref-type="bibr">191</xref> can increase synaptic glycine concentrations and activate glycine receptors, effects associated with the attenuation of depression, anxiety, and pain.<xref rid="R321" ref-type="bibr">321</xref> ATP-dependent (Kir 6.2) potassium channel agonists decrease pain,<xref rid="R270" ref-type="bibr">270</xref><xref rid="R271" ref-type="bibr">271</xref><xref rid="R272" ref-type="bibr">272</xref> and TREK-1 potassium channel activators may increase depression while decreasing pain.<xref rid="R322" ref-type="bibr">322</xref></p></sec><sec id="sec2-5"><title>GSK3</title><p>Xenon inhibition of GSK3 predicts antidepressant,<xref rid="R153" ref-type="bibr">153</xref><xref rid="R323" ref-type="bibr">323</xref><xref rid="R324" ref-type="bibr">324</xref> anxiolytic,<xref rid="R325" ref-type="bibr">325</xref> and analgesic effects,<xref rid="R326" ref-type="bibr">326</xref><xref rid="R327" ref-type="bibr">327</xref> including antihyperalgesia effects.<xref rid="R328" ref-type="bibr">328</xref><xref rid="R329" ref-type="bibr">329</xref></p></sec><sec id="sec2-6"><title>Transporters</title><p>Xenon-induced increases in NE concentrations<xref rid="R173" ref-type="bibr">173</xref><xref rid="R174" ref-type="bibr">174</xref><xref rid="R175" ref-type="bibr">175</xref> secondary to NE transporter downregulation<xref rid="R176" ref-type="bibr">176</xref> could exert antidepressant, anxiolytic, and analgesic effects.<xref rid="R330" ref-type="bibr">330</xref><xref rid="R331" ref-type="bibr">331</xref><xref rid="R332" ref-type="bibr">332</xref> By inhibiting GSK3, xenon could also upregulate serotonin transporter expression and activity,<xref rid="R185" ref-type="bibr">185</xref><xref rid="R186" ref-type="bibr">186</xref> thereby decreasing synaptic or extracellular 5-HT concentrations. Such an effect has yet to be demonstrated, but if it occurs, it could oppose the antidepressant effects of xenon. However, a recent systematic review challenged the serotonin theory of depression.<xref rid="R333" ref-type="bibr">333</xref></p></sec><sec id="sec2-7"><title>Other targets</title><p>The effects of xenon on several other targets predict its antidepressant, anxiolytic, and analgesic effects. In this context, increases in BDNF and phosphorylated CREB exert antidepressant<xref rid="R334" ref-type="bibr">334</xref><xref rid="R335" ref-type="bibr">335</xref><xref rid="R336" ref-type="bibr">336</xref> and antianxiety<xref rid="R337" ref-type="bibr">337</xref><xref rid="R338" ref-type="bibr">338</xref> effects, increases in hypoxia inducible factor-1&#945; are associated with antidepressant<xref rid="R339" ref-type="bibr">339</xref> and analgesic<xref rid="R340" ref-type="bibr">340</xref> effects, and increases in miR-21 promote antidepressant<xref rid="R341" ref-type="bibr">341</xref> and analgesic<xref rid="R342" ref-type="bibr">342</xref> effects. Caspase3 reductions are associated with analgesia,<xref rid="R343" ref-type="bibr">343</xref> whereas gut dysbiosis and inflammation are associated with depression and anxiety,<xref rid="R228" ref-type="bibr">228</xref><xref rid="R231" ref-type="bibr">231</xref><xref rid="R344" ref-type="bibr">344</xref><xref rid="R345" ref-type="bibr">345</xref><xref rid="R346" ref-type="bibr">346</xref> effects potentially countered by the probiotic effects of xenon.<xref rid="R275" ref-type="bibr">275</xref></p><p>In summary, most of xenon&#8217;s known molecular effects are consistent with its ability to reduce or relieve hyperkatifeia symptoms (<bold><xref rid="mgr.MEDGASRES-D-24-00063-F6" ref-type="fig">Figure 6</xref></bold>). Accordingly, xenon could fill what is considered a hyperkatifeia treatment gap.<xref rid="R29" ref-type="bibr">29</xref> More human data on how xenon moderates hyperkatifeia symptoms may result from registered clinical trials (Clinicaltrials.gov) aimed at evaluating xenon as a treatment for major depressive disorder (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03748446">NCT03748446</ext-link>), posttraumatic stress disorder (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03635827">NCT03635827</ext-link>), panic disorder (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04432155">NCT04432155</ext-link>), and &#8220;psychoemotional&#8221; stress (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06080100">NCT06080100</ext-link>).</p><fig position="float" id="mgr.MEDGASRES-D-24-00063-F6" orientation="portrait"><label>Figure 6</label><caption><p>Xenon (Xe) targets that may moderate hyperkatifeia symptoms of major depression, anxiety, and/or pain.</p><p>(A) Xe inhibits (thick red arrows) depression,<xref rid="R120" ref-type="bibr">120</xref><xref rid="R236" ref-type="bibr">236</xref><xref rid="R275" ref-type="bibr">275</xref><xref rid="R292" ref-type="bibr">292</xref><xref rid="R293" ref-type="bibr">293</xref> anxiety,<xref rid="R19" ref-type="bibr">19</xref><xref rid="R36" ref-type="bibr">36</xref><xref rid="R236" ref-type="bibr">236</xref><xref rid="R241" ref-type="bibr">241</xref><xref rid="R242" ref-type="bibr">242</xref><xref rid="R275" ref-type="bibr">275</xref><xref rid="R291" ref-type="bibr">291</xref> and pain.<xref rid="R18" ref-type="bibr">18</xref><xref rid="R71" ref-type="bibr">71</xref><xref rid="R82" ref-type="bibr">82</xref><xref rid="R84" ref-type="bibr">84</xref><xref rid="R233" ref-type="bibr">233</xref><xref rid="R272" ref-type="bibr">272</xref><xref rid="R294" ref-type="bibr">294</xref><xref rid="R295" ref-type="bibr">295</xref><xref rid="R296" ref-type="bibr">296</xref><xref rid="R297" ref-type="bibr">297</xref><xref rid="R298" ref-type="bibr">298</xref><xref rid="R299" ref-type="bibr">299</xref><xref rid="R300" ref-type="bibr">300</xref> Xe activates (thick green arrows) and inhibits (thick red arrows) targets that have been shown by others to inhibit or enhance hyperkatifeia symptoms. Xe targets have yet to be confirmed as mediators (thin arrows) of its antidepressant, anxiolytic, or analgesic effects. Absent lines indicate either no effect or current knowledge gaps. (B) Citations reporting Xe targets and citations reporting effects of these targets on hyperkatifeia symptoms. **Strychnine-sensitive glycine receptor binding site. AMPA: &#945;-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic receptor; ASIC: acid-sensing ion channel; BDNF: brain-derived neurotrophic factor; HCN2: hyperpolarization-activated cyclic nucleotide-gated channel; K<sub>ATP</sub> (6.2): ATP-dependent potassium (6.2) channel; GSK3: glycogen synthase kinase-3; miR-21: microRNA-21; NE: norepinephrine; pCREB: phosphorylated cyclic-AMP-response element binding protein; PMCA: P-type membrane calcium ATPases; TREK-1: two-pore-domain background potassium channel; TRPV1: transient receptor potential vanilloid-1 receptor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="MGR-15-234-g006.jpg"/></fig></sec><sec id="sec2-8"><title>Tolerance</title><p>During exposures to opioids, alcohol, or other drugs, physiological adaptations occur that result in tolerance, which requires escalating substance doses to achieve rewarding or relieving effects.<xref rid="R29" ref-type="bibr">29</xref> Opioid analgesic tolerance develops quickly, within hours, faster than tolerance for opioid-induced respiratory depression, meaning that if opioid dose escalation is used to preserve analgesia (or rewarding or relieving effects), the risk increases for overdose due to respiratory depression.<xref rid="R347" ref-type="bibr">347</xref> Tolerance often leads to substance misuse and the development of dependence, especially OUD and AUD.<xref rid="R29" ref-type="bibr">29</xref> For example, an estimated 3.7 million pain patients in the US misused prescribed opioid analgesics in 2021.<xref rid="R348" ref-type="bibr">348</xref> Accordingly, developing treatments that limit tolerance could help prevent the development of OUD and perhaps other SUDs.</p><p>To date, no research has directly tested whether xenon blunts opioid tolerance. However, the analgesic effects of xenon at subsedative concentrations, which are not mediated by opioid receptors and are not subject to rapid tolerance, along with its opioid-sparing ability and ability to prevent hyperalgesia,<xref rid="R18" ref-type="bibr">18</xref><xref rid="R71" ref-type="bibr">71</xref><xref rid="R82" ref-type="bibr">82</xref><xref rid="R84" ref-type="bibr">84</xref><xref rid="R233" ref-type="bibr">233</xref><xref rid="R272" ref-type="bibr">272</xref><xref rid="R294" ref-type="bibr">294</xref><xref rid="R295" ref-type="bibr">295</xref><xref rid="R296" ref-type="bibr">296</xref><xref rid="R297" ref-type="bibr">297</xref><xref rid="R298" ref-type="bibr">298</xref><xref rid="R299" ref-type="bibr">299</xref><xref rid="R300" ref-type="bibr">300</xref><xref rid="R349" ref-type="bibr">349</xref> support our theory that xenon has strong potential for use as an opioid-sparing treatment. Xenon, if used in combination with opioid analgesics, could limit opioid dosing requirements for effective pain relief, thereby reducing the risk of OUD development.<xref rid="R350" ref-type="bibr">350</xref></p><p>Because NMDA,<xref rid="R351" ref-type="bibr">351</xref><xref rid="R352" ref-type="bibr">352</xref><xref rid="R353" ref-type="bibr">353</xref><xref rid="R354" ref-type="bibr">354</xref><xref rid="R355" ref-type="bibr">355</xref><xref rid="R356" ref-type="bibr">356</xref> AMPA,<xref rid="R351" ref-type="bibr">351</xref><xref rid="R357" ref-type="bibr">357</xref> 5HT<sub>3</sub><xref rid="R253" ref-type="bibr">253</xref><xref rid="R254" ref-type="bibr">254</xref><xref rid="R358" ref-type="bibr">358</xref> receptor inhibitors, GSK3 inhibitors,<xref rid="R266" ref-type="bibr">266</xref><xref rid="R359" ref-type="bibr">359</xref><xref rid="R360" ref-type="bibr">360</xref><xref rid="R361" ref-type="bibr">361</xref><xref rid="R362" ref-type="bibr">362</xref> K<sub>ATP</sub> channel openers,<xref rid="R270" ref-type="bibr">270</xref><xref rid="R272" ref-type="bibr">272</xref> TRPV1 channel antagonists,<xref rid="R363" ref-type="bibr">363</xref><xref rid="R364" ref-type="bibr">364</xref> and gut microbiome enhancers<xref rid="R365" ref-type="bibr">365</xref> prevent or reduce opioid tolerance, and because TREK-1 channels activated by xenon<xref rid="R66" ref-type="bibr">66</xref><xref rid="R210" ref-type="bibr">210</xref> mediate opioid analgesia but not opioid tolerance,<xref rid="R366" ref-type="bibr">366</xref> xenon&#8217;s multitargeting effects predict its ability to attenuate opioid tolerance (<bold><xref rid="mgr.MEDGASRES-D-24-00063-F7" ref-type="fig">Figure 7</xref></bold>).</p><fig position="float" id="mgr.MEDGASRES-D-24-00063-F7" orientation="portrait"><label>Figure 7</label><caption><p>Xenon (Xe) targets that could attenuate opioid tolerance/hyperalgesia.</p><p>(A) Xe inhibits (thick red arrows) and activates (thick green arrows) targets that reportedly increase and decrease, respectively, opioid tolerance/hyperalgesia (thin arrows). (B) Citations reporting Xe targets and citations reporting the effects of these targets on opioid tolerance/hyperalgesia. 5-HT<sub>3</sub>: 5-Hydroxytryptamine 3 subtype receptor; AMPA: &#945;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic receptor; K<sub>ATP</sub> (6.2): ATP-dependent potassium (6.2) channels; GSK3: glycogen synthase kinase-3; TREK-1: two-pore-domain background potassium channel; TRPV1: transient receptor potential vanilloid-1 receptor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="MGR-15-234-g007.jpg"/></fig><p>Additionally, because our bodies release endogenous opioids to limit the effects of stress and to accelerate stress recovery,<xref rid="R367" ref-type="bibr">367</xref><xref rid="R368" ref-type="bibr">368</xref><xref rid="R369" ref-type="bibr">369</xref> endogenous opioid tolerance also develops in people exposed to prolonged stress. Stress-induced opioid tolerance increases susceptibility to future stresses and pain and leads to greater preference for exogenous opioids,<xref rid="R367" ref-type="bibr">367</xref><xref rid="R368" ref-type="bibr">368</xref><xref rid="R370" ref-type="bibr">370</xref><xref rid="R371" ref-type="bibr">371</xref><xref rid="R372" ref-type="bibr">372</xref><xref rid="R373" ref-type="bibr">373</xref><xref rid="R374" ref-type="bibr">374</xref> perhaps as a form of self-medication that counters low endogenous opioid efficacy.<xref rid="R375" ref-type="bibr">375</xref><xref rid="R376" ref-type="bibr">376</xref><xref rid="R377" ref-type="bibr">377</xref> For example, having PTSD increases the risk of developing OUD following opioid analgesic use.<xref rid="R378" ref-type="bibr">378</xref> Conversely, prior chronic morphine exposure potentiates aversive memory formation and enhances fear learning,<xref rid="R379" ref-type="bibr">379</xref> an effect mimicked by opioid antagonists that blunt endogenous opioid effects.<xref rid="R380" ref-type="bibr">380</xref><xref rid="R381" ref-type="bibr">381</xref><xref rid="R382" ref-type="bibr">382</xref> Moreover, high proportions of opioid users either experience or witness drug overdoses,<xref rid="R383" ref-type="bibr">383</xref> which are stressful events that increase the risk of developing PTSD.<xref rid="R384" ref-type="bibr">384</xref> Together, these seemingly bidirectional processes likely contribute to the high comorbidity of stress disorders such as PTSD with OUD,<xref rid="R385" ref-type="bibr">385</xref><xref rid="R386" ref-type="bibr">386</xref><xref rid="R387" ref-type="bibr">387</xref><xref rid="R388" ref-type="bibr">388</xref> either or both of which could benefit from xenon&#8217;s multitargeting effects.</p></sec><sec id="sec2-9"><title>Drug reward and preference</title><p>Many psychoactive substances, including alcohol, opioids, and stimulants increase dopamine concentrations, a neurochemical signal of reward and an effect that results from interactions between multiple neurotransmitter signaling systems.<xref rid="R389" ref-type="bibr">389</xref> Alcohol or drug preference develops after rewarding (or relieving) effects trigger neuroplasticity, including the formation of memories that support alcohol or drug seeking.<xref rid="R390" ref-type="bibr">390</xref> Accordingly, interventions that can inhibit reward signals could help disrupt the chain of behaviors and allostatic changes that increase the risk of developing SUDs.<xref rid="R29" ref-type="bibr">29</xref></p><p>Xenon attenuates stimulant (amphetamine and ketamine)-induced dopamine increases<xref rid="R24" ref-type="bibr">24</xref><xref rid="R25" ref-type="bibr">25</xref> and alcohol seeking<xref rid="R26" ref-type="bibr">26</xref>, indicating that it could be used to limit alcohol or drug reward, as well as memories of their rewarding or relieving effects. The xenon inhibition of nicotinic &#945;7 and &#945;4&#946;2 receptors<xref rid="R56" ref-type="bibr">56</xref><xref rid="R88" ref-type="bibr">88</xref> predict its ability to attenuate dopamine increases that signal nicotine reward.<xref rid="R391" ref-type="bibr">391</xref> Xenon reward-attenuating effects are predicted for these and other substances through their multitargeting of ionotropic receptors,<xref rid="R247" ref-type="bibr">247</xref><xref rid="R390" ref-type="bibr">390</xref><xref rid="R391" ref-type="bibr">391</xref><xref rid="R392" ref-type="bibr">392</xref><xref rid="R393" ref-type="bibr">393</xref><xref rid="R394" ref-type="bibr">394</xref> ion channels,<xref rid="R395" ref-type="bibr">395</xref><xref rid="R396" ref-type="bibr">396</xref> GSK3,<xref rid="R137" ref-type="bibr">137</xref><xref rid="R138" ref-type="bibr">138</xref><xref rid="R373" ref-type="bibr">373</xref><xref rid="R397" ref-type="bibr">397</xref><xref rid="R398" ref-type="bibr">398</xref><xref rid="R399" ref-type="bibr">399</xref><xref rid="R400" ref-type="bibr">400</xref><xref rid="R401" ref-type="bibr">401</xref><xref rid="R402" ref-type="bibr">402</xref><xref rid="R403" ref-type="bibr">403</xref><xref rid="R404" ref-type="bibr">404</xref><xref rid="R405" ref-type="bibr">405</xref><xref rid="R406" ref-type="bibr">406</xref> and the gut microbiome.<xref rid="R407" ref-type="bibr">407</xref><xref rid="R408" ref-type="bibr">408</xref><xref rid="R409" ref-type="bibr">409</xref></p></sec><sec id="sec2-10"><title>Human immunodeficiency virus and GSK3</title><p>Human immunodeficiency virus (HIV) is relevant to this review because it is highly comorbid with SUDs<xref rid="R410" ref-type="bibr">410</xref><xref rid="R411" ref-type="bibr">411</xref> and because SUD/HIV comorbidity is associated with increased risks for psychiatric and medical impairments of greater severity that lead to worse outcomes.<xref rid="R411" ref-type="bibr">411</xref><xref rid="R412" ref-type="bibr">412</xref><xref rid="R413" ref-type="bibr">413</xref><xref rid="R414" ref-type="bibr">414</xref><xref rid="R415" ref-type="bibr">415</xref><xref rid="R416" ref-type="bibr">416</xref><xref rid="R417" ref-type="bibr">417</xref> By inhibiting GSK3, xenon targets an important intersection between HIV and OUD or AUD: GSK3 is regulated not only by opioids and alcohol but also by the HIV proteins transactivator of transcription (Tat) and glycoprotein 120 (gp120).<xref rid="R134" ref-type="bibr">134</xref><xref rid="R418" ref-type="bibr">418</xref><xref rid="R419" ref-type="bibr">419</xref><xref rid="R420" ref-type="bibr">420</xref><xref rid="R421" ref-type="bibr">421</xref><xref rid="R422" ref-type="bibr">422</xref><xref rid="R423" ref-type="bibr">423</xref><xref rid="R424" ref-type="bibr">424</xref><xref rid="R425" ref-type="bibr">425</xref><xref rid="R426" ref-type="bibr">426</xref> Tat protein likely contributes to ongoing HIV pathophysiology despite antiretroviral therapy because during effective antiretroviral therapy, Tat protein continues to be synthesized and released from HIV reservoirs to impair brain function and physiology.<xref rid="R427" ref-type="bibr">427</xref><xref rid="R428" ref-type="bibr">428</xref><xref rid="R429" ref-type="bibr">429</xref> Selective Tat protein expression in animal models induces memory impairments,<xref rid="R430" ref-type="bibr">430</xref><xref rid="R431" ref-type="bibr">431</xref><xref rid="R432" ref-type="bibr">432</xref><xref rid="R433" ref-type="bibr">433</xref><xref rid="R434" ref-type="bibr">434</xref><xref rid="R435" ref-type="bibr">435</xref><xref rid="R436" ref-type="bibr">436</xref> anxiety- and depression-like phenotypes,<xref rid="R434" ref-type="bibr">434</xref><xref rid="R437" ref-type="bibr">437</xref><xref rid="R438" ref-type="bibr">438</xref><xref rid="R439" ref-type="bibr">439</xref><xref rid="R440" ref-type="bibr">440</xref><xref rid="R441" ref-type="bibr">441</xref> pain-like phenotypes,<xref rid="R441" ref-type="bibr">441</xref><xref rid="R442" ref-type="bibr">442</xref><xref rid="R443" ref-type="bibr">443</xref><xref rid="R444" ref-type="bibr">444</xref> and analgesic tolerance,<xref rid="R445" ref-type="bibr">445</xref><xref rid="R446" ref-type="bibr">446</xref> effects analogous to those found in people living with HIV. Tat protein also induces dopamine system deficits and alters stimulant-related behaviors,<xref rid="R447" ref-type="bibr">447</xref><xref rid="R448" ref-type="bibr">448</xref><xref rid="R449" ref-type="bibr">449</xref><xref rid="R450" ref-type="bibr">450</xref> perhaps by upregulating DAT expression, a downstream effect of GSK3 activation.<xref rid="R171" ref-type="bibr">171</xref> Tat protein also enhances ethanol reward.<xref rid="R451" ref-type="bibr">451</xref> GSK3 has been proposed as an HIV therapeutic target,<xref rid="R452" ref-type="bibr">452</xref> and GSK3 inhibitors including lithium, valproic acid, and synthetics, attenuate the effects of Tat or gp120 protein-mediated HIV effects.<xref rid="R6" ref-type="bibr">6</xref><xref rid="R134" ref-type="bibr">134</xref><xref rid="R418" ref-type="bibr">418</xref><xref rid="R420" ref-type="bibr">420</xref><xref rid="R421" ref-type="bibr">421</xref><xref rid="R425" ref-type="bibr">425</xref><xref rid="R453" ref-type="bibr">453</xref> These findings support the possibility that xenon inhibition of GSK3 could exert several different beneficial effects on HIV. The inhibition of GSK3 by xenon could also be exploited to reactivate antiretroviral therapy-resistant viral reservoirs,<xref rid="R454" ref-type="bibr">454</xref><xref rid="R455" ref-type="bibr">455</xref><xref rid="R456" ref-type="bibr">456</xref><xref rid="R457" ref-type="bibr">457</xref> increasing their vulnerability to attack, elimination, and HIV cure.<xref rid="R458" ref-type="bibr">458</xref></p></sec></sec><sec id="sec1-4"><title>Xenon Slows the Development, Invasiveness, or Progression of Cancers</title><p>While cancers might seem out of the scope of this review, accumulating evidence suggests that xenon multitargeting effects relevant to SUDs, including the inhibition of ionotropic glutamate and nicotinic receptors and GSK3, may have therapeutic potential for treating cancers, including the brain cancer glioblastoma multiforme (GBM).<xref rid="R140" ref-type="bibr">140</xref><xref rid="R157" ref-type="bibr">157</xref><xref rid="R459" ref-type="bibr">459</xref><xref rid="R460" ref-type="bibr">460</xref><xref rid="R461" ref-type="bibr">461</xref><xref rid="R462" ref-type="bibr">462</xref><xref rid="R463" ref-type="bibr">463</xref> GBM is the most common type of brain tumor; it is aggressive, its prognosis is poor (median survival time of ~15 months), and treatment options are limited and compromised by tumor resistance.<xref rid="R464" ref-type="bibr">464</xref><xref rid="R465" ref-type="bibr">465</xref></p><p>Xenon inhibition of glutamate receptors could be beneficial in GBM because these glial cell-like tumors (gliomas) secrete glutamate to activate local NMDA and AMPA receptors, which increase tumor growth,<xref rid="R466" ref-type="bibr">466</xref><xref rid="R467" ref-type="bibr">467</xref> induce excitotoxicity in surrounding host tissues,<xref rid="R468" ref-type="bibr">468</xref> and enhance DNA repair,<xref rid="R469" ref-type="bibr">469</xref> conferring tumor resistance by limiting chemo- or radiotherapy efficacy. GBM glutamate release also induces seizures.<xref rid="R468" ref-type="bibr">468</xref> Direct evidence supporting the efficacy of xenon against GBM comes from a cell culture study reporting that 50% xenon sensitizes GBM cell lines to radiation therapy.<xref rid="R470" ref-type="bibr">470</xref> By inhibiting GSK3, the concentrations of which are elevated in GBM cells,<xref rid="R471" ref-type="bibr">471</xref> xenon can exert this and several other beneficial effects. For example, the synthetic GSK3 inhibitor kenpaullone sensitizes GBM stem cells to chemotherapy (temozolomide) treatment,<xref rid="R472" ref-type="bibr">472</xref> and the GSK3 inhibitor tideglusib reduces GBM cell line proliferation and viability and increases radiation sensitivity.<xref rid="R473" ref-type="bibr">473</xref> The GSK3&#946; inhibitor TDZD-8 slowed tumor growth and prolonged survival in a mouse GBM model.<xref rid="R474" ref-type="bibr">474</xref> GSK3 inhibition could also enhance several immune system effects that are beneficial for targeting GBM, including by augmenting the effects of immune checkpoint inhibitors or chimeric antigen receptor therapy, by enhancing natural killer cell sensitivity and activity, and by increasing interferon-&#947;.<xref rid="R475" ref-type="bibr">475</xref> Xenon increases interferon-&#947; signaling in Alzheimer&#8217;s disease models.<xref rid="R170" ref-type="bibr">170</xref> Xenon induction of metaphase arrest in glial cells<xref rid="R476" ref-type="bibr">476</xref> could also trigger glioma cell cycle arrest/senescence.<xref rid="R477" ref-type="bibr">477</xref><xref rid="R478" ref-type="bibr">478</xref> Xenon&#8217;s anticonvulsant effects<xref rid="R276" ref-type="bibr">276</xref><xref rid="R277" ref-type="bibr">277</xref><xref rid="R278" ref-type="bibr">278</xref><xref rid="R279" ref-type="bibr">279</xref><xref rid="R280" ref-type="bibr">280</xref><xref rid="R281" ref-type="bibr">281</xref><xref rid="R282" ref-type="bibr">282</xref> could attenuate GBM-associated seizures,<xref rid="R468" ref-type="bibr">468</xref> and in the ~20% of patients who continue to smoke despite being diagnosed with GBM,<xref rid="R460" ref-type="bibr">460</xref> xenon could blunt &#945;7 nicotinic receptor activation-induced chemo- or radiation resistance.<xref rid="R461" ref-type="bibr">461</xref></p><p>Additionally, stress catalyzes the development of GBM and worsens outcomes in brain cancer patients,<xref rid="R479" ref-type="bibr">479</xref><xref rid="R480" ref-type="bibr">480</xref> who, in turn, have very high rates of anxiety disorders and stress,<xref rid="R480" ref-type="bibr">480</xref> resulting in a vicious cycle. Accordingly, by blunting anxiety and major depression symptoms,<xref rid="R19" ref-type="bibr">19</xref><xref rid="R36" ref-type="bibr">36</xref><xref rid="R236" ref-type="bibr">236</xref><xref rid="R241" ref-type="bibr">241</xref><xref rid="R242" ref-type="bibr">242</xref><xref rid="R275" ref-type="bibr">275</xref><xref rid="R291" ref-type="bibr">291</xref><xref rid="R292" ref-type="bibr">292</xref><xref rid="R293" ref-type="bibr">293</xref> xenon could slow the development, invasiveness, or progression of these and perhaps other cancers.</p><sec id="sec2-11"><title>Xenon abuse liability</title><p>Xenon reportedly induces mildly pleasant subjective experiences up to and including euphoria at high subsedative concentrations.<xref rid="R481" ref-type="bibr">481</xref><xref rid="R482" ref-type="bibr">482</xref> However, in rats, subsedative (43%) xenon does not increase the concentration of extracellular dopamine in the nucleus accumbens,<xref rid="R25" ref-type="bibr">25</xref> a biomarker of reward.<xref rid="R389" ref-type="bibr">389</xref> Furthermore, xenon decreases amphetamine- or ketamine-induced dopamine increases,<xref rid="R24" ref-type="bibr">24</xref><xref rid="R25" ref-type="bibr">25</xref> suggesting that it is likely to inhibit stimulant and perhaps other substance-induced reward signals. By blocking the NMDA receptor glycine/D-serine binding site,<xref rid="R60" ref-type="bibr">60</xref> xenon is predicted to reduce the reinforcing effects of morphine<xref rid="R247" ref-type="bibr">247</xref> or alcohol<xref rid="R392" ref-type="bibr">392</xref> and to reduce motivation either to self-administer or reinstate ketamine seeking.<xref rid="R394" ref-type="bibr">394</xref> NMDA receptor glycine/D-serine binding site inhibitors also fail either to generalize to phencyclidine effects<xref rid="R483" ref-type="bibr">483</xref> or to induce psychotomimetic effects,<xref rid="R484" ref-type="bibr">484</xref> predicting that xenon does not have appreciable abuse liability. Additional support for this idea comes from neurophysiological studies reporting that xenon does not induce open channel NMDA receptor blockade,<xref rid="R70" ref-type="bibr">70</xref> differentiating it from other NMDA receptor antagonists with abuse liability, including ketamine, MK-801, or phencyclidine. If additional testing confirms this theory, it is plausible that xenon could be used as an ambulatory patient-controlled treatment for SUDs. Additionally, by mimicking some of the effects of alcohol, including by inhibiting NMDA receptors via interactions with several of the same receptor domains as alcohol and by activating GABA and glycine receptors,<xref rid="R56" ref-type="bibr">56</xref><xref rid="R72" ref-type="bibr">72</xref> xenon could be developed as a nonaddictive agonist substitution treatment for AUD.<xref rid="R258" ref-type="bibr">258</xref> Xenon could be superior to existing treatments that mimic some of the properties of alcohol, including NMDA receptor antagonists, benzodiazepines, and barbiturates, each of which has significant abuse liability.<xref rid="R223" ref-type="bibr">223</xref><xref rid="R258" ref-type="bibr">258</xref><xref rid="R485" ref-type="bibr">485</xref> Given xenon&#8217;s broad therapeutic potential for treating SUDs, additional abuse liability studies, including human studies, clearly are warranted.</p></sec><sec id="sec2-12"><title>Xenon costs now and in the future</title><p>Xenon is obtained primarily during air purification via cryogenic distillation, an energetically costly process of finite capacity.<xref rid="R486" ref-type="bibr">486</xref><xref rid="R487" ref-type="bibr">487</xref> This contributes to the high cost of xenon, which is a barrier to its therapeutic use. However, new xenon purification methods utilizing sophisticated molecular separation methods are being developed<xref rid="R488" ref-type="bibr">488</xref><xref rid="R489" ref-type="bibr">489</xref><xref rid="R490" ref-type="bibr">490</xref><xref rid="R491" ref-type="bibr">491</xref> to lower purification costs and enable high-efficiency xenon recovery and recycling from exhalates.<xref rid="R492" ref-type="bibr">492</xref> Furthermore, the high xenon concentrations needed for anesthesia (60&#8211;70%) and evaluated in many studies of xenon effects are not necessary to exert potentially beneficial effects. In our studies, subsedative xenon concentrations (15&#8211;30%) inhibited aversive MR<xref rid="R19" ref-type="bibr">19</xref><xref rid="R36" ref-type="bibr">36</xref> and naltrexone-precipitated morphine withdrawal symptoms.<xref rid="R27" ref-type="bibr">27</xref> Multiple treatments with xenon (15&#8211;30%) reduce anxiety in panic disorder patients.<xref rid="R291" ref-type="bibr">291</xref> Subsedative (35%) xenon inhibited &#945;7-nicotinic receptor-mediated signaling,<xref rid="R88" ref-type="bibr">88</xref> 18&#8211;30% xenon inhibited NMDA and AMPA glutamatergic signaling,<xref rid="R61" ref-type="bibr">61</xref><xref rid="R62" ref-type="bibr">62</xref><xref rid="R63" ref-type="bibr">63</xref><xref rid="R67" ref-type="bibr">67</xref> 25% xenon conferred neuroprotection after transient brain ischemia,<xref rid="R493" ref-type="bibr">493</xref> and 30% xenon attenuated human infantile asphyxial seizures.<xref rid="R276" ref-type="bibr">276</xref> Much lower xenon concentrations (0.5&#8211;1%) administered briefly to humans intraocularly inhibited the perception of and brain activation patterns associated with pain and its sensitization.<xref rid="R82" ref-type="bibr">82</xref> Microliter-volume xenon concentrations administered to neuronal cell cultures via lipid emulsions inhibited NMDA receptor currents.<xref rid="R69" ref-type="bibr">69</xref> Similarly, the administration of microliter xenon concentrations <italic toggle="yes">in vivo</italic> to rodents via liposomes increased the brain concentrations of BDNF and phosphorylated Akt (which inhibits GSK3) while exerting antidepressant effects.<xref rid="R120" ref-type="bibr">120</xref><xref rid="R236" ref-type="bibr">236</xref> In rodent brain injury studies, microliter volume xenon concentrations given once or repetitively conferred neuroprotection, preserved motor function, increased the expression of beneficial mediators including BDNF and phosphorylated Akt, or improved the gut microbiome.<xref rid="R117" ref-type="bibr">117</xref><xref rid="R195" ref-type="bibr">195</xref><xref rid="R275" ref-type="bibr">275</xref><xref rid="R494" ref-type="bibr">494</xref><xref rid="R495" ref-type="bibr">495</xref> An important focus for future research should be to expand our knowledge of the effects of xenon at low concentrations to determine threshold effective concentrations for different indications.</p></sec></sec><sec sec-type="conclusion" id="sec1-5"><title>Conclusions</title><p>This review illustrates that xenon has strong potential for therapeutic development to treat and possibly prevent opioid, alcohol, stimulant, and other SUDs, HIV, and certain cancers. By concurrently targeting multiple proteins that regulate SUD-related processes in beneficial ways, xenon could be more effective than more selective agents, e.g., glutamatergic NMDA receptor antagonists,<xref rid="R496" ref-type="bibr">496</xref><xref rid="R497" ref-type="bibr">497</xref> at inhibiting multiple stages in the chain of events that lead to or sustain SUDs, including alcohol or drug reward/preference, memory, tolerance, or physical, affective, or pain-related withdrawal symptoms, and the maladaptive memories they induce or strengthen (<bold><xref rid="mgr.MEDGASRES-D-24-00063-F8" ref-type="fig">Figure 8</xref></bold>).</p><fig position="float" id="mgr.MEDGASRES-D-24-00063-F8" orientation="portrait"><label>Figure 8</label><caption><p>Xenon multitargeting for SUDs.</p><p>Xenon has the potential to prevent or disrupt SUDs by concurrently interfering with multiple steps in the progression of feed forward effects that enable or sustain SUDs. The green and red arrows represent activating and inhibiting paths, respectively. SUDs: Substance use disorders; MR: memory reconsolidation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="MGR-15-234-g008.jpg"/></fig><p>While much is known about xenon&#8217;s targets and effects, many critical knowledge gaps exist. Xenon dose-effect and pharmacodynamics studies are needed to help identify optimal administration protocols to achieve beneficial effects. For example, could xenon be inhaled briefly after maladaptive memory reactivation to disrupt MR while sparing effects of xenon-sensitive extinction learning mechanisms? Abuse liability and safety testing are needed to determine whether xenon could be made available to patients for real-world on-demand use when maladaptive memories, physical withdrawal, or hyperkatifeia symptoms emerge. This is the time at which xenon, by attenuating maladaptive memories and symptoms that trigger risky drinking or substance use for reward or relief, could be especially beneficial, including by disrupting MR. This mode of treatment could help people resist future alcohol or drug urges or cravings. The potential of xenon to attenuate opioid tolerance merits study because mitigating opioid tolerance could reduce the risk that prescription opioid analgesic use will lead to OUD.</p><p>Given the numerous roles that GSK3 plays in moderating SUDs and other disorders and the fact that inhibition of its constitutive activity could amplify xenon&#8217;s multitargeting effects, it will be important to better understand how xenon affects GSK3&#945; and &#946; paralogs and differentially impacts cytosolic and nuclear processes in different cell types.<xref rid="R149" ref-type="bibr">149</xref><xref rid="R150" ref-type="bibr">150</xref><xref rid="R151" ref-type="bibr">151</xref> Furthermore, it will be important to characterize targets of potential therapeutic relevance, such as &#945;1 adrenergic receptors<xref rid="R42" ref-type="bibr">42</xref>, to determine whether xenon inhibits receptor activity under dosing conditions suitable for human use. Our hope is that this review will stimulate interest in conducting research to answer these questions, new ones that will emerge, and that future xenon research will lead to novel treatments that benefit people living with SUDs, HIV, cancers, and other disorders.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Conflicts of interest:</bold>
<italic toggle="yes">MJK and EGM are inventors on United States and European Union patents assigned to the McLean Hospital Corporation, covering the use of inhaled xenon gas as a treatment for psychiatric disorders and SUDs. They received past research support and royalties from Nobilis Therapeutics, Inc. MJK is a consultant for Pop Test Oncology LLC and Ria Technology Management, Inc.</italic></p></fn></fn-group><sec sec-type="data-availability"><title>Data availability statement</title><p><italic toggle="yes">No additional data are available</italic>.</p></sec><ref-list><title>References</title><ref id="R1"><label>1.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Latchaw</surname><given-names>RE</given-names></name><name name-style="western"><surname>Yonas</surname><given-names>H</given-names></name><name name-style="western"><surname>Pentheny</surname><given-names>SL</given-names></name><name name-style="western"><surname>Gur</surname><given-names>D</given-names></name></person-group><article-title>Adverse reactions to xenon-enhanced CT cerebral blood flow determination</article-title><source>Radiology</source><year>1987</year><volume>163</volume><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">3823444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiology.163.1.3823444</pub-id></element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Rossaint</surname><given-names>R</given-names></name><name name-style="western"><surname>Reyle-Hahn</surname><given-names>M</given-names></name><name name-style="western"><surname>Schulte Am Esch</surname><given-names>J</given-names></name><etal/></person-group><article-title>Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery</article-title><source>Anesthesiology</source><year>2003</year><volume>98</volume><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">12502972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200301000-00005</pub-id></element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>RD</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name><name name-style="western"><surname>Maze</surname><given-names>M</given-names></name></person-group><article-title>Xenon: elemental anaesthesia in clinical practice</article-title><source>Br Med Bull</source><year>2004</year><volume>71</volume><fpage>115</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">15728132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bmb/ldh034</pub-id></element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Carlson</surname><given-names>AP</given-names></name><name name-style="western"><surname>Brown</surname><given-names>AM</given-names></name><name name-style="western"><surname>Zager</surname><given-names>E</given-names></name><etal/></person-group><article-title>Xenon-enhanced cerebral blood flow at 28% xenon provides uniquely safe access to quantitative, clinically useful cerebral blood flow information: a multicenter study</article-title><source>AJNR Am J Neuroradiol</source><year>2011</year><volume>32</volume><fpage>1315</fpage><lpage>1320</lpage><pub-id pub-id-type="pmid">21700787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3174/ajnr.A2522</pub-id><pub-id pub-id-type="pmcid">PMC7966067</pub-id></element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Driehuys</surname><given-names>B</given-names></name><name name-style="western"><surname>Martinez-Jimenez</surname><given-names>S</given-names></name><name name-style="western"><surname>Cleveland</surname><given-names>ZI</given-names></name><etal/></person-group><article-title>Chronic obstructive pulmonary disease: safety and tolerability of hyperpolarized 129Xe MR imaging in healthy volunteers and patients</article-title><source>Radiology</source><year>2012</year><volume>262</volume><fpage>279</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">22056683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.11102172</pub-id><pub-id pub-id-type="pmcid">PMC3244666</pub-id></element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bedi</surname><given-names>A</given-names></name><name name-style="western"><surname>Murray</surname><given-names>JM</given-names></name><name name-style="western"><surname>Dingley</surname><given-names>J</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Fee</surname><given-names>JP</given-names></name></person-group><article-title>Use of xenon as a sedative for patients receiving critical care</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>2470</fpage><lpage>2477</lpage><pub-id pub-id-type="pmid">14530753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.CCM.0000089934.66049.76</pub-id></element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Esencan</surname><given-names>E</given-names></name><name name-style="western"><surname>Yuksel</surname><given-names>S</given-names></name><name name-style="western"><surname>Tosun</surname><given-names>YB</given-names></name><name name-style="western"><surname>Robinot</surname><given-names>A</given-names></name><name name-style="western"><surname>Solaroglu</surname><given-names>I</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>JH</given-names></name></person-group><article-title>XENON in medical area: emphasis on neuroprotection in hypoxia and anesthesia</article-title><source>Med Gas Res</source><year>2013</year><volume>3</volume><fpage>4</fpage><pub-id pub-id-type="pmid">23369273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/2045-9912-3-4</pub-id><pub-id pub-id-type="pmcid">PMC3626616</pub-id></element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Law</surname><given-names>LS</given-names></name><name name-style="western"><surname>Lo</surname><given-names>EA</given-names></name><name name-style="western"><surname>Gan</surname><given-names>TJ</given-names></name></person-group><article-title>Xenon anesthesia: a systematic review and meta-analysis of randomized controlled trials</article-title><source>Anesth Analg</source><year>2016</year><volume>122</volume><fpage>678</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">26273750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0000000000000914</pub-id></element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Shepelytskyi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Grynko</surname><given-names>V</given-names></name><name name-style="western"><surname>Rao</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Hyperpolarized (129) Xe imaging of the brain: Achievements and future challenges</article-title><source>Magn Reson Med</source><year>2022</year><volume>88</volume><fpage>83</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">35253919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrm.29200</pub-id><pub-id pub-id-type="pmcid">PMC9314594</pub-id></element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Anna</surname><given-names>R</given-names></name><name name-style="western"><surname>Rolf</surname><given-names>R</given-names></name><name name-style="western"><surname>Mark</surname><given-names>C</given-names></name></person-group><article-title>Update of the organoprotective properties of xenon and argon: from bench to beside</article-title><source>Intensive Care Med Exp</source><year>2020</year><volume>8</volume><fpage>11</fpage><pub-id pub-id-type="pmid">32096000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40635-020-0294-6</pub-id><pub-id pub-id-type="pmcid">PMC7040108</pub-id></element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zafonte</surname><given-names>RD</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Arbelaez</surname><given-names>CA</given-names></name><name name-style="western"><surname>Dennison</surname><given-names>R</given-names></name><name name-style="western"><surname>Teng</surname><given-names>YD</given-names></name></person-group><article-title>Medical gas therapy for tissue, organ, and CNS protection: a systematic review of effects, mechanisms, and challenges</article-title><source>Adv Sci (Weinh)</source><year>2022</year><volume>9</volume><fpage>e2104136</fpage><pub-id pub-id-type="pmid">35243825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202104136</pub-id><pub-id pub-id-type="pmcid">PMC9069381</pub-id></element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dickinson</surname><given-names>R</given-names></name><name name-style="western"><surname>Franks</surname><given-names>NP</given-names></name></person-group><article-title>Bench-to-bedside review: Molecular pharmacology and clinical use of inert gases in anesthesia and neuroprotection</article-title><source>Crit Care</source><year>2010</year><volume>14</volume><fpage>229</fpage><pub-id pub-id-type="pmid">20836899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc9051</pub-id><pub-id pub-id-type="pmcid">PMC2945072</pub-id></element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Alam</surname><given-names>A</given-names></name><name name-style="western"><surname>Suen</surname><given-names>KC</given-names></name><name name-style="western"><surname>Hana</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>RD</given-names></name><name name-style="western"><surname>Maze</surname><given-names>M</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name></person-group><article-title>Neuroprotection and neurotoxicity in the developing brain: an update on the effects of dexmedetomidine and xenon</article-title><source>Neurotoxicol Teratol</source><year>2017</year><volume>60</volume><fpage>102</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">28065636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ntt.2017.01.001</pub-id></element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name></person-group><article-title>The neuroprotective effect and possible therapeutic application of xenon in neurological diseases</article-title><source>J Neurosci Res</source><year>2021</year><volume>99</volume><fpage>3274</fpage><lpage>3283</lpage><pub-id pub-id-type="pmid">34716615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jnr.24958</pub-id></element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>M</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>F</given-names></name><name name-style="western"><surname>Dickinson</surname><given-names>R</given-names></name></person-group><article-title>Neuroprotection by the noble gases argon and xenon as treatments for acquired brain injury: a preclinical systematic review and meta-analysis</article-title><source>Br J Anaesth</source><year>2022</year><volume>129</volume><fpage>200</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">35688658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bja.2022.04.016</pub-id><pub-id pub-id-type="pmcid">PMC9428918</pub-id></element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name></person-group><article-title>Noble gas and neuroprotection: From bench to bedside</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><fpage>1028688</fpage><pub-id pub-id-type="pmid">36532733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.1028688</pub-id><pub-id pub-id-type="pmcid">PMC9750501</pub-id></element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Maze</surname><given-names>M</given-names></name><name name-style="western"><surname>Laitio</surname><given-names>T</given-names></name></person-group><article-title>Neuroprotective properties of xenon</article-title><source>Mol Neurobiol</source><year>2020</year><volume>57</volume><fpage>118</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">31758401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-019-01761-z</pub-id></element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Giacalone</surname><given-names>M</given-names></name><name name-style="western"><surname>Abramo</surname><given-names>A</given-names></name><name name-style="western"><surname>Giunta</surname><given-names>F</given-names></name><name name-style="western"><surname>Forfori</surname><given-names>F</given-names></name></person-group><article-title>Xenon-related analgesia: a new target for pain treatment</article-title><source>Clin J Pain</source><year>2013</year><volume>29</volume><fpage>639</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">23328329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AJP.0b013e31826b12f5</pub-id></element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dobrovolsky</surname><given-names>A</given-names></name><name name-style="western"><surname>Bogin</surname><given-names>V</given-names></name><name name-style="western"><surname>Meloni</surname><given-names>EG</given-names></name></person-group><article-title>Combining xenon inhalation with trauma memory reactivation to reduce symptoms of posttraumatic stress disorder: case report, justification of approach, and review of the literature</article-title><source>Prim Care Companion CNS Disord</source><year>2019</year><volume>21</volume><fpage>18nr02395</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.4088/PCC.18nr02395</pub-id><pub-id pub-id-type="pmid">31538751</pub-id></element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wiebelhaus</surname><given-names>N</given-names></name><name name-style="western"><surname>Singh</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Craig</surname><given-names>SL</given-names></name><name name-style="western"><surname>Beratan</surname><given-names>DN</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>MC</given-names></name></person-group><article-title>Discovery of the xenon-protein interactome using large-scale measurements of protein folding and stability</article-title><source>J Am Chem Soc</source><year>2022</year><volume>144</volume><fpage>3925</fpage><lpage>3938</lpage><pub-id pub-id-type="pmid">35213151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.1c11900</pub-id><pub-id pub-id-type="pmcid">PMC10166008</pub-id></element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Winkler</surname><given-names>DA</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>A</given-names></name><name name-style="western"><surname>Farjot</surname><given-names>G</given-names></name><name name-style="western"><surname>Katz</surname><given-names>I</given-names></name></person-group><article-title>The diverse biological properties of the chemically inert noble gases</article-title><source>Pharmacol Ther</source><year>2016</year><volume>160</volume><fpage>44</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">26896563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2016.02.002</pub-id></element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Winkler</surname><given-names>DA</given-names></name><name name-style="western"><surname>Katz</surname><given-names>I</given-names></name><name name-style="western"><surname>Warden</surname><given-names>A</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>AW</given-names></name><name name-style="western"><surname>Farjot</surname><given-names>G</given-names></name></person-group><article-title>Identifying medically relevant xenon protein targets by in silico screening of the structural proteome</article-title><source>Med Gas Res</source><year>2023</year><volume>13</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">35946221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/2045-9912.333858</pub-id><pub-id pub-id-type="pmcid">PMC9480358</pub-id></element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>McGuigan</surname><given-names>S</given-names></name><name name-style="western"><surname>Marie</surname><given-names>DJ</given-names></name><name name-style="western"><surname>O&#8217;Bryan</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>The cellular mechanisms associated with the anesthetic and neuroprotective properties of xenon: a systematic review of the preclinical literature</article-title><source>Front Neurosci</source><year>2023</year><volume>17</volume><fpage>1225191</fpage><pub-id pub-id-type="pmid">37521706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2023.1225191</pub-id><pub-id pub-id-type="pmcid">PMC10380949</pub-id></element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>HN</given-names></name><name name-style="western"><surname>Ansseau</surname><given-names>M</given-names></name><name name-style="western"><surname>Lemaire</surname><given-names>M</given-names></name><name name-style="western"><surname>Abraini</surname><given-names>JH</given-names></name></person-group><article-title>Nitrous oxide and xenon prevent amphetamine-induced carrier-mediated dopamine release in a memantine-like fashion and protect against behavioral sensitization</article-title><source>Biol Psychiatry</source><year>2006</year><volume>60</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">16427030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2005.10.007</pub-id></element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Sakamoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Nakao</surname><given-names>S</given-names></name><name name-style="western"><surname>Masuzawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>The differential effects of nitrous oxide and xenon on extracellular dopamine levels in the rat nucleus accumbens: a microdialysis study</article-title><source>Anesth Analg</source><year>2006</year><volume>103</volume><fpage>1459</fpage><lpage>1463</lpage><pub-id pub-id-type="pmid">17122223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/01.ane.0000247792.03959.f1</pub-id></element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Vengeliene</surname><given-names>V</given-names></name><name name-style="western"><surname>Bessiere</surname><given-names>B</given-names></name><name name-style="western"><surname>Pype</surname><given-names>J</given-names></name><name name-style="western"><surname>Spanagel</surname><given-names>R</given-names></name></person-group><article-title>The effects of xenon and nitrous oxide gases on alcohol relapse</article-title><source>Alcohol Clin Exp Res</source><year>2014</year><volume>38</volume><fpage>557</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">24118055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acer.12264</pub-id></element-citation></ref><ref id="R27"><label>27.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Meloni</surname><given-names>EG</given-names></name><name name-style="western"><surname>Qrareya</surname><given-names>AN</given-names></name><name name-style="western"><surname>Paronis</surname><given-names>CA</given-names></name><name name-style="western"><surname>Bogin</surname><given-names>V</given-names></name></person-group><article-title>Effects of inhaled low-concentration xenon gas on naltrexone-precipitated withdrawal symptoms in morphine-dependent mice</article-title><source>Drug Alcohol Depend</source><year>2024</year><volume>255</volume><fpage>110967</fpage><pub-id pub-id-type="pmid">38150894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2023.110967</pub-id><pub-id pub-id-type="pmcid">PMC10841182</pub-id></element-citation></ref><ref id="R28"><label>28.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Tzigankov</surname><given-names>BD</given-names></name><name name-style="western"><surname>Shamov</surname><given-names>SA</given-names></name><name name-style="western"><surname>Rykhletskiy</surname><given-names>PZ</given-names></name><name name-style="western"><surname>Davletov</surname><given-names>LA</given-names></name></person-group><article-title>The possibilities of xenon application in complex therapy of psycho-pathologic disorders in patients of narcologic profile</article-title><source>Ross Med Zh</source><year>2013</year><volume>19</volume><fpage>11</fpage><lpage>14</lpage></element-citation></ref><ref id="R29"><label>29.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Koob</surname><given-names>GF</given-names></name></person-group><article-title>Drug addiction: hyperkatifeia/negative reinforcement as a framework for medications development</article-title><source>Pharmacol Rev</source><year>2021</year><volume>73</volume><fpage>163</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">33318153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/pharmrev.120.000083</pub-id><pub-id pub-id-type="pmcid">PMC7770492</pub-id></element-citation></ref><ref id="R30"><label>30.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kessler</surname><given-names>RC</given-names></name></person-group><article-title>The epidemiology of dual diagnosis</article-title><source>Biol Psychiatry</source><year>2004</year><volume>56</volume><fpage>730</fpage><lpage>737</lpage><pub-id pub-id-type="pmid">15556117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2004.06.034</pub-id></element-citation></ref><ref id="R31"><label>31.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>DeMarce</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lash</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>RS</given-names></name><name name-style="western"><surname>Grambow</surname><given-names>SC</given-names></name><name name-style="western"><surname>Burden</surname><given-names>JL</given-names></name></person-group><article-title>Promoting continuing care adherence among substance abusers with co-occurring psychiatric disorders following residential treatment</article-title><source>Addict Behav</source><year>2008</year><volume>33</volume><fpage>1104</fpage><lpage>1112</lpage><pub-id pub-id-type="pmid">18573617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addbeh.2008.02.008</pub-id></element-citation></ref><ref id="R32"><label>32.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Berenz</surname><given-names>EC</given-names></name><name name-style="western"><surname>Coffey</surname><given-names>SF</given-names></name></person-group><article-title>Treatment of co-occurring posttraumatic stress disorder and substance use disorders</article-title><source>Curr Psychiatry Rep</source><year>2012</year><volume>14</volume><fpage>469</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">22825992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11920-012-0300-0</pub-id><pub-id pub-id-type="pmcid">PMC3466083</pub-id></element-citation></ref><ref id="R33"><label>33.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Torrens</surname><given-names>M</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>PC</given-names></name><name name-style="western"><surname>Martinez-Riera</surname><given-names>R</given-names></name><name name-style="western"><surname>Martinez-Sanvisens</surname><given-names>D</given-names></name><name name-style="western"><surname>Bulbena</surname><given-names>A</given-names></name></person-group><article-title>Psychiatric co-morbidity and substance use disorders: treatment in parallel systems or in one integrated system?</article-title><source>Subst Use Misuse</source><year>2012</year><volume>47</volume><fpage>1005</fpage><lpage>1014</lpage><pub-id pub-id-type="pmid">22676568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/10826084.2012.663296</pub-id></element-citation></ref><ref id="R34"><label>34.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Teeters</surname><given-names>JB</given-names></name><name name-style="western"><surname>Lancaster</surname><given-names>CL</given-names></name><name name-style="western"><surname>Brown</surname><given-names>DG</given-names></name><name name-style="western"><surname>Back</surname><given-names>SE</given-names></name></person-group><article-title>Substance use disorders in military veterans: prevalence and treatment challenges</article-title><source>Subst Abuse Rehabil</source><year>2017</year><volume>8</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">28919834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/SAR.S116720</pub-id><pub-id pub-id-type="pmcid">PMC5587184</pub-id></element-citation></ref><ref id="R35"><label>35.</label><element-citation publication-type="book" publication-format="print"><person-group person-group-type="author"><collab>National Institute on Drug Abuse (US)</collab></person-group><article-title>Common comorbidities with substance use disorders</article-title><source>Research Report</source><publisher-loc>Bethesda, MD</publisher-loc><publisher-name>DHHS</publisher-name><year>2020</year><pub-id pub-id-type="pmid">34185444</pub-id></element-citation></ref><ref id="R36"><label>36.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Meloni</surname><given-names>EG</given-names></name><name name-style="western"><surname>Gillis</surname><given-names>TE</given-names></name><name name-style="western"><surname>Manoukian</surname><given-names>J</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>MJ</given-names></name></person-group><article-title>Xenon impairs reconsolidation of fear memories in a rat model of post-traumatic stress disorder (PTSD)</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e106189</fpage><pub-id pub-id-type="pmid">25162644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0106189</pub-id><pub-id pub-id-type="pmcid">PMC4146606</pub-id></element-citation></ref><ref id="R37"><label>37.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Milton</surname><given-names>AL</given-names></name></person-group><article-title>Drug memory reconsolidation: from molecular mechanisms to the clinical context</article-title><source>Transl Psychiatry</source><year>2023</year><volume>13</volume><fpage>370</fpage><pub-id pub-id-type="pmid">38040677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-023-02666-1</pub-id><pub-id pub-id-type="pmcid">PMC10692359</pub-id></element-citation></ref><ref id="R38"><label>38.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kosten</surname><given-names>TR</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>PG</given-names></name></person-group><article-title>Management of drug and alcohol withdrawal</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>1786</fpage><lpage>1795</lpage><pub-id pub-id-type="pmid">12724485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra020617</pub-id></element-citation></ref><ref id="R39"><label>39.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kosten</surname><given-names>TR</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>LE</given-names></name></person-group><article-title>Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment</article-title><source>Am J Addict</source><year>2019</year><volume>28</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">30701615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajad.12862</pub-id><pub-id pub-id-type="pmcid">PMC6590307</pub-id></element-citation></ref><ref id="R40"><label>40.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Colloc&#8217;h</surname><given-names>N</given-names></name><name name-style="western"><surname>Sopkova-de Oliveira Santos</surname><given-names>J</given-names></name><name name-style="western"><surname>Retailleau</surname><given-names>P</given-names></name><etal/></person-group><article-title>Protein crystallography under xenon and nitrous oxide pressure: comparison with in vivo pharmacology studies and implications for the mechanism of inhaled anesthetic action</article-title><source>Biophys J</source><year>2007</year><volume>92</volume><fpage>217</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">17028130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1529/biophysj.106.093807</pub-id><pub-id pub-id-type="pmcid">PMC1697869</pub-id></element-citation></ref><ref id="R41"><label>41.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Roose</surname><given-names>BW</given-names></name><name name-style="western"><surname>Zemerov</surname><given-names>SD</given-names></name><name name-style="western"><surname>Dmochowski</surname><given-names>IJ</given-names></name></person-group><article-title>Xenon-protein interactions: characterization by X-ray crystallography and hyper-CEST NMR</article-title><source>Methods Enzymol</source><year>2018</year><volume>602</volume><fpage>249</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">29588032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.mie.2018.02.005</pub-id><pub-id pub-id-type="pmcid">PMC6467505</pub-id></element-citation></ref><ref id="R42"><label>42.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Abiko</surname><given-names>LA</given-names></name><name name-style="western"><surname>Dias Teixeira</surname><given-names>R</given-names></name><name name-style="western"><surname>Engilberge</surname><given-names>S</given-names></name><etal/></person-group><article-title>Filling of a water-free void explains the allosteric regulation of the &#946;(1)-adrenergic receptor by cholesterol</article-title><source>Nat Chem</source><year>2022</year><volume>14</volume><fpage>1133</fpage><lpage>1141</lpage><pub-id pub-id-type="pmid">35953642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41557-022-01009-9</pub-id></element-citation></ref><ref id="R43"><label>43.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Weinrich</surname><given-names>M</given-names></name><name name-style="western"><surname>Worcester</surname><given-names>DL</given-names></name></person-group><article-title>Xenon and other volatile anesthetics change domain structure in model lipid raft membranes</article-title><source>J Phys Chem B</source><year>2013</year><volume>117</volume><fpage>16141</fpage><lpage>16147</lpage><pub-id pub-id-type="pmid">24299622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jp411261g</pub-id><pub-id pub-id-type="pmcid">PMC3914297</pub-id></element-citation></ref><ref id="R44"><label>44.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Pavel</surname><given-names>MA</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>EN</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Lerner</surname><given-names>RA</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>SB</given-names></name></person-group><article-title>Studies on the mechanism of general anesthesia</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year><volume>117</volume><fpage>13757</fpage><lpage>13766</lpage><pub-id pub-id-type="pmid">32467161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2004259117</pub-id><pub-id pub-id-type="pmcid">PMC7306821</pub-id></element-citation></ref><ref id="R45"><label>45.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Reyes-Figueroa</surname><given-names>AD</given-names></name><name name-style="western"><surname>Karttunen</surname><given-names>M</given-names></name><name name-style="western"><surname>Ruiz-Su&#225;rez</surname><given-names>JC</given-names></name></person-group><article-title>Cholesterol sequestration by xenon nano bubbles leads to lipid raft destabilization</article-title><source>Soft Matter</source><year>2020</year><volume>16</volume><fpage>9655</fpage><lpage>9661</lpage><pub-id pub-id-type="pmid">33078812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0sm01256d</pub-id></element-citation></ref><ref id="R46"><label>46.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hyman</surname><given-names>SE</given-names></name></person-group><article-title>Addiction: a disease of learning and memory</article-title><source>Am J Psychiatry</source><year>2005</year><volume>162</volume><fpage>1414</fpage><lpage>1422</lpage><pub-id pub-id-type="pmid">16055762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.162.8.1414</pub-id></element-citation></ref><ref id="R47"><label>47.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Tronson</surname><given-names>NC</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>JR</given-names></name></person-group><article-title>Molecular mechanisms of memory reconsolidation</article-title><source>Nat Rev Neurosci</source><year>2007</year><volume>8</volume><fpage>262</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">17342174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn2090</pub-id></element-citation></ref><ref id="R48"><label>48.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Reichelt</surname><given-names>AC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JL</given-names></name></person-group><article-title>Memory reconsolidation in aversive and appetitive settings</article-title><source>Front Behav Neurosci</source><year>2013</year><volume>7</volume><fpage>118</fpage><pub-id pub-id-type="pmid">24058336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnbeh.2013.00118</pub-id><pub-id pub-id-type="pmcid">PMC3766793</pub-id></element-citation></ref><ref id="R49"><label>49.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wideman</surname><given-names>CE</given-names></name><name name-style="western"><surname>Jardine</surname><given-names>KH</given-names></name><name name-style="western"><surname>Winters</surname><given-names>BD</given-names></name></person-group><article-title>Involvement of classical neurotransmitter systems in memory reconsolidation: Focus on destabilization</article-title><source>Neurobiol Learn Mem</source><year>2018</year><volume>156</volume><fpage>68</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">30395938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nlm.2018.11.001</pub-id></element-citation></ref><ref id="R50"><label>50.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Vafaie</surname><given-names>N</given-names></name><name name-style="western"><surname>Kober</surname><given-names>H</given-names></name></person-group><article-title>Association of drug cues and craving with drug use and relapse: a systematic review and meta-analysis</article-title><source>JAMA Psychiatry</source><year>2022</year><volume>79</volume><fpage>641</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">35648415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2022.1240</pub-id><pub-id pub-id-type="pmcid">PMC9161117</pub-id></element-citation></ref><ref id="R51"><label>51.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Vizcaychipi</surname><given-names>MP</given-names></name><name name-style="western"><surname>Lloyd</surname><given-names>DG</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Palazzo</surname><given-names>MG</given-names></name><name name-style="western"><surname>Maze</surname><given-names>M</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name></person-group><article-title>Xenon pretreatment may prevent early memory decline after isoflurane anesthesia and surgery in mice</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e26394</fpage><pub-id pub-id-type="pmid">22073162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0026394</pub-id><pub-id pub-id-type="pmcid">PMC3207823</pub-id></element-citation></ref><ref id="R52"><label>52.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Przybyslawski</surname><given-names>J</given-names></name><name name-style="western"><surname>Sara</surname><given-names>SJ</given-names></name></person-group><article-title>Reconsolidation of memory after its reactivation</article-title><source>Behav Brain Res</source><year>1997</year><volume>84</volume><fpage>241</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">9079788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0166-4328(96)00153-2</pub-id></element-citation></ref><ref id="R53"><label>53.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Nader</surname><given-names>K</given-names></name><name name-style="western"><surname>Schafe</surname><given-names>GE</given-names></name><name name-style="western"><surname>Le Doux</surname><given-names>JE</given-names></name></person-group><article-title>Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval</article-title><source>Nature</source><year>2000</year><volume>406</volume><fpage>722</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">10963596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35021052</pub-id></element-citation></ref><ref id="R54"><label>54.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Agren</surname><given-names>H</given-names></name><name name-style="western"><surname>Terenius</surname><given-names>L</given-names></name></person-group><article-title>Depression and CSF endorphin fraction I: seasonal variation and higher levels in unipolar than bipolar patients</article-title><source>Psychiatry Res</source><year>1983</year><volume>10</volume><fpage>303</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">6583719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-1781(83)90077-x</pub-id></element-citation></ref><ref id="R55"><label>55.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Franks</surname><given-names>NP</given-names></name><name name-style="western"><surname>Dickinson</surname><given-names>R</given-names></name><name name-style="western"><surname>de Sousa</surname><given-names>SL</given-names></name><name name-style="western"><surname>Hall</surname><given-names>AC</given-names></name><name name-style="western"><surname>Lieb</surname><given-names>WR</given-names></name></person-group><article-title>How does xenon produce anaesthesia?</article-title><source>Nature</source><year>1998</year><volume>396</volume><fpage>324</fpage><pub-id pub-id-type="pmid">9845069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/24525</pub-id></element-citation></ref><ref id="R56"><label>56.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yamakura</surname><given-names>T</given-names></name><name name-style="western"><surname>Harris</surname><given-names>RA</given-names></name></person-group><article-title>Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol</article-title><source>Anesthesiology</source><year>2000</year><volume>93</volume><fpage>1095</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">11020766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200010000-00034</pub-id></element-citation></ref><ref id="R57"><label>57.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>HN</given-names></name><name name-style="western"><surname>Leveille</surname><given-names>F</given-names></name><name name-style="western"><surname>Chazalviel</surname><given-names>L</given-names></name><etal/></person-group><article-title>Reduction of ischemic brain damage by nitrous oxide and xenon</article-title><source>J Cereb Blood Flow Metab</source><year>2003</year><volume>23</volume><fpage>1168</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">14526227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.WCB.0000087342.31689.18</pub-id></element-citation></ref><ref id="R58"><label>58.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Plested</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Wildman</surname><given-names>SS</given-names></name><name name-style="western"><surname>Lieb</surname><given-names>WR</given-names></name><name name-style="western"><surname>Franks</surname><given-names>NP</given-names></name></person-group><article-title>Determinants of the sensitivity of AMPA receptors to xenon</article-title><source>Anesthesiology</source><year>2004</year><volume>100</volume><fpage>347</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">14739810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200402000-00025</pub-id></element-citation></ref><ref id="R59"><label>59.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dinse</surname><given-names>A</given-names></name><name name-style="western"><surname>F&#246;hr</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Georgieff</surname><given-names>M</given-names></name><name name-style="western"><surname>Beyer</surname><given-names>C</given-names></name><name name-style="western"><surname>Bulling</surname><given-names>A</given-names></name><name name-style="western"><surname>Weigt</surname><given-names>HU</given-names></name></person-group><article-title>Xenon reduces glutamate-, AMPA-, and kainate-induced membrane currents in cortical neurones</article-title><source>Br J Anaesth</source><year>2005</year><volume>94</volume><fpage>479</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">15695547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/aei080</pub-id></element-citation></ref><ref id="R60"><label>60.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dickinson</surname><given-names>R</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>BK</given-names></name><name name-style="western"><surname>Banks</surname><given-names>P</given-names></name><etal/></person-group><article-title>Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor by the anesthetics xenon and isoflurane: evidence from molecular modeling and electrophysiology</article-title><source>Anesthesiology</source><year>2007</year><volume>107</volume><fpage>756</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">18073551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.anes.0000287061.77674.71</pub-id></element-citation></ref><ref id="R61"><label>61.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Haseneder</surname><given-names>R</given-names></name><name name-style="western"><surname>Kratzer</surname><given-names>S</given-names></name><name name-style="western"><surname>Kochs</surname><given-names>E</given-names></name><name name-style="western"><surname>Eckle</surname><given-names>VS</given-names></name><name name-style="western"><surname>Zieglg&#228;nsberger</surname><given-names>W</given-names></name><name name-style="western"><surname>Rammes</surname><given-names>G</given-names></name></person-group><article-title>Xenon reduces N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-mediated synaptic transmission in the amygdala</article-title><source>Anesthesiology</source><year>2008</year><volume>109</volume><fpage>998</fpage><lpage>1006</lpage><pub-id pub-id-type="pmid">19034096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0b013e31818d6aee</pub-id></element-citation></ref><ref id="R62"><label>62.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Haseneder</surname><given-names>R</given-names></name><name name-style="western"><surname>Kratzer</surname><given-names>S</given-names></name><name name-style="western"><surname>Kochs</surname><given-names>E</given-names></name><name name-style="western"><surname>Mattusch</surname><given-names>C</given-names></name><name name-style="western"><surname>Eder</surname><given-names>M</given-names></name><name name-style="western"><surname>Rammes</surname><given-names>G</given-names></name></person-group><article-title>Xenon attenuates excitatory synaptic transmission in the rodent prefrontal cortex and spinal cord dorsal horn</article-title><source>Anesthesiology</source><year>2009</year><volume>111</volume><fpage>1297</fpage><lpage>1307</lpage><pub-id pub-id-type="pmid">19934875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0b013e3181c14c05</pub-id></element-citation></ref><ref id="R63"><label>63.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Haseneder</surname><given-names>R</given-names></name><name name-style="western"><surname>Kratzer</surname><given-names>S</given-names></name><name name-style="western"><surname>Kochs</surname><given-names>E</given-names></name><etal/></person-group><article-title>The xenon-mediated antagonism against the NMDA receptor is non-selective for receptors containing either NR2A or NR2B subunits in the mouse amygdala</article-title><source>Eur J Pharmacol</source><year>2009</year><volume>619</volume><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">19686722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2009.08.011</pub-id></element-citation></ref><ref id="R64"><label>64.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Weigt</surname><given-names>HU</given-names></name><name name-style="western"><surname>Fohr</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Georgieff</surname><given-names>M</given-names></name><name name-style="western"><surname>Georgieff</surname><given-names>EM</given-names></name><name name-style="western"><surname>Senftleben</surname><given-names>U</given-names></name><name name-style="western"><surname>Adolph</surname><given-names>O</given-names></name></person-group><article-title>Xenon blocks AMPA and NMDA receptor channels by different mechanisms</article-title><source>Acta Neurobiol Exp (Wars)</source><year>2009</year><volume>69</volume><fpage>429</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">20048760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.55782/ane-2009-1754</pub-id></element-citation></ref><ref id="R65"><label>65.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kratzer</surname><given-names>S</given-names></name><name name-style="western"><surname>Mattusch</surname><given-names>C</given-names></name><name name-style="western"><surname>Kochs</surname><given-names>E</given-names></name><name name-style="western"><surname>Eder</surname><given-names>M</given-names></name><name name-style="western"><surname>Haseneder</surname><given-names>R</given-names></name><name name-style="western"><surname>Rammes</surname><given-names>G</given-names></name></person-group><article-title>Xenon attenuates hippocampal long-term potentiation by diminishing synaptic and extrasynaptic N-methyl-D-aspartate receptor currents</article-title><source>Anesthesiology</source><year>2012</year><volume>116</volume><fpage>673</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">22293720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0b013e3182475d66</pub-id></element-citation></ref><ref id="R66"><label>66.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>K</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>SP</given-names></name><name name-style="western"><surname>Campos-Pires</surname><given-names>R</given-names></name><name name-style="western"><surname>Kiru</surname><given-names>L</given-names></name><name name-style="western"><surname>Franks</surname><given-names>NP</given-names></name><name name-style="western"><surname>Dickinson</surname><given-names>R</given-names></name></person-group><article-title>Neuroprotection against traumatic brain injury by xenon, but not argon, is mediated by inhibition at the N-methyl-D-aspartate receptor glycine site</article-title><source>Anesthesiology</source><year>2013</year><volume>119</volume><fpage>1137</fpage><lpage>1148</lpage><pub-id pub-id-type="pmid">23867231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0b013e3182a2a265</pub-id></element-citation></ref><ref id="R67"><label>67.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Nonaka</surname><given-names>K</given-names></name><name name-style="western"><surname>Kotani</surname><given-names>N</given-names></name><name name-style="western"><surname>Akaike</surname><given-names>H</given-names></name><etal/></person-group><article-title>Xenon modulates synaptic transmission to rat hippocampal CA3 neurons at both pre- and postsynaptic sites</article-title><source>J Physiol</source><year>2019</year><volume>597</volume><fpage>5915</fpage><lpage>5933</lpage><pub-id pub-id-type="pmid">31598974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1113/JP278762</pub-id></element-citation></ref><ref id="R68"><label>68.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kotani</surname><given-names>N</given-names></name><name name-style="western"><surname>Jang</surname><given-names>IS</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M</given-names></name><name name-style="western"><surname>Nonaka</surname><given-names>K</given-names></name><name name-style="western"><surname>Nagami</surname><given-names>H</given-names></name><name name-style="western"><surname>Akaike</surname><given-names>N</given-names></name></person-group><article-title>Depression of Synaptic N-methyl-D-Aspartate Responses by Xenon and Nitrous Oxide</article-title><source>J Pharmacol Exp Ther</source><year>2023</year><volume>384</volume><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">36272733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.122.001346</pub-id></element-citation></ref><ref id="R69"><label>69.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Weigt</surname><given-names>HU</given-names></name><name name-style="western"><surname>Georgieff</surname><given-names>M</given-names></name><name name-style="western"><surname>Beyer</surname><given-names>C</given-names></name><name name-style="western"><surname>Wachter</surname><given-names>U</given-names></name><name name-style="western"><surname>F&#246;hr</surname><given-names>KJ</given-names></name></person-group><article-title>Xenon incorporated in a lipid emulsion inhibits NMDA receptor channels</article-title><source>Acta Anaesthesiol Scand</source><year>2003</year><volume>47</volume><fpage>1119</fpage><lpage>1124</lpage><pub-id pub-id-type="pmid">12969106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1034/j.1399-6576.2003.00221.x</pub-id></element-citation></ref><ref id="R70"><label>70.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Weigt</surname><given-names>HU</given-names></name><name name-style="western"><surname>Adolph</surname><given-names>O</given-names></name><name name-style="western"><surname>Georgieff</surname><given-names>M</given-names></name><name name-style="western"><surname>Georgieff</surname><given-names>EM</given-names></name><name name-style="western"><surname>F&#246;hr</surname><given-names>KJ</given-names></name></person-group><article-title>Evidence that Xenon does not produce open channel blockade of the NMDA receptor</article-title><source>J Neurophysiol</source><year>2008</year><volume>99</volume><fpage>1983</fpage><lpage>1987</lpage><pub-id pub-id-type="pmid">18234987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/jn.00631.2007</pub-id></element-citation></ref><ref id="R71"><label>71.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Georgiev</surname><given-names>SK</given-names></name><name name-style="western"><surname>Furue</surname><given-names>H</given-names></name><name name-style="western"><surname>Baba</surname><given-names>H</given-names></name><name name-style="western"><surname>Kohno</surname><given-names>T</given-names></name></person-group><article-title>Xenon inhibits excitatory but not inhibitory transmission in rat spinal cord dorsal horn neurons</article-title><source>Mol Pain</source><year>2010</year><volume>6</volume><fpage>25</fpage><pub-id pub-id-type="pmid">20444263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1744-8069-6-25</pub-id><pub-id pub-id-type="pmcid">PMC2873505</pub-id></element-citation></ref><ref id="R72"><label>72.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ogata</surname><given-names>J</given-names></name><name name-style="western"><surname>Shiraishi</surname><given-names>M</given-names></name><name name-style="western"><surname>Namba</surname><given-names>T</given-names></name><name name-style="western"><surname>Smothers</surname><given-names>CT</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Harris</surname><given-names>RA</given-names></name></person-group><article-title>Effects of anesthetics on mutant N-methyl-D-aspartate receptors expressed in Xenopus oocytes</article-title><source>J Pharmacol Exp Ther</source><year>2006</year><volume>318</volume><fpage>434</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">16622040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.106.101691</pub-id></element-citation></ref><ref id="R73"><label>73.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>RK</given-names></name><name name-style="western"><surname>Gale</surname><given-names>G</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>K</given-names></name><etal/></person-group><article-title>Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>5187</fpage><pub-id pub-id-type="pmid">31772157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-13162-w</pub-id><pub-id pub-id-type="pmcid">PMC6879579</pub-id></element-citation></ref><ref id="R74"><label>74.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>RK</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>K</given-names></name><name name-style="western"><surname>Hannaford</surname><given-names>J</given-names></name><name name-style="western"><surname>Lazzarino</surname><given-names>AI</given-names></name><name name-style="western"><surname>Kamboj</surname><given-names>SK</given-names></name></person-group><article-title>Nitrous oxide may interfere with the reconsolidation of drinking memories in hazardous drinkers in a prediction-error-dependent manner</article-title><source>Eur Neuropsychopharmacol</source><year>2018</year><volume>28</volume><fpage>828</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">29887289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.euroneuro.2018.05.001</pub-id></element-citation></ref><ref id="R75"><label>75.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>AB</given-names></name><name name-style="western"><surname>Mariani</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Levin</surname><given-names>FR</given-names></name></person-group><article-title>New directions in the treatment of opioid withdrawal</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1938</fpage><lpage>1948</lpage><pub-id pub-id-type="pmid">32563380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30852-7</pub-id><pub-id pub-id-type="pmcid">PMC7385662</pub-id></element-citation></ref><ref id="R76"><label>76.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yue</surname><given-names>JL</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>K</given-names></name><name name-style="western"><surname>Bao</surname><given-names>YP</given-names></name><etal/></person-group><article-title>The effect of a methadone-initiated memory reconsolidation updating procedure in opioid use disorder: a translational study</article-title><source>EBioMedicine</source><year>2022</year><volume>85</volume><fpage>104283</fpage><pub-id pub-id-type="pmid">36182773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2022.104283</pub-id><pub-id pub-id-type="pmcid">PMC9525804</pub-id></element-citation></ref><ref id="R77"><label>77.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Gale</surname><given-names>G</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>K</given-names></name><name name-style="western"><surname>Hennessy</surname><given-names>VE</given-names></name><etal/></person-group><article-title>Long-term behavioural rewriting of maladaptive drinking memories via reconsolidation-update mechanisms</article-title><source>Psychol Med</source><year>2021</year><volume>51</volume><fpage>2875</fpage><lpage>2885</lpage><pub-id pub-id-type="pmid">32539883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0033291720001531</pub-id></element-citation></ref><ref id="R78"><label>78.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>YX</given-names></name><name name-style="western"><surname>Luo</surname><given-names>YX</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><etal/></person-group><article-title>A memory retrieval-extinction procedure to prevent drug craving and relapse</article-title><source>Science</source><year>2012</year><volume>336</volume><fpage>241</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">22499948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1215070</pub-id><pub-id pub-id-type="pmcid">PMC3695463</pub-id></element-citation></ref><ref id="R79"><label>79.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>A</given-names></name><name name-style="western"><surname>Josselyn</surname><given-names>SA</given-names></name><name name-style="western"><surname>Frankland</surname><given-names>PW</given-names></name><name name-style="western"><surname>Masushige</surname><given-names>S</given-names></name><name name-style="western"><surname>Silva</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Kida</surname><given-names>S</given-names></name></person-group><article-title>Memory reconsolidation and extinction have distinct temporal and biochemical signatures</article-title><source>J Neurosci</source><year>2004</year><volume>24</volume><fpage>4787</fpage><lpage>4795</lpage><pub-id pub-id-type="pmid">15152039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5491-03.2004</pub-id><pub-id pub-id-type="pmcid">PMC6729467</pub-id></element-citation></ref><ref id="R80"><label>80.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Lebois</surname><given-names>LAM</given-names></name><name name-style="western"><surname>Seligowski</surname><given-names>AV</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>JD</given-names></name><name name-style="western"><surname>Hill</surname><given-names>SB</given-names></name><name name-style="western"><surname>Ressler</surname><given-names>KJ</given-names></name></person-group><article-title>Augmentation of extinction and inhibitory learning in anxiety and trauma-related disorders</article-title><source>Annu Rev Clin Psychol</source><year>2019</year><volume>15</volume><fpage>257</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">30698994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-clinpsy-050718-095634</pub-id><pub-id pub-id-type="pmcid">PMC6547363</pub-id></element-citation></ref><ref id="R81"><label>81.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JL</given-names></name><name name-style="western"><surname>Milton</surname><given-names>AL</given-names></name><name name-style="western"><surname>Everitt</surname><given-names>BJ</given-names></name></person-group><article-title>Reconsolidation and extinction of conditioned fear: inhibition and potentiation</article-title><source>J Neurosci</source><year>2006</year><volume>26</volume><fpage>10051</fpage><lpage>10056</lpage><pub-id pub-id-type="pmid">17005868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2466-06.2006</pub-id><pub-id pub-id-type="pmcid">PMC6674482</pub-id></element-citation></ref><ref id="R82"><label>82.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Adolph</surname><given-names>O</given-names></name><name name-style="western"><surname>K&#246;ster</surname><given-names>S</given-names></name><name name-style="western"><surname>Georgieff</surname><given-names>M</given-names></name><etal/></person-group><article-title>Xenon-induced changes in CNS sensitization to pain</article-title><source>Neuroimage</source><year>2010</year><volume>49</volume><fpage>720</fpage><lpage>730</lpage><pub-id pub-id-type="pmid">19703572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2009.08.034</pub-id></element-citation></ref><ref id="R83"><label>83.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Nalos</surname><given-names>M</given-names></name><name name-style="western"><surname>Wachter</surname><given-names>U</given-names></name><name name-style="western"><surname>Pittner</surname><given-names>A</given-names></name><name name-style="western"><surname>Georgieff</surname><given-names>M</given-names></name><name name-style="western"><surname>Radermacher</surname><given-names>P</given-names></name><name name-style="western"><surname>Froeba</surname><given-names>G</given-names></name></person-group><article-title>Arterial and mixed venous xenon blood concentrations in pigs during wash-in of inhalational anaesthesia</article-title><source>Br J Anaesth</source><year>2001</year><volume>87</volume><fpage>497</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">11517138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/87.3.497</pub-id></element-citation></ref><ref id="R84"><label>84.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Froeba</surname><given-names>G</given-names></name><name name-style="western"><surname>Georgieff</surname><given-names>M</given-names></name><name name-style="western"><surname>Linder</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Intranasal application of xenon: describing the pharmacokinetics in experimental animals and the increased pain tolerance within a placebo-controlled experimental human study</article-title><source>Br J Anaesth</source><year>2010</year><volume>104</volume><fpage>351</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">20118146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/aep395</pub-id></element-citation></ref><ref id="R85"><label>85.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Katz</surname><given-names>I</given-names></name><name name-style="western"><surname>Murdock</surname><given-names>J</given-names></name><name name-style="western"><surname>Palgen</surname><given-names>M</given-names></name><name name-style="western"><surname>Pype</surname><given-names>J</given-names></name><name name-style="western"><surname>Caillibotte</surname><given-names>G</given-names></name></person-group><article-title>Pharmacokinetic analysis of the chronic administration of the inert gases Xe and Ar using a physiological based model</article-title><source>Med Gas Res</source><year>2015</year><volume>5</volume><fpage>8</fpage><pub-id pub-id-type="pmid">26113973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13618-015-0029-z</pub-id><pub-id pub-id-type="pmcid">PMC4480577</pub-id></element-citation></ref><ref id="R86"><label>86.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Schaefer</surname><given-names>MS</given-names></name><name name-style="western"><surname>Piper</surname><given-names>T</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>H</given-names></name><etal/></person-group><article-title>Xenon elimination kinetics following brief exposure</article-title><source>Drug Test Anal</source><year>2017</year><volume>9</volume><fpage>666</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">27341380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dta.2001</pub-id></element-citation></ref><ref id="R87"><label>87.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Koyama</surname><given-names>H</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>I</given-names></name><name name-style="western"><surname>Mashimo</surname><given-names>T</given-names></name></person-group><article-title>The diverse actions of volatile and gaseous anesthetics on human-cloned 5-hydroxytryptamine3 receptors expressed in Xenopus oocytes</article-title><source>Anesthesiology</source><year>2002</year><volume>96</volume><fpage>699</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">11873047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200203000-00028</pub-id></element-citation></ref><ref id="R88"><label>88.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Ueta</surname><given-names>K</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>I</given-names></name><name name-style="western"><surname>Mashimo</surname><given-names>T</given-names></name></person-group><article-title>Nitrous oxide and xenon inhibit the human (alpha 7)5 nicotinic acetylcholine receptor expressed in Xenopus oocyte</article-title><source>Anesth Analg</source><year>2003</year><volume>96</volume><fpage>443</fpage><lpage>448</lpage><comment>table of contents</comment><pub-id pub-id-type="pmid">12538194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000539-200302000-00028</pub-id></element-citation></ref><ref id="R89"><label>89.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hapfelmeier</surname><given-names>G</given-names></name><name name-style="western"><surname>Zieglg&#228;nsberger</surname><given-names>W</given-names></name><name name-style="western"><surname>Haseneder</surname><given-names>R</given-names></name><name name-style="western"><surname>Schneck</surname><given-names>H</given-names></name><name name-style="western"><surname>Kochs</surname><given-names>E</given-names></name></person-group><article-title>Nitrous oxide and xenon increase the efficacy of GABA at recombinant mammalian GABA(A) receptors</article-title><source>Anesth Analg</source><year>2000</year><volume>91</volume><fpage>1542</fpage><lpage>1549</lpage><pub-id pub-id-type="pmid">11094015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000539-200012000-00045</pub-id></element-citation></ref><ref id="R90"><label>90.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Mattusch</surname><given-names>C</given-names></name><name name-style="western"><surname>Kratzer</surname><given-names>S</given-names></name><name name-style="western"><surname>Buerge</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impact of hyperpolarization-activated, cyclic nucleotide-gated cation channel type 2 for the xenon-mediated anesthetic effect: evidence from in vitro and in vivo experiments</article-title><source>Anesthesiology</source><year>2015</year><volume>122</volume><fpage>1047</fpage><lpage>1059</lpage><pub-id pub-id-type="pmid">25782754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0000000000000635</pub-id></element-citation></ref><ref id="R91"><label>91.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>NC</given-names></name><name name-style="western"><surname>Toma</surname><given-names>O</given-names></name><name name-style="western"><surname>Damla</surname><given-names>H</given-names></name><name name-style="western"><surname>Wolter</surname><given-names>JI</given-names></name><name name-style="western"><surname>Schlack</surname><given-names>W</given-names></name><name name-style="western"><surname>Preckel</surname><given-names>B</given-names></name></person-group><article-title>Upstream signaling of protein kinase C-epsilon in xenon-induced pharmacological preconditioning. Implication of mitochondrial adenosine triphosphate dependent potassium channels and phosphatidylinositol-dependent kinase-1</article-title><source>Eur J Pharmacol</source><year>2006</year><volume>539</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16716295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2006.03.054</pub-id></element-citation></ref><ref id="R92"><label>92.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>MT</given-names></name><name name-style="western"><surname>Crary</surname><given-names>JF</given-names></name><name name-style="western"><surname>Sacktor</surname><given-names>TC</given-names></name></person-group><article-title>Regulation of protein kinase Mzeta synthesis by multiple kinases in long-term potentiation</article-title><source>J Neurosci</source><year>2007</year><volume>27</volume><fpage>3439</fpage><lpage>3444</lpage><pub-id pub-id-type="pmid">17392460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5612-06.2007</pub-id><pub-id pub-id-type="pmcid">PMC6672124</pub-id></element-citation></ref><ref id="R93"><label>93.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Sacktor</surname><given-names>TC</given-names></name></person-group><article-title>Karim Nader and the unification of memory erasure: PKM&#950; inhibition and reconsolidation blockade</article-title><source>Brain Res Bull</source><year>2023</year><volume>194</volume><fpage>124</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">36739095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainresbull.2023.02.001</pub-id></element-citation></ref><ref id="R94"><label>94.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Sanejouand</surname><given-names>YH</given-names></name></person-group><article-title>At least three xenon binding sites in the glycine binding domain of the N-methyl D-aspartate receptor</article-title><source>Arch Biochem Biophys</source><year>2022</year><volume>724</volume><fpage>109265</fpage><pub-id pub-id-type="pmid">35500669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.abb.2022.109265</pub-id></element-citation></ref><ref id="R95"><label>95.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Andrijchenko</surname><given-names>NN</given-names></name><name name-style="western"><surname>Ermilov</surname><given-names>AY</given-names></name><name name-style="western"><surname>Khriachtchev</surname><given-names>L</given-names></name><name name-style="western"><surname>R&#228;s&#228;nen</surname><given-names>M</given-names></name><name name-style="western"><surname>Nemukhin</surname><given-names>AV</given-names></name></person-group><article-title>Toward molecular mechanism of xenon anesthesia: a link to studies of xenon complexes with small aromatic molecules</article-title><source>J Phys Chem A</source><year>2015</year><volume>119</volume><fpage>2517</fpage><lpage>2521</lpage><pub-id pub-id-type="pmid">25285819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jp508800k</pub-id></element-citation></ref><ref id="R96"><label>96.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wolosker</surname><given-names>H</given-names></name><name name-style="western"><surname>Balu</surname><given-names>DT</given-names></name></person-group><article-title>D-Serine as the gatekeeper of NMDA receptor activity: implications for the pharmacologic management of anxiety disorders</article-title><source>Transl Psychiatry</source><year>2020</year><volume>10</volume><fpage>184</fpage><pub-id pub-id-type="pmid">32518273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-020-00870-x</pub-id><pub-id pub-id-type="pmcid">PMC7283225</pub-id></element-citation></ref><ref id="R97"><label>97.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Coyle</surname><given-names>JT</given-names></name><name name-style="western"><surname>Balu</surname><given-names>D</given-names></name><name name-style="western"><surname>Wolosker</surname><given-names>H</given-names></name></person-group><article-title>D-serine, the shape-shifting NMDA receptor co-agonist</article-title><source>Neurochem Res</source><year>2020</year><volume>45</volume><fpage>1344</fpage><lpage>1353</lpage><pub-id pub-id-type="pmid">32189130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-020-03014-1</pub-id><pub-id pub-id-type="pmcid">PMC7313399</pub-id></element-citation></ref><ref id="R98"><label>98.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Honda</surname><given-names>H</given-names></name><name name-style="western"><surname>Baba</surname><given-names>H</given-names></name><name name-style="western"><surname>Kohno</surname><given-names>T</given-names></name></person-group><article-title>Effect of xenon on excitatory and inhibitory transmission in rat spinal ventral horn neurons</article-title><source>Anesthesiology</source><year>2012</year><volume>116</volume><fpage>1025</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">22411062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0b013e31825037a1</pub-id></element-citation></ref><ref id="R99"><label>99.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>I</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group><article-title>AMPA receptor exchange underlies transient memory destabilization on retrieval</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>8218</fpage><lpage>8223</lpage><pub-id pub-id-type="pmid">23630279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1305235110</pub-id><pub-id pub-id-type="pmcid">PMC3657785</pub-id></element-citation></ref><ref id="R100"><label>100.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Newpher</surname><given-names>TM</given-names></name><name name-style="western"><surname>Ehlers</surname><given-names>MD</given-names></name></person-group><article-title>Glutamate receptor dynamics in dendritic microdomains</article-title><source>Neuron</source><year>2008</year><volume>58</volume><fpage>472</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">18498731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2008.04.030</pub-id><pub-id pub-id-type="pmcid">PMC2572138</pub-id></element-citation></ref><ref id="R101"><label>101.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Nishimoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Kihara</surname><given-names>T</given-names></name><name name-style="western"><surname>Akaike</surname><given-names>A</given-names></name><name name-style="western"><surname>Niidome</surname><given-names>T</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>H</given-names></name></person-group><article-title>AMPA reduces surface expression of NR1 through regulation of GSK3beta</article-title><source>Neuroreport</source><year>2009</year><volume>20</volume><fpage>161</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">19151600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNR.0b013e3283118450</pub-id></element-citation></ref><ref id="R102"><label>102.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jaafari</surname><given-names>N</given-names></name><name name-style="western"><surname>Henley</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>JG</given-names></name></person-group><article-title>PICK1 mediates transient synaptic expression of GluA2-lacking AMPA receptors during glycine-induced AMPA receptor trafficking</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>11618</fpage><lpage>11630</lpage><pub-id pub-id-type="pmid">22915106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5068-11.2012</pub-id><pub-id pub-id-type="pmcid">PMC6703756</pub-id></element-citation></ref><ref id="R103"><label>103.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Fukushima</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Archbold</surname><given-names>G</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>R</given-names></name><name name-style="western"><surname>Nader</surname><given-names>K</given-names></name><name name-style="western"><surname>Kida</surname><given-names>S</given-names></name></person-group><article-title>Enhancement of fear memory by retrieval through reconsolidation</article-title><source>Elife</source><year>2014</year><volume>3</volume><fpage>e02736</fpage><pub-id pub-id-type="pmid">24963141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.02736</pub-id><pub-id pub-id-type="pmcid">PMC4067750</pub-id></element-citation></ref><ref id="R104"><label>104.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>&#945;CaMKII in the lateral amygdala mediates PTSD-Like behaviors and NMDAR-Dependent LTD</article-title><source>Neurobiol Stress</source><year>2021</year><volume>15</volume><fpage>100359</fpage><pub-id pub-id-type="pmid">34258335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ynstr.2021.100359</pub-id><pub-id pub-id-type="pmcid">PMC8252123</pub-id></element-citation></ref><ref id="R105"><label>105.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Daniels</surname><given-names>S</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>RJ</given-names></name></person-group><article-title>Post-synaptic inhibitory mechanisms of anaesthesia; glycine receptors</article-title><source>Toxicol Lett</source><year>1998</year><fpage>100</fpage><lpage>101</lpage><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-4274(98)00167-2</pub-id><pub-id pub-id-type="pmid">10049183</pub-id></element-citation></ref><ref id="R106"><label>106.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Haskel</surname><given-names>MVL</given-names></name><name name-style="western"><surname>da Silva Correa</surname><given-names>V</given-names></name><name name-style="western"><surname>Queiroz</surname><given-names>R</given-names></name><name name-style="western"><surname>Bonini</surname><given-names>JS</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>WC</given-names></name></person-group><article-title>On the participation of glycine receptors in the reconsolidation of spatial long-term memory in male rats</article-title><source>Behav Brain Res</source><year>2024</year><volume>471</volume><fpage>115086</fpage><pub-id pub-id-type="pmid">38825024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2024.115086</pub-id></element-citation></ref><ref id="R107"><label>107.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Makkar</surname><given-names>SR</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>SQ</given-names></name><name name-style="western"><surname>Cranney</surname><given-names>J</given-names></name></person-group><article-title>Behavioral and neural analysis of GABA in the acquisition, consolidation, reconsolidation, and extinction of fear memory</article-title><source>Neuropsychopharmacology</source><year>2010</year><volume>35</volume><fpage>1625</fpage><lpage>1652</lpage><pub-id pub-id-type="pmid">20410874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npp.2010.53</pub-id><pub-id pub-id-type="pmcid">PMC3055480</pub-id></element-citation></ref><ref id="R108"><label>108.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><etal/></person-group><article-title>Nicotine enhances contextual fear memory reconsolidation in rats</article-title><source>Neurosci Lett</source><year>2011</year><volume>487</volume><fpage>368</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">21035521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2010.10.058</pub-id></element-citation></ref><ref id="R109"><label>109.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>S</given-names></name><name name-style="western"><surname>Pan</surname><given-names>S</given-names></name><name name-style="western"><surname>You</surname><given-names>Y</given-names></name></person-group><article-title>Nicotine enhances the reconsolidation of novel object recognition memory in rats</article-title><source>Pharmacol Biochem Behav</source><year>2015</year><volume>129</volume><fpage>14</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">25482325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pbb.2014.11.019</pub-id></element-citation></ref><ref id="R110"><label>110.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Boccia</surname><given-names>MM</given-names></name><name name-style="western"><surname>Blake</surname><given-names>MG</given-names></name><name name-style="western"><surname>Krawczyk</surname><given-names>MC</given-names></name><name name-style="western"><surname>Baratti</surname><given-names>CM</given-names></name></person-group><article-title>Hippocampal &#945;7 nicotinic receptors modulate memory reconsolidation of an inhibitory avoidance task in mice</article-title><source>Neuroscience</source><year>2010</year><volume>171</volume><fpage>531</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">20832455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2010.08.027</pub-id></element-citation></ref><ref id="R111"><label>111.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wideman</surname><given-names>CE</given-names></name><name name-style="western"><surname>Minard</surname><given-names>EP</given-names></name><name name-style="western"><surname>Zakaria</surname><given-names>JM</given-names></name><name name-style="western"><surname>Capistrano</surname><given-names>JDR</given-names></name><name name-style="western"><surname>Scott</surname><given-names>GA</given-names></name><name name-style="western"><surname>Winters</surname><given-names>BD</given-names></name></person-group><article-title>Dissociating the involvement of muscarinic and nicotinic cholinergic receptors in object memory destabilization and reconsolidation</article-title><source>Neurobiol Learn Mem</source><year>2022</year><volume>195</volume><fpage>107686</fpage><pub-id pub-id-type="pmid">36174889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nlm.2022.107686</pub-id></element-citation></ref><ref id="R112"><label>112.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bhatia</surname><given-names>KS</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>ST</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>JC</given-names></name><name name-style="western"><surname>Wetsel</surname><given-names>WC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>TH</given-names></name></person-group><article-title>Reversal of long-term methamphetamine sensitization by combination of pergolide with ondansetron or ketanserin, but not mirtazapine</article-title><source>Behav Brain Res</source><year>2011</year><volume>223</volume><fpage>227</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">21571009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2011.04.045</pub-id><pub-id pub-id-type="pmcid">PMC3113440</pub-id></element-citation></ref><ref id="R113"><label>113.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>IS</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M</given-names></name><name name-style="western"><surname>Nonaka</surname><given-names>K</given-names></name><etal/></person-group><article-title>Protein kinase A is responsible for the presynaptic inhibition of glycinergic and glutamatergic transmissions by xenon in rat spinal cord and hippocampal CA3 neurons</article-title><source>J Pharmacol Exp Ther</source><year>2023</year><volume>386</volume><fpage>331</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">37391223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.123.001599</pub-id></element-citation></ref><ref id="R114"><label>114.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Mio</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shim</surname><given-names>YH</given-names></name><name name-style="western"><surname>Richards</surname><given-names>E</given-names></name><name name-style="western"><surname>Bosnjak</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Pagel</surname><given-names>PS</given-names></name><name name-style="western"><surname>Bienengraeber</surname><given-names>M</given-names></name></person-group><article-title>Xenon preconditioning: the role of prosurvival signaling, mitochondrial permeability transition and bioenergetics in rats</article-title><source>Anesth Analg</source><year>2009</year><volume>108</volume><fpage>858</fpage><lpage>866</lpage><pub-id pub-id-type="pmid">19224794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ane.0b013e318192a520</pub-id><pub-id pub-id-type="pmcid">PMC2748301</pub-id></element-citation></ref><ref id="R115"><label>115.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Limatola</surname><given-names>V</given-names></name><name name-style="western"><surname>Ward</surname><given-names>P</given-names></name><name name-style="western"><surname>Cattano</surname><given-names>D</given-names></name><etal/></person-group><article-title>Xenon preconditioning confers neuroprotection regardless of gender in a mouse model of transient middle cerebral artery occlusion</article-title><source>Neuroscience</source><year>2010</year><volume>165</volume><fpage>874</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">19895874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2009.10.063</pub-id></element-citation></ref><ref id="R116"><label>116.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Rizvi</surname><given-names>M</given-names></name><name name-style="western"><surname>Jawad</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Vizcaychipi</surname><given-names>MP</given-names></name><name name-style="western"><surname>Maze</surname><given-names>M</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name></person-group><article-title>Effect of noble gases on oxygen and glucose deprived injury in human tubular kidney cells</article-title><source>Exp Biol Med (Maywood)</source><year>2010</year><volume>235</volume><fpage>886</fpage><lpage>891</lpage><pub-id pub-id-type="pmid">20472713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1258/ebm.2010.009366</pub-id></element-citation></ref><ref id="R117"><label>117.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>T</given-names></name><name name-style="western"><surname>Britton</surname><given-names>GL</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><etal/></person-group><article-title>Therapeutic time window and dose dependence of xenon delivered via echogenic liposomes for neuroprotection in stroke</article-title><source>CNS Neurosci Ther</source><year>2013</year><volume>19</volume><fpage>773</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">23981565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cns.12159</pub-id><pub-id pub-id-type="pmcid">PMC3806289</pub-id></element-citation></ref><ref id="R118"><label>118.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>P</given-names></name><name name-style="western"><surname>Teng</surname><given-names>J</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J</given-names></name><etal/></person-group><article-title>Xenon protects against septic acute kidney injury via miR-21 target signaling pathway</article-title><source>Crit Care Med</source><year>2015</year><volume>43</volume><fpage>e250</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">25844699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000001001</pub-id><pub-id pub-id-type="pmcid">PMC4467582</pub-id></element-citation></ref><ref id="R119"><label>119.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Xenon-delayed postconditioning attenuates spinal cord ischemia/reperfusion injury through activation AKT and ERK signaling pathways in rats</article-title><source>J Neurol Sci</source><year>2016</year><volume>368</volume><fpage>277</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">27538649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2016.07.009</pub-id></element-citation></ref><ref id="R120"><label>120.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dandekar</surname><given-names>MP</given-names></name><name name-style="western"><surname>Peng</surname><given-names>T</given-names></name><name name-style="western"><surname>McPherson</surname><given-names>DD</given-names></name><name name-style="western"><surname>Quevedo</surname><given-names>J</given-names></name><name name-style="western"><surname>Soares</surname><given-names>JC</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SL</given-names></name></person-group><article-title>Intravenous infusion of xenon-containing liposomes generates rapid antidepressant-like effects</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2018</year><volume>86</volume><fpage>140</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">29559371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pnpbp.2018.03.011</pub-id></element-citation></ref><ref id="R121"><label>121.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>NC</given-names></name><name name-style="western"><surname>Toma</surname><given-names>O</given-names></name><name name-style="western"><surname>Wolter</surname><given-names>JI</given-names></name><etal/></person-group><article-title>The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC-epsilon and p38 MAPK</article-title><source>Br J Pharmacol</source><year>2005</year><volume>144</volume><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">15644876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjp.0706063</pub-id><pub-id pub-id-type="pmcid">PMC1575984</pub-id></element-citation></ref><ref id="R122"><label>122.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>NC</given-names></name><name name-style="western"><surname>Stursberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Wirthle</surname><given-names>NM</given-names></name><name name-style="western"><surname>Toma</surname><given-names>O</given-names></name><name name-style="western"><surname>Schlack</surname><given-names>W</given-names></name><name name-style="western"><surname>Preckel</surname><given-names>B</given-names></name></person-group><article-title>Xenon preconditioning differently regulates p44/42 MAPK (ERK 1/2) and p46/54 MAPK (JNK 1/2 and 3) in vivo</article-title><source>Br J Anaesth</source><year>2006</year><volume>97</volume><fpage>298</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">16793779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/ael153</pub-id></element-citation></ref><ref id="R123"><label>123.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Galley</surname><given-names>HF</given-names></name><name name-style="western"><surname>Le Cras</surname><given-names>AE</given-names></name><name name-style="western"><surname>Logan</surname><given-names>SD</given-names></name><name name-style="western"><surname>Webster</surname><given-names>NR</given-names></name></person-group><article-title>Differential nitric oxide synthase activity, cofactor availability and cGMP accumulation in the central nervous system during anaesthesia</article-title><source>Br J Anaesth</source><year>2001</year><volume>86</volume><fpage>388</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">11573530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/86.3.388</pub-id></element-citation></ref><ref id="R124"><label>124.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Petzelt</surname><given-names>CP</given-names></name><name name-style="western"><surname>Kodirov</surname><given-names>S</given-names></name><name name-style="western"><surname>Taschenberger</surname><given-names>G</given-names></name><name name-style="western"><surname>Kox</surname><given-names>WJ</given-names></name></person-group><article-title>Participation of the Ca(2+)-calmodulin-activated Kinase II in the control of metaphase-anaphase transition in human cells</article-title><source>Cell Biol Int</source><year>2001</year><volume>25</volume><fpage>403</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">11401327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/cbir.2000.0646</pub-id></element-citation></ref><ref id="R125"><label>125.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Early treatment with xenon protects against the cold ischemia associated with chronic allograft nephropathy in rats</article-title><source>Kidney Int</source><year>2014</year><volume>85</volume><fpage>112</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">24025645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ki.2013.334</pub-id></element-citation></ref><ref id="R126"><label>126.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ologunde</surname><given-names>R</given-names></name><etal/></person-group><article-title>Xenon Treatment Protects against Remote Lung Injury after Kidney Transplantation in Rats</article-title><source>Anesthesiology</source><year>2015</year><volume>122</volume><fpage>1312</fpage><lpage>1326</lpage><pub-id pub-id-type="pmid">25856291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0000000000000664</pub-id></element-citation></ref><ref id="R127"><label>127.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kuzovlev</surname><given-names>AN</given-names></name><name name-style="western"><surname>Shpichko</surname><given-names>AI</given-names></name><name name-style="western"><surname>Ryzhkov</surname><given-names>IA</given-names></name><etal/></person-group><article-title>Effect of xenon on the phosphorylation of glycogen synthase kinase 3&#946; and antioxidant enzymes in rat brain</article-title><source>Russ Sklifosovsky J Emerg Med Care</source><year>2020</year><volume>9</volume><fpage>564</fpage><lpage>572</lpage></element-citation></ref><ref id="R128"><label>128.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>AM</given-names></name><name name-style="western"><surname>Messing</surname><given-names>RO</given-names></name></person-group><article-title>Protein kinases and addiction</article-title><source>Ann N Y Acad Sci</source><year>2008</year><volume>1141</volume><fpage>22</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">18991950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1196/annals.1441.022</pub-id><pub-id pub-id-type="pmcid">PMC3050040</pub-id></element-citation></ref><ref id="R129"><label>129.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Pardo</surname><given-names>MP</given-names></name><name name-style="western"><surname>Roger-Sanchez</surname><given-names>C</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Arias</surname><given-names>M</given-names></name><name name-style="western"><surname>Mi&#241;arro</surname><given-names>J</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>MA</given-names></name></person-group><article-title>Pharmacological modulation of protein kinases as a new approach to treat addiction to cocaine and opiates</article-title><source>Eur J Pharmacol</source><year>2016</year><volume>781</volume><fpage>10</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">27056740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2016.03.065</pub-id></element-citation></ref><ref id="R130"><label>130.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Amaral</surname><given-names>IM</given-names></name><name name-style="western"><surname>Scheffauer</surname><given-names>L</given-names></name><name name-style="western"><surname>Hofer</surname><given-names>A</given-names></name><name name-style="western"><surname>El Rawas</surname><given-names>R</given-names></name></person-group><article-title>Protein kinases in natural versus drug reward</article-title><source>Pharmacol Biochem Behav</source><year>2022</year><volume>221</volume><fpage>173472</fpage><pub-id pub-id-type="pmid">36244528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pbb.2022.173472</pub-id></element-citation></ref><ref id="R131"><label>131.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>X</given-names></name><name name-style="western"><surname>von Weltin</surname><given-names>E</given-names></name><name name-style="western"><surname>Fitzsimmons</surname><given-names>E</given-names></name><etal/></person-group><article-title>Reactivation of cocaine contextual memory engages mechanistic target of rapamycin/S6 kinase 1 signaling</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><fpage>976932</fpage><pub-id pub-id-type="pmid">36238569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.976932</pub-id><pub-id pub-id-type="pmcid">PMC9552424</pub-id></element-citation></ref><ref id="R132"><label>132.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Rahamim</surname><given-names>N</given-names></name><name name-style="western"><surname>Liran</surname><given-names>M</given-names></name><name name-style="western"><surname>Aronovici</surname><given-names>C</given-names></name><etal/></person-group><article-title>Inhibition of ERK1/2 or CRMP2 disrupts alcohol memory reconsolidation and prevents relapse in rats</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><fpage>5478</fpage><pub-id pub-id-type="pmid">38791516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25105478</pub-id><pub-id pub-id-type="pmcid">PMC11122309</pub-id></element-citation></ref><ref id="R133"><label>133.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Anthony</surname><given-names>IC</given-names></name><name name-style="western"><surname>Norrby</surname><given-names>KE</given-names></name><name name-style="western"><surname>Dingwall</surname><given-names>T</given-names></name><etal/></person-group><article-title>Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers</article-title><source>Brain</source><year>2010</year><volume>133</volume><fpage>3685</fpage><lpage>3698</lpage><pub-id pub-id-type="pmid">21126996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awq263</pub-id></element-citation></ref><ref id="R134"><label>134.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Masvekar</surname><given-names>RR</given-names></name><name name-style="western"><surname>El-Hage</surname><given-names>N</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>KF</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>PE</given-names></name></person-group><article-title>GSK3&#946;-activation is a point of convergence for HIV-1 and opiate-mediated interactive neurotoxicity</article-title><source>Mol Cell Neurosci</source><year>2015</year><volume>65</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">25616162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcn.2015.01.001</pub-id><pub-id pub-id-type="pmcid">PMC4393771</pub-id></element-citation></ref><ref id="R135"><label>135.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J</given-names></name><etal/></person-group><article-title>Opiate-associated contextual memory formation and retrieval are differentially modulated by dopamine D1 and D2 signaling in hippocampal-prefrontal connectivity</article-title><source>Neuropsychopharmacology</source><year>2019</year><volume>44</volume><fpage>334</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">29728647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41386-018-0068-y</pub-id><pub-id pub-id-type="pmcid">PMC6300561</pub-id></element-citation></ref><ref id="R136"><label>136.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Fatahi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zeinaddini-Meymand</surname><given-names>A</given-names></name><name name-style="western"><surname>Karimi-Haghighi</surname><given-names>S</given-names></name><name name-style="western"><surname>Moradi</surname><given-names>M</given-names></name><name name-style="western"><surname>Khodagholi</surname><given-names>F</given-names></name><name name-style="western"><surname>Haghparast</surname><given-names>A</given-names></name></person-group><article-title>Naloxone-precipitated withdrawal ameliorates impairment of cost-benefit decision making in morphine-treated rats: Involvement of BDNF, p-GSK3-&#946;, and p-CREB in the amygdala</article-title><source>Neurobiol Learn Mem</source><year>2020</year><volume>167</volume><fpage>107138</fpage><pub-id pub-id-type="pmid">31838222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nlm.2019.107138</pub-id></element-citation></ref><ref id="R137"><label>137.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Oka</surname><given-names>M</given-names></name><name name-style="western"><surname>Yoshino</surname><given-names>R</given-names></name><name name-style="western"><surname>Kitanaka</surname><given-names>N</given-names></name><name name-style="western"><surname>Hall</surname><given-names>FS</given-names></name><name name-style="western"><surname>Uhl</surname><given-names>GR</given-names></name><name name-style="western"><surname>Kitanaka</surname><given-names>J</given-names></name></person-group><article-title>Role of glycogen synthase kinase-3&#946; in dependence and abuse liability of alcohol</article-title><source>Alcohol Alcohol</source><year>2024</year><volume>59</volume><fpage>agad086</fpage><pub-id pub-id-type="pmid">38145944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/alcalc/agad086</pub-id></element-citation></ref><ref id="R138"><label>138.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>van der Vaart</surname><given-names>A</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X</given-names></name><name name-style="western"><surname>Bowers</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Glycogen synthase kinase 3 beta regulates ethanol consumption and is a risk factor for alcohol dependence</article-title><source>Neuropsychopharmacology</source><year>2018</year><volume>43</volume><fpage>2521</fpage><lpage>2531</lpage><pub-id pub-id-type="pmid">30188517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41386-018-0202-x</pub-id><pub-id pub-id-type="pmcid">PMC6224501</pub-id></element-citation></ref><ref id="R139"><label>139.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name></person-group><article-title>Inhibition of glycogen synthase kinase 3&#946; activity in the basolateral amygdala disrupts reconsolidation and attenuates heroin relapse</article-title><source>Front Mol Neurosci</source><year>2022</year><volume>15</volume><fpage>932939</fpage><pub-id pub-id-type="pmid">35832395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnmol.2022.932939</pub-id><pub-id pub-id-type="pmcid">PMC9271698</pub-id></element-citation></ref><ref id="R140"><label>140.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Beurel</surname><given-names>E</given-names></name><name name-style="western"><surname>Grieco</surname><given-names>SF</given-names></name><name name-style="western"><surname>Jope</surname><given-names>RS</given-names></name></person-group><article-title>Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases</article-title><source>Pharmacol Ther</source><year>2015</year><volume>148</volume><fpage>114</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">25435019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2014.11.016</pub-id><pub-id pub-id-type="pmcid">PMC4340754</pub-id></element-citation></ref><ref id="R141"><label>141.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Krishnankutty</surname><given-names>A</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>T</given-names></name><name name-style="western"><surname>Saito</surname><given-names>T</given-names></name><etal/></person-group><article-title>In vivo regulation of glycogen synthase kinase 3&#946; activity in neurons and brains</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>8602</fpage><pub-id pub-id-type="pmid">28819213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-09239-5</pub-id><pub-id pub-id-type="pmcid">PMC5561119</pub-id></element-citation></ref><ref id="R142"><label>142.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>HB</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>PC</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CC</given-names></name><name name-style="western"><surname>Wan</surname><given-names>DC</given-names></name></person-group><article-title>Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain</article-title><source>J Chem Neuroanat</source><year>2002</year><volume>23</volume><fpage>291</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">12048112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0891-0618(02)00014-5</pub-id></element-citation></ref><ref id="R143"><label>143.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>T</given-names></name></person-group><article-title>GSK3 in Alzheimer&#8217;s disease: mind the isoforms</article-title><source>J Alzheimers Dis</source><year>2014</year><volume>39</volume><fpage>707</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">24254703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-131661</pub-id><pub-id pub-id-type="pmcid">PMC8009280</pub-id></element-citation></ref><ref id="R144"><label>144.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Boss</surname><given-names>GR</given-names></name><name name-style="western"><surname>Pilz</surname><given-names>RB</given-names></name></person-group><article-title>Cyclic GMP-dependent protein kinase regulates CCAAT enhancer-binding protein beta functions through inhibition of glycogen synthase kinase-3</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>32683</fpage><lpage>32692</lpage><pub-id pub-id-type="pmid">16055922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M505486200</pub-id></element-citation></ref><ref id="R145"><label>145.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Doble</surname><given-names>BW</given-names></name><name name-style="western"><surname>Woodgett</surname><given-names>JR</given-names></name></person-group><article-title>GSK-3: tricks of the trade for a multi-tasking kinase</article-title><source>J Cell Sci</source><year>2003</year><volume>116</volume><fpage>1175</fpage><lpage>1186</lpage><pub-id pub-id-type="pmid">12615961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/jcs.00384</pub-id><pub-id pub-id-type="pmcid">PMC3006448</pub-id></element-citation></ref><ref id="R146"><label>146.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Di</surname><given-names>LJ</given-names></name></person-group><article-title>Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases</article-title><source>Med Res Rev</source><year>2022</year><volume>42</volume><fpage>946</fpage><lpage>982</lpage><pub-id pub-id-type="pmid">34729791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/med.21867</pub-id><pub-id pub-id-type="pmcid">PMC9298385</pub-id></element-citation></ref><ref id="R147"><label>147.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Umbarkar</surname><given-names>P</given-names></name><name name-style="western"><surname>Ruiz Ramirez</surname><given-names>SY</given-names></name><name name-style="western"><surname>Toro Cora</surname><given-names>A</given-names></name><name name-style="western"><surname>Tousif</surname><given-names>S</given-names></name><name name-style="western"><surname>Lal</surname><given-names>H</given-names></name></person-group><article-title>GSK-3 at the heart of cardiometabolic diseases: Isoform-specific targeting is critical to therapeutic benefit</article-title><source>Biochim Biophys Acta Mol Basis Dis</source><year>2023</year><volume>1869</volume><fpage>166724</fpage><pub-id pub-id-type="pmid">37094727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2023.166724</pub-id><pub-id pub-id-type="pmcid">PMC10247467</pub-id></element-citation></ref><ref id="R148"><label>148.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>B</given-names></name><name name-style="western"><surname>Lai</surname><given-names>B</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Inhibitory phosphorylation of GSK-3 by CaMKII couples depolarization to neuronal survival</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>41122</fpage><lpage>41134</lpage><pub-id pub-id-type="pmid">20841359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M110.130351</pub-id><pub-id pub-id-type="pmcid">PMC3003410</pub-id></element-citation></ref><ref id="R149"><label>149.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Thornton</surname><given-names>TM</given-names></name><name name-style="western"><surname>Pedraza-Alva</surname><given-names>G</given-names></name><name name-style="western"><surname>Deng</surname><given-names>B</given-names></name><etal/></person-group><article-title>Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation</article-title><source>Science</source><year>2008</year><volume>320</volume><fpage>667</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">18451303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1156037</pub-id><pub-id pub-id-type="pmcid">PMC2597039</pub-id></element-citation></ref><ref id="R150"><label>150.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Thornton</surname><given-names>TM</given-names></name><name name-style="western"><surname>Delgado</surname><given-names>P</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><etal/></person-group><article-title>Inactivation of nuclear GSK3&#946; by Ser(389) phosphorylation promotes lymphocyte fitness during DNA double-strand break response</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>10553</fpage><pub-id pub-id-type="pmid">26822034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms10553</pub-id><pub-id pub-id-type="pmcid">PMC4740185</pub-id></element-citation></ref><ref id="R151"><label>151.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Thornton</surname><given-names>TM</given-names></name><name name-style="western"><surname>Hare</surname><given-names>B</given-names></name><name name-style="western"><surname>Coli&#233;</surname><given-names>S</given-names></name><etal/></person-group><article-title>Failure to inactivate nuclear GSK3&#946; by Ser(389)-phosphorylation leads to focal neuronal death and prolonged fear response</article-title><source>Neuropsychopharmacology</source><year>2018</year><volume>43</volume><fpage>393</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">28832021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npp.2017.187</pub-id><pub-id pub-id-type="pmcid">PMC5729567</pub-id></element-citation></ref><ref id="R152"><label>152.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kwok</surname><given-names>JB</given-names></name><name name-style="western"><surname>Hallupp</surname><given-names>M</given-names></name><name name-style="western"><surname>Loy</surname><given-names>CT</given-names></name><etal/></person-group><article-title>GSK3B polymorphisms alter transcription and splicing in Parkinson&#8217;s disease</article-title><source>Ann Neurol</source><year>2005</year><volume>58</volume><fpage>829</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">16315267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.20691</pub-id></element-citation></ref><ref id="R153"><label>153.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>N</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Possible association of the GSK3&#946; gene with the anxiety symptoms of major depressive disorder and P300 waveform</article-title><source>Genet Test Mol Biomarkers</source><year>2012</year><volume>16</volume><fpage>1382</fpage><lpage>1389</lpage><pub-id pub-id-type="pmid">23030648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/gtmb.2012.0227</pub-id><pub-id pub-id-type="pmcid">PMC3501115</pub-id></element-citation></ref><ref id="R154"><label>154.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ke</surname><given-names>S</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Interactions between glycogen synthase kinase-3&#946; gene polymorphisms, negative life events, and susceptibility to major depressive disorder in a Chinese population</article-title><source>Front Psychiatry</source><year>2020</year><volume>11</volume><fpage>503477</fpage><pub-id pub-id-type="pmid">33658947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2020.503477</pub-id><pub-id pub-id-type="pmcid">PMC7917206</pub-id></element-citation></ref><ref id="R155"><label>155.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Tripathi</surname><given-names>R</given-names></name><name name-style="western"><surname>Saber</surname><given-names>H</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>V</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>K</given-names></name><name name-style="western"><surname>Factor</surname><given-names>S</given-names></name></person-group><article-title>Parkinson disease from long term drug abuse: meta-analysis of amphetamine/methamphetamine and Parkinson disease (P6.079)</article-title><source>Neurology</source><year>2018</year><volume>90</volume><fpage>P6.079</fpage></element-citation></ref><ref id="R156"><label>156.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bhat</surname><given-names>R</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Berg</surname><given-names>S</given-names></name><etal/></person-group><article-title>Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>45937</fpage><lpage>45945</lpage><pub-id pub-id-type="pmid">12928438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M306268200</pub-id></element-citation></ref><ref id="R157"><label>157.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Thapa</surname><given-names>R</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>G</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>AA</given-names></name><etal/></person-group><article-title>A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies</article-title><source>Int J Biol Macromol</source><year>2023</year><volume>253</volume><fpage>127375</fpage><pub-id pub-id-type="pmid">37839597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2023.127375</pub-id></element-citation></ref><ref id="R158"><label>158.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Vainio</surname><given-names>L</given-names></name><name name-style="western"><surname>Taponen</surname><given-names>S</given-names></name><name name-style="western"><surname>Kinnunen</surname><given-names>SM</given-names></name><etal/></person-group><article-title>GSK3&#946; serine 389 phosphorylation modulates cardiomyocyte hypertrophy and ischemic injury</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>13586</fpage><pub-id pub-id-type="pmid">34948382</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms222413586</pub-id><pub-id pub-id-type="pmcid">PMC8707850</pub-id></element-citation></ref><ref id="R159"><label>159.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>S</given-names></name><name name-style="western"><surname>Nakao</surname><given-names>S</given-names></name><etal/></person-group><article-title>GSK-3beta is required for memory reconsolidation in adult brain</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><fpage>e3540</fpage><pub-id pub-id-type="pmid">18958152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0003540</pub-id><pub-id pub-id-type="pmcid">PMC2568810</pub-id></element-citation></ref><ref id="R160"><label>160.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><name name-style="western"><surname>Sakurai</surname><given-names>T</given-names></name><name name-style="western"><surname>Takata</surname><given-names>T</given-names></name><name name-style="western"><surname>Yokono</surname><given-names>K</given-names></name></person-group><article-title>Effects of lactate/pyruvate on synaptic plasticity in the hippocampal dentate gyrus</article-title><source>Neurosci Res</source><year>2003</year><volume>46</volume><fpage>333</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">12804794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0168-0102(03)00096-8</pub-id></element-citation></ref><ref id="R161"><label>161.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><etal/></person-group><article-title>The key roles of GSK-3&#946; in regulating mitochondrial activity</article-title><source>Cell Physiol Biochem</source><year>2017</year><volume>44</volume><fpage>1445</fpage><lpage>1459</lpage><pub-id pub-id-type="pmid">29190615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000485580</pub-id></element-citation></ref><ref id="R162"><label>162.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Z</given-names></name></person-group><article-title>Regulation of AMPA receptor trafficking and function by glycogen synthase kinase 3</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>26369</fpage><lpage>26376</lpage><pub-id pub-id-type="pmid">20584904</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M110.121376</pub-id><pub-id pub-id-type="pmcid">PMC2924064</pub-id></element-citation></ref><ref id="R163"><label>163.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Amici</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pope</surname><given-names>RJP</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>CA</given-names></name><name name-style="western"><surname>Cole</surname><given-names>A</given-names></name><name name-style="western"><surname>Collingridge</surname><given-names>GL</given-names></name></person-group><article-title>GSK-3&#946; regulates the synaptic expression of NMDA receptors via phosphorylation of phosphatidylinositol 4 kinase type II&#945;</article-title><source>Eur J Neurosci</source><year>2021</year><volume>54</volume><fpage>6815</fpage><lpage>6825</lpage><pub-id pub-id-type="pmid">32463939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ejn.14841</pub-id><pub-id pub-id-type="pmcid">PMC8554790</pub-id></element-citation></ref><ref id="R164"><label>164.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Peineau</surname><given-names>S</given-names></name><name name-style="western"><surname>Taghibiglou</surname><given-names>C</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>C</given-names></name><etal/></person-group><article-title>LTP inhibits LTD in the hippocampus via regulation of GSK3beta</article-title><source>Neuron</source><year>2007</year><volume>53</volume><fpage>703</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">17329210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2007.01.029</pub-id></element-citation></ref><ref id="R165"><label>165.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Sui</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kov&#225;cs</surname><given-names>AD</given-names></name><name name-style="western"><surname>Maggirwar</surname><given-names>SB</given-names></name></person-group><article-title>Recruitment of active glycogen synthase kinase-3 into neuronal lipid rafts</article-title><source>Biochem Biophys Res Commun</source><year>2006</year><volume>345</volume><fpage>1643</fpage><lpage>1648</lpage><pub-id pub-id-type="pmid">16735023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2006.05.087</pub-id></element-citation></ref><ref id="R166"><label>166.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Egawa</surname><given-names>J</given-names></name><name name-style="western"><surname>Pearn</surname><given-names>ML</given-names></name><name name-style="western"><surname>Lemkuil</surname><given-names>BP</given-names></name><name name-style="western"><surname>Patel</surname><given-names>PM</given-names></name><name name-style="western"><surname>Head</surname><given-names>BP</given-names></name></person-group><article-title>Membrane lipid rafts and neurobiology: age-related changes in membrane lipids and loss of neuronal function</article-title><source>J Physiol</source><year>2016</year><volume>594</volume><fpage>4565</fpage><lpage>4579</lpage><pub-id pub-id-type="pmid">26332795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1113/JP270590</pub-id><pub-id pub-id-type="pmcid">PMC4983616</pub-id></element-citation></ref><ref id="R167"><label>167.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hofmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Sander</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XX</given-names></name><etal/></person-group><article-title>Inhalational anesthetics do not deteriorate amyloid-&#946;-derived pathophysiology in Alzheimer&#8217;s disease: investigations on the molecular, neuronal, and behavioral level</article-title><source>J Alzheimers Dis</source><year>2021</year><volume>84</volume><fpage>1193</fpage><lpage>1218</lpage><pub-id pub-id-type="pmid">34657881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-201185</pub-id></element-citation></ref><ref id="R168"><label>168.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kawarabayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Sato</surname><given-names>K</given-names></name><etal/></person-group><article-title>Lipid rafts act as a common platform for amyloid-&#946; oligomer-induced Alzheimer&#8217;s disease pathology</article-title><source>J Alzheimers Dis</source><year>2022</year><volume>87</volume><fpage>1189</fpage><lpage>1203</lpage><pub-id pub-id-type="pmid">35431249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215662</pub-id></element-citation></ref><ref id="R169"><label>169.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Lavaur</surname><given-names>J</given-names></name><name name-style="western"><surname>Lemaire</surname><given-names>M</given-names></name><name name-style="western"><surname>Pype</surname><given-names>J</given-names></name><name name-style="western"><surname>Le Nogue</surname><given-names>D</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>EC</given-names></name><name name-style="western"><surname>Michel</surname><given-names>PP</given-names></name></person-group><article-title>Xenon-mediated neuroprotection in response to sustained, low-level excitotoxic stress</article-title><source>Cell Death Discov</source><year>2016</year><volume>2</volume><fpage>16018</fpage><pub-id pub-id-type="pmid">27551511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cddiscovery.2016.18</pub-id><pub-id pub-id-type="pmcid">PMC4979450</pub-id></element-citation></ref><ref id="R170"><label>170.</label><element-citation publication-type="book" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ilin</surname><given-names>I</given-names></name><name name-style="western"><surname>Brandao</surname><given-names>W</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N</given-names></name><etal/></person-group><article-title>Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy</article-title><source>AD/PD 2024 International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases and Related Neurological Disorders</source><publisher-loc>Lisbon, Portugal</publisher-loc><month>March</month><year>2024</year></element-citation></ref><ref id="R171"><label>171.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Perry</surname><given-names>SW</given-names></name><name name-style="western"><surname>Barbieri</surname><given-names>J</given-names></name><name name-style="western"><surname>Tong</surname><given-names>N</given-names></name><etal/></person-group><article-title>Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>14153</fpage><lpage>14164</lpage><pub-id pub-id-type="pmid">20962236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.1042-10.2010</pub-id><pub-id pub-id-type="pmcid">PMC2972730</pub-id></element-citation></ref><ref id="R172"><label>172.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>MC</given-names></name><name name-style="western"><surname>Rossato</surname><given-names>JI</given-names></name><name name-style="western"><surname>Radiske</surname><given-names>A</given-names></name><name name-style="western"><surname>Bevilaqua</surname><given-names>LRM</given-names></name><name name-style="western"><surname>Cammarota</surname><given-names>M</given-names></name></person-group><article-title>Dopamine controls whether new declarative information updates reactivated memories through reconsolidation</article-title><source>Proc Natl Acad Sci U S A</source><year>2021</year><volume>118</volume><fpage>e2025275118</fpage><pub-id pub-id-type="pmid">34253612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2025275118</pub-id><pub-id pub-id-type="pmcid">PMC8307459</pub-id></element-citation></ref><ref id="R173"><label>173.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>H</given-names></name><name name-style="western"><surname>Kushikata</surname><given-names>T</given-names></name><name name-style="western"><surname>Kubota</surname><given-names>T</given-names></name><name name-style="western"><surname>Hirota</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishihara</surname><given-names>H</given-names></name><name name-style="western"><surname>Matsuki</surname><given-names>A</given-names></name></person-group><article-title>Xenon inhalation increases norepinephrine release from the anterior and posterior hypothalamus in rats</article-title><source>Can J Anaesth</source><year>2001</year><volume>48</volume><fpage>651</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">11495871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF03016198</pub-id></element-citation></ref><ref id="R174"><label>174.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>H</given-names></name><name name-style="western"><surname>Kushikata</surname><given-names>T</given-names></name><name name-style="western"><surname>Tose</surname><given-names>R</given-names></name><name name-style="western"><surname>Kudo</surname><given-names>M</given-names></name><name name-style="western"><surname>Kudo</surname><given-names>T</given-names></name><name name-style="western"><surname>Hirota</surname><given-names>K</given-names></name></person-group><article-title>Nitrous oxide and xenon increase noradrenaline release in the cerebral cortex in vivo and in vitro</article-title><source>Neurosci Lett</source><year>2010</year><volume>469</volume><fpage>199</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">19962430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2009.11.074</pub-id></element-citation></ref><ref id="R175"><label>175.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Neukirchen</surname><given-names>M</given-names></name><name name-style="western"><surname>Hipp</surname><given-names>J</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Cardiovascular stability and unchanged muscle sympathetic activity during xenon anaesthesia: role of norepinephrine uptake inhibition</article-title><source>Br J Anaesth</source><year>2012</year><volume>109</volume><fpage>887</fpage><lpage>896</lpage><pub-id pub-id-type="pmid">22945969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/aes303</pub-id></element-citation></ref><ref id="R176"><label>176.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Robertson</surname><given-names>SD</given-names></name><name name-style="western"><surname>Matthies</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Owens</surname><given-names>WA</given-names></name><etal/></person-group><article-title>Insulin reveals Akt signaling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>11305</fpage><lpage>11316</lpage><pub-id pub-id-type="pmid">20739551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0126-10.2010</pub-id><pub-id pub-id-type="pmcid">PMC3448453</pub-id></element-citation></ref><ref id="R177"><label>177.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Gazarini</surname><given-names>L</given-names></name><name name-style="western"><surname>Stern</surname><given-names>CA</given-names></name><name name-style="western"><surname>Carobrez</surname><given-names>AP</given-names></name><name name-style="western"><surname>Bertoglio</surname><given-names>LJ</given-names></name></person-group><article-title>Enhanced noradrenergic activity potentiates fear memory consolidation and reconsolidation by differentially recruiting &#945;1- and &#946;-adrenergic receptors</article-title><source>Learn Mem</source><year>2013</year><volume>20</volume><fpage>210</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">23512937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/lm.030007.112</pub-id></element-citation></ref><ref id="R178"><label>178.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Sui</surname><given-names>N</given-names></name></person-group><article-title>Differential effect of beta-adrenergic receptor antagonism in basolateral amygdala on reconsolidation of aversive and appetitive memories associated with morphine in rats</article-title><source>Addict Biol</source><year>2014</year><volume>19</volume><fpage>5</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">22458530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1369-1600.2012.00443.x</pub-id></element-citation></ref><ref id="R179"><label>179.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Blockade of &#946;-adrenergic receptors by propranolol disrupts reconsolidation of drug memory and attenuates heroin seeking</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>686845</fpage><pub-id pub-id-type="pmid">34113256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2021.686845</pub-id><pub-id pub-id-type="pmcid">PMC8185332</pub-id></element-citation></ref><ref id="R180"><label>180.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wouda</surname><given-names>JA</given-names></name><name name-style="western"><surname>Diergaarde</surname><given-names>L</given-names></name><name name-style="western"><surname>Riga</surname><given-names>D</given-names></name><name name-style="western"><surname>van Mourik</surname><given-names>Y</given-names></name><name name-style="western"><surname>Schoffelmeer</surname><given-names>AN</given-names></name><name name-style="western"><surname>De Vries</surname><given-names>TJ</given-names></name></person-group><article-title>Disruption of long-term alcohol-related memory reconsolidation: role of &#946;-adrenoceptors and NMDA receptors</article-title><source>Front Behav Neurosci</source><year>2010</year><volume>4</volume><fpage>179</fpage><pub-id pub-id-type="pmid">21152256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnbeh.2010.00179</pub-id><pub-id pub-id-type="pmcid">PMC2998860</pub-id></element-citation></ref><ref id="R181"><label>181.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Chesworth</surname><given-names>R</given-names></name><name name-style="western"><surname>Corbit</surname><given-names>LH</given-names></name></person-group><article-title>Noradrenergic &#946;-receptor antagonism in the basolateral amygdala impairs reconsolidation, but not extinction, of alcohol self-administration: intra-BLA propranolol impairs reconsolidation of alcohol self-administration</article-title><source>Neurobiol Learn Mem</source><year>2018</year><volume>151</volume><fpage>59</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">29649583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nlm.2018.04.009</pub-id></element-citation></ref><ref id="R182"><label>182.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>&#946;1&#8211;Adrenoceptor in the Central Amygdala Is Required for Unconditioned Stimulus-Induced Drug Memory Reconsolidation</article-title><source>Int J Neuropsychopharmacol</source><year>2018</year><volume>21</volume><fpage>267</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">29216351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ijnp/pyx104</pub-id><pub-id pub-id-type="pmcid">PMC5838817</pub-id></element-citation></ref><ref id="R183"><label>183.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Delfs</surname><given-names>JM</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Druhan</surname><given-names>JP</given-names></name><name name-style="western"><surname>Aston-Jones</surname><given-names>G</given-names></name></person-group><article-title>Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion</article-title><source>Nature</source><year>2000</year><volume>403</volume><fpage>430</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">10667795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35000212</pub-id></element-citation></ref><ref id="R184"><label>184.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>R</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>A</given-names></name><name name-style="western"><surname>Minami</surname><given-names>M</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>M</given-names></name></person-group><article-title>Involvement of noradrenergic system within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats</article-title><source>Psychopharmacology (Berl)</source><year>2003</year><volume>170</volume><fpage>80</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">12768272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-003-1504-0</pub-id></element-citation></ref><ref id="R185"><label>185.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Rajamanickam</surname><given-names>J</given-names></name><name name-style="western"><surname>Annamalai</surname><given-names>B</given-names></name><name name-style="western"><surname>Rahbek-Clemmensen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Akt-mediated regulation of antidepressant-sensitive serotonin transporter function, cell-surface expression and phosphorylation</article-title><source>Biochem J</source><year>2015</year><volume>468</volume><fpage>177</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">25761794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BJ20140826</pub-id></element-citation></ref><ref id="R186"><label>186.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ragu Varman</surname><given-names>D</given-names></name><name name-style="western"><surname>Jayanthi</surname><given-names>LD</given-names></name><name name-style="western"><surname>Ramamoorthy</surname><given-names>S</given-names></name></person-group><article-title>Glycogen synthase kinase-3&#223; supports serotonin transporter function and trafficking in a phosphorylation-dependent manner</article-title><source>J Neurochem</source><year>2021</year><volume>156</volume><fpage>445</fpage><lpage>464</lpage><pub-id pub-id-type="pmid">32797733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.15152</pub-id><pub-id pub-id-type="pmcid">PMC7882002</pub-id></element-citation></ref><ref id="R187"><label>187.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Franks</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Horn</surname><given-names>JL</given-names></name><name name-style="western"><surname>Janicki</surname><given-names>PK</given-names></name><name name-style="western"><surname>Singh</surname><given-names>G</given-names></name></person-group><article-title>Halothane, isoflurane, xenon, and nitrous oxide inhibit calcium ATPase pump activity in rat brain synaptic plasma membranes</article-title><source>Anesthesiology</source><year>1995</year><volume>82</volume><fpage>108</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">7832292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-199501000-00015</pub-id></element-citation></ref><ref id="R188"><label>188.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Franks</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Wamil</surname><given-names>AW</given-names></name><name name-style="western"><surname>Janicki</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Anesthetic-induced alteration of Ca<sup>2+</sup> homeostasis in neural cells: a temperature-sensitive process that is enhanced by blockade of plasma membrane Ca<sup>2+</sup>-ATPase isoforms</article-title><source>Anesthesiology</source><year>1998</year><volume>89</volume><fpage>149</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">9667305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-199807000-00022</pub-id></element-citation></ref><ref id="R189"><label>189.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Horn</surname><given-names>JL</given-names></name><name name-style="western"><surname>Janicki</surname><given-names>PK</given-names></name><name name-style="western"><surname>Franks</surname><given-names>JJ</given-names></name></person-group><article-title>Nitrous oxide and xenon enhance phospholipid-N-methylation in rat brain synaptic plasma membranes</article-title><source>Life Sci</source><year>1995</year><volume>56</volume><fpage>PL455</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">7791507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0024-3205(95)00220-z</pub-id></element-citation></ref><ref id="R190"><label>190.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>G</given-names></name><name name-style="western"><surname>Janicki</surname><given-names>PK</given-names></name><name name-style="western"><surname>Horn</surname><given-names>JL</given-names></name><name name-style="western"><surname>Janson</surname><given-names>VE</given-names></name><name name-style="western"><surname>Franks</surname><given-names>JJ</given-names></name></person-group><article-title>Inhibition of plasma membrane Ca(2+)-ATPase pump activity in cultured C6 glioma cells by halothane and xenon</article-title><source>Life Sci</source><year>1995</year><volume>56</volume><fpage>PL219</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">7885185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0024-3205(95)00011-t</pub-id></element-citation></ref><ref id="R191"><label>191.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>de Juan-Sanz</surname><given-names>J</given-names></name><name name-style="western"><surname>N&#250;&#241;ez</surname><given-names>E</given-names></name><name name-style="western"><surname>Zafra</surname><given-names>F</given-names></name><etal/></person-group><article-title>Presynaptic control of glycine transporter 2 (GlyT2) by physical and functional association with plasma membrane Ca<sup>2+</sup>-ATPase (PMCA) and Na<sup>+</sup>-Ca<sup>2+</sup> exchanger (NCX)</article-title><source>J Biol Chem</source><year>2014</year><volume>289</volume><fpage>34308</fpage><lpage>34324</lpage><pub-id pub-id-type="pmid">25315779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M114.586966</pub-id><pub-id pub-id-type="pmcid">PMC4256361</pub-id></element-citation></ref><ref id="R192"><label>192.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Harvey</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Yee</surname><given-names>BK</given-names></name></person-group><article-title>Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain</article-title><source>Nat Rev Drug Discov</source><year>2013</year><volume>12</volume><fpage>866</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">24172334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd3893</pub-id></element-citation></ref><ref id="R193"><label>193.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><etal/></person-group><article-title>The protective profile of argon, helium, and xenon in a model of neonatal asphyxia in rats</article-title><source>Crit Care Med</source><year>2012</year><volume>40</volume><fpage>1724</fpage><lpage>1730</lpage><pub-id pub-id-type="pmid">22610177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0b013e3182452164</pub-id></element-citation></ref><ref id="R194"><label>194.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>YW</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>WP</given-names></name><name name-style="western"><surname>Lu</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Timing of xenon-induced delayed postconditioning to protect against spinal cord ischaemia-reperfusion injury in rats</article-title><source>Br J Anaesth</source><year>2014</year><volume>113</volume><fpage>168</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">24277726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/aet352</pub-id></element-citation></ref><ref id="R195"><label>195.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Xenon nanobubbles for the image-guided preemptive treatment of acute ischemic stroke via neuroprotection and microcirculatory restoration</article-title><source>ACS Appl Mater Interfaces</source><year>2021</year><volume>13</volume><fpage>43880</fpage><lpage>43891</lpage><pub-id pub-id-type="pmid">34493044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsami.1c06014</pub-id></element-citation></ref><ref id="R196"><label>196.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>M</given-names></name><name name-style="western"><surname>Pettet</surname><given-names>GK</given-names></name><etal/></person-group><article-title>Xenon preconditioning reduces brain damage from neonatal asphyxia in rats</article-title><source>J Cereb Blood Flow Metab</source><year>2006</year><volume>26</volume><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">16034370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.jcbfm.9600184</pub-id></element-citation></ref><ref id="R197"><label>197.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Shu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Patel</surname><given-names>SM</given-names></name><name name-style="western"><surname>Pac-Soo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Xenon pretreatment attenuates anesthetic-induced apoptosis in the developing brain in comparison with nitrous oxide and hypoxia</article-title><source>Anesthesiology</source><year>2010</year><volume>113</volume><fpage>360</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">20613483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0b013e3181d960d7</pub-id></element-citation></ref><ref id="R198"><label>198.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Aykac</surname><given-names>A</given-names></name><name name-style="western"><surname>&#350;ehirli</surname><given-names>A</given-names></name><name name-style="western"><surname>G&#246;ren</surname><given-names>MZ</given-names></name></person-group><article-title>Evaluation of the effect of prazosin treatment on &#945;-2c adrenoceptor and apoptosis protein levels in the predator scent-induced rat model of post-traumatic stress disorder</article-title><source>J Mol Neurosci</source><year>2020</year><volume>70</volume><fpage>1120</fpage><lpage>1129</lpage><pub-id pub-id-type="pmid">32133592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12031-020-01518-7</pub-id></element-citation></ref><ref id="R199"><label>199.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name><name name-style="western"><surname>Ieong</surname><given-names>E</given-names></name><etal/></person-group><article-title>Xenon and sevoflurane protect against brain injury in a neonatal asphyxia model</article-title><source>Anesthesiology</source><year>2008</year><volume>109</volume><fpage>782</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">18946288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0b013e3181895f88</pub-id></element-citation></ref><ref id="R200"><label>200.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Grimes</surname><given-names>CA</given-names></name><name name-style="western"><surname>Jope</surname><given-names>RS</given-names></name></person-group><article-title>CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium</article-title><source>J Neurochem</source><year>2001</year><volume>78</volume><fpage>1219</fpage><lpage>1232</lpage><pub-id pub-id-type="pmid">11579131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1471-4159.2001.00495.x</pub-id><pub-id pub-id-type="pmcid">PMC1947002</pub-id></element-citation></ref><ref id="R201"><label>201.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jornada</surname><given-names>LK</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>M</given-names></name><name name-style="western"><surname>Valvassori</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain</article-title><source>J Psychiatr Res</source><year>2010</year><volume>44</volume><fpage>506</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">19954800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpsychires.2009.11.002</pub-id></element-citation></ref><ref id="R202"><label>202.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Gim&#233;nez-Cassina</surname><given-names>A</given-names></name><name name-style="western"><surname>Lim</surname><given-names>F</given-names></name><name name-style="western"><surname>D&#237;az-Nido</surname><given-names>J</given-names></name></person-group><article-title>Chronic inhibition of glycogen synthase kinase-3 protects against rotenone-induced cell death in human neuron-like cells by increasing BDNF secretion</article-title><source>Neurosci Lett</source><year>2012</year><volume>531</volume><fpage>182</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">23123787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2012.10.046</pub-id></element-citation></ref><ref id="R203"><label>203.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Rossato</surname><given-names>JI</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>MC</given-names></name><name name-style="western"><surname>Radiske</surname><given-names>A</given-names></name><etal/></person-group><article-title>PKM&#950; inhibition disrupts reconsolidation and erases object recognition memory</article-title><source>J Neurosci</source><year>2019</year><volume>39</volume><fpage>1828</fpage><lpage>1841</lpage><pub-id pub-id-type="pmid">30622166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2270-18.2018</pub-id><pub-id pub-id-type="pmcid">PMC6407297</pub-id></element-citation></ref><ref id="R204"><label>204.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kida</surname><given-names>S</given-names></name><name name-style="western"><surname>Josselyn</surname><given-names>SA</given-names></name><name name-style="western"><surname>Pe&#241;a de Ortiz</surname><given-names>S</given-names></name><etal/></person-group><article-title>CREB required for the stability of new and reactivated fear memories</article-title><source>Nat Neurosci</source><year>2002</year><volume>5</volume><fpage>348</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">11889468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn819</pub-id></element-citation></ref><ref id="R205"><label>205.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Tronson</surname><given-names>NC</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>SL</given-names></name><name name-style="western"><surname>Neve</surname><given-names>RL</given-names></name><name name-style="western"><surname>Nestler</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Olausson</surname><given-names>P</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>JR</given-names></name></person-group><article-title>Distinctive roles for amygdalar CREB in reconsolidation and extinction of fear memory</article-title><source>Learn Mem</source><year>2012</year><volume>19</volume><fpage>178</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">22505719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/lm.025783.112</pub-id><pub-id pub-id-type="pmcid">PMC3348518</pub-id></element-citation></ref><ref id="R206"><label>206.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Borlikova</surname><given-names>G</given-names></name><name name-style="western"><surname>Endo</surname><given-names>S</given-names></name></person-group><article-title>Inducible cAMP early repressor (ICER) and brain functions</article-title><source>Mol Neurobiol</source><year>2009</year><volume>40</volume><fpage>73</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">19434522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-009-8072-1</pub-id><pub-id pub-id-type="pmcid">PMC2699388</pub-id></element-citation></ref><ref id="R207"><label>207.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Spencer</surname><given-names>CM</given-names></name><name name-style="western"><surname>Jahng</surname><given-names>JW</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>V</given-names></name><name name-style="western"><surname>Houpt</surname><given-names>TA</given-names></name></person-group><article-title>Lithium-induced gene expression of inducible cyclic adenosine monophosphate early repressor in the rat adrenal gland</article-title><source>J Neurosci Res</source><year>2005</year><volume>82</volume><fpage>273</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">16175568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jnr.20617</pub-id></element-citation></ref><ref id="R208"><label>208.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Lehmke</surname><given-names>L</given-names></name><name name-style="western"><surname>Coburn</surname><given-names>M</given-names></name><name name-style="western"><surname>M&#246;ller</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inhalational anesthetics accelerate desensitization of acid-sensing ion channels</article-title><source>Neuropharmacology</source><year>2018</year><volume>135</volume><fpage>496</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">29627444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2018.04.004</pub-id></element-citation></ref><ref id="R209"><label>209.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Koffman</surname><given-names>EE</given-names></name><name name-style="western"><surname>Kruse</surname><given-names>CM</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K</given-names></name><etal/></person-group><article-title>Acid-sensing ion channel 1a regulates the specificity of reconsolidation of conditioned threat responses</article-title><source>JCI Insight</source><year>2022</year><volume>7</volume><fpage>e155341</fpage><pub-id pub-id-type="pmid">35025766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.155341</pub-id><pub-id pub-id-type="pmcid">PMC8876458</pub-id></element-citation></ref><ref id="R210"><label>210.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Gruss</surname><given-names>M</given-names></name><name name-style="western"><surname>Bushell</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Bright</surname><given-names>DP</given-names></name><name name-style="western"><surname>Lieb</surname><given-names>WR</given-names></name><name name-style="western"><surname>Mathie</surname><given-names>A</given-names></name><name name-style="western"><surname>Franks</surname><given-names>NP</given-names></name></person-group><article-title>Two-pore-domain K<sup>+</sup> channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane</article-title><source>Mol Pharmacol</source><year>2004</year><volume>65</volume><fpage>443</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">14742687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/mol.65.2.443</pub-id></element-citation></ref><ref id="R211"><label>211.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bantel</surname><given-names>C</given-names></name><name name-style="western"><surname>Maze</surname><given-names>M</given-names></name><name name-style="western"><surname>Trapp</surname><given-names>S</given-names></name></person-group><article-title>Neuronal preconditioning by inhalational anesthetics: evidence for the role of plasmalemmal adenosine triphosphate-sensitive potassium channels</article-title><source>Anesthesiology</source><year>2009</year><volume>110</volume><fpage>986</fpage><lpage>995</lpage><pub-id pub-id-type="pmid">19352153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0b013e31819dadc7</pub-id><pub-id pub-id-type="pmcid">PMC2930813</pub-id></element-citation></ref><ref id="R212"><label>212.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bantel</surname><given-names>C</given-names></name><name name-style="western"><surname>Maze</surname><given-names>M</given-names></name><name name-style="western"><surname>Trapp</surname><given-names>S</given-names></name></person-group><article-title>Noble gas xenon is a novel adenosine triphosphate-sensitive potassium channel opener</article-title><source>Anesthesiology</source><year>2010</year><volume>112</volume><fpage>623</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">20179498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0b013e3181cf894a</pub-id><pub-id pub-id-type="pmcid">PMC2935677</pub-id></element-citation></ref><ref id="R213"><label>213.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lian</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name></person-group><article-title>Pretreatment with xenon protected immature rabbit heart from ischaemia/reperfusion injury by opening of the mitoKATP channel</article-title><source>Heart Lung Circ</source><year>2013</year><volume>22</volume><fpage>276</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">23261327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hlc.2012.10.016</pub-id></element-citation></ref><ref id="R214"><label>214.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>P</given-names></name><name name-style="western"><surname>Teng</surname><given-names>J</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J</given-names></name><etal/></person-group><article-title>Intermittent exposure to xenon protects against gentamicin-induced nephrotoxicity</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e64329</fpage><pub-id pub-id-type="pmid">23737979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0064329</pub-id><pub-id pub-id-type="pmcid">PMC3667819</pub-id></element-citation></ref><ref id="R215"><label>215.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>P</given-names></name><name name-style="western"><surname>Teng</surname><given-names>J</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J</given-names></name><etal/></person-group><article-title>miR-21 contributes to xenon-conferred amelioration of renal ischemia-reperfusion injury in mice</article-title><source>Anesthesiology</source><year>2013</year><volume>119</volume><fpage>621</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">23681145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0b013e318298e5f1</pub-id><pub-id pub-id-type="pmcid">PMC4428598</pub-id></element-citation></ref><ref id="R216"><label>216.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kassab</surname><given-names>NED</given-names></name><name name-style="western"><surname>Mehlfeld</surname><given-names>V</given-names></name><name name-style="western"><surname>Kass</surname><given-names>J</given-names></name><name name-style="western"><surname>Biel</surname><given-names>M</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>G</given-names></name><name name-style="western"><surname>Rammes</surname><given-names>G</given-names></name></person-group><article-title>Xenon&#8217;s sedative effect is mediated by interaction with the cyclic nucleotide-binding domain (CNBD) of HCN2 channels expressed by thalamocortical neurons of the ventrobasal nucleus in mice</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><fpage>8613</fpage><pub-id pub-id-type="pmid">37239964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24108613</pub-id><pub-id pub-id-type="pmcid">PMC10218445</pub-id></element-citation></ref><ref id="R217"><label>217.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>JP</given-names></name><name name-style="western"><surname>Calcott</surname><given-names>G</given-names></name><name name-style="western"><surname>Jenes</surname><given-names>A</given-names></name><etal/></person-group><article-title>Xenon reduces activation of transient receptor potential vanilloid type 1 (TRPV1) in rat dorsal root ganglion cells and in human TRPV1-expressing HEK293 cells</article-title><source>Life Sci</source><year>2011</year><volume>88</volume><fpage>141</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">21056583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2010.11.002</pub-id></element-citation></ref><ref id="R218"><label>218.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>P</given-names></name><name name-style="western"><surname>Januszewski</surname><given-names>A</given-names></name><etal/></person-group><article-title>Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain</article-title><source>Anesthesiology</source><year>2007</year><volume>106</volume><fpage>746</fpage><lpage>753</lpage><pub-id pub-id-type="pmid">17413912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.anes.0000264762.48920.80</pub-id></element-citation></ref><ref id="R219"><label>219.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>HN</given-names></name><name name-style="western"><surname>Haelewyn</surname><given-names>B</given-names></name><name name-style="western"><surname>Risso</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Colloc&#8217;h</surname><given-names>N</given-names></name><name name-style="western"><surname>Abraini</surname><given-names>JH</given-names></name></person-group><article-title>Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke</article-title><source>J Cereb Blood Flow Metab</source><year>2010</year><volume>30</volume><fpage>718</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">20087367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jcbfm.2009.275</pub-id><pub-id pub-id-type="pmcid">PMC2949169</pub-id></element-citation></ref><ref id="R220"><label>220.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Cahill</surname><given-names>J</given-names></name><name name-style="western"><surname>Ruffing</surname><given-names>AM</given-names></name></person-group><article-title>Revisiting the effects of xenon on urate oxidase and tissue plasminogen activator: no evidence for inhibition by noble gases</article-title><source>Front Mol Biosci</source><year>2020</year><volume>7</volume><fpage>574477</fpage><pub-id pub-id-type="pmid">33024747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2020.574477</pub-id><pub-id pub-id-type="pmcid">PMC7516214</pub-id></element-citation></ref><ref id="R221"><label>221.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>T</given-names></name><name name-style="western"><surname>Booher</surname><given-names>K</given-names></name><name name-style="western"><surname>Moody</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Enhanced cerebroprotection of xenon-loaded liposomes in combination with rtPA thrombolysis for embolic ischemic stroke</article-title><source>Biomolecules</source><year>2023</year><volume>13</volume><fpage>1256</fpage><pub-id pub-id-type="pmid">37627321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom13081256</pub-id><pub-id pub-id-type="pmcid">PMC10452377</pub-id></element-citation></ref><ref id="R222"><label>222.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Epstein</surname><given-names>DH</given-names></name><name name-style="western"><surname>Preston</surname><given-names>KL</given-names></name></person-group><article-title>Daily life hour by hour, with and without cocaine: an ecological momentary assessment study</article-title><source>Psychopharmacology (Berl)</source><year>2010</year><volume>211</volume><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">20532873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-010-1884-x</pub-id><pub-id pub-id-type="pmcid">PMC2940233</pub-id></element-citation></ref><ref id="R223"><label>223.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jesse</surname><given-names>S</given-names></name><name name-style="western"><surname>Br&#229;then</surname><given-names>G</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>M</given-names></name><etal/></person-group><article-title>Alcohol withdrawal syndrome: mechanisms, manifestations, and management</article-title><source>Acta Neurol Scand</source><year>2017</year><volume>135</volume><fpage>4</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">27586815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ane.12671</pub-id><pub-id pub-id-type="pmcid">PMC6084325</pub-id></element-citation></ref><ref id="R224"><label>224.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></name><name name-style="western"><surname>Jones</surname><given-names>EB</given-names></name><name name-style="western"><surname>Einstein</surname><given-names>EB</given-names></name><name name-style="western"><surname>Wargo</surname><given-names>EM</given-names></name></person-group><article-title>Prevention and treatment of opioid misuse and addiction: a review</article-title><source>JAMA Psychiatry</source><year>2019</year><volume>76</volume><fpage>208</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">30516809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2018.3126</pub-id></element-citation></ref><ref id="R225"><label>225.</label><element-citation publication-type="webpage" publication-format="web"><person-group person-group-type="author"><collab>Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration (FDA)</collab></person-group><article-title>The voice of the patient</article-title><comment><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/124391/download">https://www.fda.gov/media/124391/download</uri>. Accessed August 2, 2024</comment></element-citation></ref><ref id="R226"><label>226.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Becker</surname><given-names>HC</given-names></name></person-group><article-title>Alcohol dependence, withdrawal, and relapse</article-title><source>Alcohol Res Health</source><year>2008</year><volume>31</volume><fpage>348</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">23584009</pub-id><pub-id pub-id-type="pmcid">PMC3860472</pub-id></element-citation></ref><ref id="R227"><label>227.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Pantazis</surname><given-names>CB</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>LA</given-names></name><name name-style="western"><surname>Tunstall</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Carmack</surname><given-names>SA</given-names></name><name name-style="western"><surname>Koob</surname><given-names>GF</given-names></name><name name-style="western"><surname>Vendruscolo</surname><given-names>LF</given-names></name></person-group><article-title>Cues conditioned to withdrawal and negative reinforcement: Neglected but key motivational elements driving opioid addiction</article-title><source>Sci Adv</source><year>2021</year><volume>7</volume><fpage>eabf0364</fpage><pub-id pub-id-type="pmid">33827822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abf0364</pub-id><pub-id pub-id-type="pmcid">PMC8026136</pub-id></element-citation></ref><ref id="R228"><label>228.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Leclercq</surname><given-names>S</given-names></name><name name-style="western"><surname>Matamoros</surname><given-names>S</given-names></name><name name-style="western"><surname>Cani</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity</article-title><source>Proc Natl Acad Sci U S A</source><year>2014</year><volume>111</volume><fpage>E4485</fpage><lpage>4493</lpage><pub-id pub-id-type="pmid">25288760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1415174111</pub-id><pub-id pub-id-type="pmcid">PMC4210345</pub-id></element-citation></ref><ref id="R229"><label>229.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Akbarali</surname><given-names>HI</given-names></name><name name-style="western"><surname>Dewey</surname><given-names>WL</given-names></name></person-group><article-title>Gastrointestinal motility, dysbiosis and opioid-induced tolerance: is there a link?</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2019</year><volume>16</volume><fpage>323</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">31024090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-019-0150-x</pub-id><pub-id pub-id-type="pmcid">PMC7045338</pub-id></element-citation></ref><ref id="R230"><label>230.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Eisenstein</surname><given-names>TK</given-names></name></person-group><article-title>The role of opioid receptors in immune system function</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>2904</fpage><pub-id pub-id-type="pmid">31921165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.02904</pub-id><pub-id pub-id-type="pmcid">PMC6934131</pub-id></element-citation></ref><ref id="R231"><label>231.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Sullivan</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Schwaber</surname><given-names>JS</given-names></name></person-group><article-title>Similarities in alcohol and opioid withdrawal syndromes suggest common negative reinforcement mechanisms involving the interoceptive antireward pathway</article-title><source>Neurosci Biobehav Rev</source><year>2021</year><volume>125</volume><fpage>355</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">33647322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2021.02.033</pub-id><pub-id pub-id-type="pmcid">PMC8555739</pub-id></element-citation></ref><ref id="R232"><label>232.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Pongratz</surname><given-names>G</given-names></name><name name-style="western"><surname>Straub</surname><given-names>RH</given-names></name></person-group><article-title>The sympathetic nervous response in inflammation</article-title><source>Arthritis Res Ther</source><year>2014</year><volume>16</volume><fpage>504</fpage><pub-id pub-id-type="pmid">25789375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-014-0504-2</pub-id><pub-id pub-id-type="pmcid">PMC4396833</pub-id></element-citation></ref><ref id="R233"><label>233.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bessi&#232;re</surname><given-names>B</given-names></name><name name-style="western"><surname>Laboureyras</surname><given-names>E</given-names></name><name name-style="western"><surname>Laulin</surname><given-names>JP</given-names></name><name name-style="western"><surname>Simonnet</surname><given-names>G</given-names></name></person-group><article-title>Xenon prevents inflammation-induced delayed pain hypersensitivity in rats</article-title><source>Neuroreport</source><year>2010</year><volume>21</volume><fpage>1167</fpage><lpage>1171</lpage><pub-id pub-id-type="pmid">20966786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNR.0b013e328340d7f6</pub-id></element-citation></ref><ref id="R234"><label>234.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Campos-Pires</surname><given-names>R</given-names></name><name name-style="western"><surname>Hirnet</surname><given-names>T</given-names></name><name name-style="western"><surname>Valeo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Xenon improves long-term cognitive function, reduces neuronal loss and chronic neuroinflammation, and improves survival after traumatic brain injury in mice</article-title><source>Br J Anaesth</source><year>2019</year><volume>123</volume><fpage>60</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">31122738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bja.2019.02.032</pub-id><pub-id pub-id-type="pmcid">PMC6676773</pub-id></element-citation></ref><ref id="R235"><label>235.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Campos-Pires</surname><given-names>R</given-names></name><name name-style="western"><surname>Onggradito</surname><given-names>H</given-names></name><name name-style="western"><surname>Ujvari</surname><given-names>E</given-names></name><etal/></person-group><article-title>Xenon treatment after severe traumatic brain injury improves locomotor outcome, reduces acute neuronal loss and enhances early beneficial neuroinflammation: a randomized, blinded, controlled animal study</article-title><source>Crit Care</source><year>2020</year><volume>24</volume><fpage>667</fpage><pub-id pub-id-type="pmid">33246487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-020-03373-9</pub-id><pub-id pub-id-type="pmcid">PMC7691958</pub-id></element-citation></ref><ref id="R236"><label>236.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>J</given-names></name><name name-style="western"><surname>Meng</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Xenon produces rapid antidepressant- and anxiolytic-like effects in lipopolysaccharide-induced depression mice model</article-title><source>Neuroreport</source><year>2020</year><volume>31</volume><fpage>387</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">32106142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNR.0000000000001415</pub-id></element-citation></ref><ref id="R237"><label>237.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>SR</given-names></name><name name-style="western"><surname>Hua</surname><given-names>KF</given-names></name><name name-style="western"><surname>Chu</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Xenon blunts NF-&#954;B/NLRP3 inflammasome activation and improves acute onset of accelerated and severe lupus nephritis in mice</article-title><source>Kidney Int</source><year>2020</year><volume>98</volume><fpage>378</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">32622527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2020.02.033</pub-id></element-citation></ref><ref id="R238"><label>238.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ou</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name></person-group><article-title>Xenon attenuated neonatal lipopolysaccharide exposure induced neuronal necroptosis and subsequently improved cognition in juvenile rats</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><fpage>1002920</fpage><pub-id pub-id-type="pmid">36534038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.1002920</pub-id><pub-id pub-id-type="pmcid">PMC9755588</pub-id></element-citation></ref><ref id="R239"><label>239.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ishiguro</surname><given-names>Y</given-names></name><name name-style="western"><surname>Goto</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Terui</surname><given-names>K</given-names></name><name name-style="western"><surname>Niimi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Morita</surname><given-names>S</given-names></name></person-group><article-title>Effect of xenon on autonomic cardiovascular control--comparison with isoflurane and nitrous oxide</article-title><source>J Clin Anesth</source><year>2000</year><volume>12</volume><fpage>196</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">10869917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0952-8180(00)00139-2</pub-id></element-citation></ref><ref id="R240"><label>240.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hanss</surname><given-names>R</given-names></name><name name-style="western"><surname>Bein</surname><given-names>B</given-names></name><name name-style="western"><surname>Turowski</surname><given-names>P</given-names></name><etal/></person-group><article-title>The influence of xenon on regulation of the autonomic nervous system in patients at high risk of perioperative cardiac complications</article-title><source>Br J Anaesth</source><year>2006</year><volume>96</volume><fpage>427</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">16500952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/ael028</pub-id></element-citation></ref><ref id="R241"><label>241.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bubeev Iu</surname><given-names>A</given-names></name><name name-style="western"><surname>Kal&#8217;manov</surname><given-names>AS</given-names></name><name name-style="western"><surname>Kotrovskaia</surname><given-names>TI</given-names></name></person-group><article-title>Correction of the functional state of deck aviation pilots by the course of inhalation of therapeutic doses of xenon during long march</article-title><source>Aviakosm Ekolog Med</source><year>2011</year><volume>45</volume><fpage>10</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">21970037</pub-id></element-citation></ref><ref id="R242"><label>242.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Igoshina</surname><given-names>TV</given-names></name><name name-style="western"><surname>Kotrovskaya</surname><given-names>TI</given-names></name><name name-style="western"><surname>Bubeev</surname><given-names>YA</given-names></name><name name-style="western"><surname>Schastlivtseva</surname><given-names>DV</given-names></name><name name-style="western"><surname>Potapov</surname><given-names>AV</given-names></name></person-group><article-title>Practicing subnarcotic xenon dose inhalation in spa treatment of posttraumatic stress-induced disorders</article-title><source>Aviakosm Ekolog Med</source><year>2014</year><volume>48</volume><fpage>58</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">26036001</pub-id></element-citation></ref><ref id="R243"><label>243.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Shulman</surname><given-names>M</given-names></name><name name-style="western"><surname>Greiner</surname><given-names>MG</given-names></name><name name-style="western"><surname>Tafessu</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Rapid initiation of injection naltrexone for opioid use disorder: a stepped-wedge cluster randomized clinical trial</article-title><source>JAMA Netw Open</source><year>2024</year><volume>7</volume><fpage>e249744</fpage><pub-id pub-id-type="pmid">38717773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2024.9744</pub-id><pub-id pub-id-type="pmcid">PMC11079685</pub-id></element-citation></ref><ref id="R244"><label>244.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Thorat</surname><given-names>SN</given-names></name><name name-style="western"><surname>Barjavel</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Matwyshyn</surname><given-names>GA</given-names></name><name name-style="western"><surname>Bhargava</surname><given-names>HN</given-names></name></person-group><article-title>Comparative effects of NG-monomethyl-L-arginine and MK-801 on the abstinence syndrome in morphine-dependent mice</article-title><source>Brain Res</source><year>1994</year><volume>642</volume><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">7518322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-8993(94)90917-2</pub-id></element-citation></ref><ref id="R245"><label>245.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Rasmussen</surname><given-names>K</given-names></name><name name-style="western"><surname>Kendrick</surname><given-names>WT</given-names></name><name name-style="western"><surname>Kogan</surname><given-names>JH</given-names></name><name name-style="western"><surname>Aghajanian</surname><given-names>GK</given-names></name></person-group><article-title>A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal</article-title><source>Neuropsychopharmacology</source><year>1996</year><volume>15</volume><fpage>497</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">8914123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0893-133X(96)00094-2</pub-id></element-citation></ref><ref id="R246"><label>246.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bristow</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Hogg</surname><given-names>JE</given-names></name><name name-style="western"><surname>Hutson</surname><given-names>PH</given-names></name></person-group><article-title>Competitive and glycine/NMDA receptor antagonists attenuate withdrawal-induced behaviours and increased hippocampal acetylcholine efflux in morphine-dependent rats</article-title><source>Neuropharmacology</source><year>1997</year><volume>36</volume><fpage>241</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">9144662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0028-3908(97)00006-3</pub-id></element-citation></ref><ref id="R247"><label>247.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Popik</surname><given-names>P</given-names></name><name name-style="western"><surname>Mamczarz</surname><given-names>J</given-names></name><name name-style="western"><surname>Fraczek</surname><given-names>M</given-names></name><name name-style="western"><surname>Wid&#322;a</surname><given-names>M</given-names></name><name name-style="western"><surname>Hesselink</surname><given-names>M</given-names></name><name name-style="western"><surname>Danysz</surname><given-names>W</given-names></name></person-group><article-title>Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists</article-title><source>Neuropharmacology</source><year>1998</year><volume>37</volume><fpage>1033</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">9833632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0028-3908(98)00105-1</pub-id></element-citation></ref><ref id="R248"><label>248.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kotli&#324;ska</surname><given-names>J</given-names></name></person-group><article-title>Attenuation of morphine dependence and withdrawal by glycine B site antagonists in rats</article-title><source>Pharmacol Biochem Behav</source><year>2001</year><volume>68</volume><fpage>157</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">11274720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0091-3057(00)00443-3</pub-id></element-citation></ref><ref id="R249"><label>249.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jovaisa</surname><given-names>T</given-names></name><name name-style="western"><surname>Laurinenas</surname><given-names>G</given-names></name><name name-style="western"><surname>Vosylius</surname><given-names>S</given-names></name><name name-style="western"><surname>Sipylaite</surname><given-names>J</given-names></name><name name-style="western"><surname>Badaras</surname><given-names>R</given-names></name><name name-style="western"><surname>Ivaskevicius</surname><given-names>J</given-names></name></person-group><article-title>Effects of ketamine on precipitated opiate withdrawal</article-title><source>Medicina (Kaunas)</source><year>2006</year><volume>42</volume><fpage>625</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">16963828</pub-id></element-citation></ref><ref id="R250"><label>250.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Krupitsky</surname><given-names>EM</given-names></name><name name-style="western"><surname>Rudenko</surname><given-names>AA</given-names></name><name name-style="western"><surname>Burakov</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam</article-title><source>Alcohol Clin Exp Res</source><year>2007</year><volume>31</volume><fpage>604</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">17374039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1530-0277.2007.00344.x</pub-id></element-citation></ref><ref id="R251"><label>251.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Fluyau</surname><given-names>D</given-names></name><name name-style="western"><surname>Revadigar</surname><given-names>N</given-names></name><name name-style="western"><surname>Pierre</surname><given-names>CG</given-names></name></person-group><article-title>Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: a systematic review</article-title><source>Drug Alcohol Depend</source><year>2020</year><volume>208</volume><fpage>107845</fpage><pub-id pub-id-type="pmid">31978670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2020.107845</pub-id></element-citation></ref><ref id="R252"><label>252.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ozkula</surname><given-names>S</given-names></name><name name-style="western"><surname>Jafarova Demirkapu</surname><given-names>M</given-names></name><name name-style="western"><surname>Yananli</surname><given-names>HR</given-names></name><name name-style="western"><surname>Aydin</surname><given-names>B</given-names></name><name name-style="western"><surname>Nacar</surname><given-names>C</given-names></name><name name-style="western"><surname>Cabadak</surname><given-names>H</given-names></name></person-group><article-title>The effect of acute topiramate administration on morphine withdrawal syndrome and brain-derived neurotrophic factor in central nervous system</article-title><source>Neurol Res</source><year>2023</year><volume>45</volume><fpage>730</fpage><lpage>737</lpage><pub-id pub-id-type="pmid">37105528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/01616412.2023.2203611</pub-id></element-citation></ref><ref id="R253"><label>253.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hui</surname><given-names>SC</given-names></name><name name-style="western"><surname>Sevilla</surname><given-names>EL</given-names></name><name name-style="western"><surname>Ogle</surname><given-names>CW</given-names></name></person-group><article-title>Prevention by the 5-HT3 receptor antagonist, ondansetron, of morphine-dependence and tolerance in the rat</article-title><source>Br J Pharmacol</source><year>1996</year><volume>118</volume><fpage>1044</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">8799580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1476-5381.1996.tb15504.x</pub-id><pub-id pub-id-type="pmcid">PMC1909532</pub-id></element-citation></ref><ref id="R254"><label>254.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Roychoudhury</surname><given-names>M</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>SK</given-names></name></person-group><article-title>Prevention of morphine discontinuation phenomenon in mice by ondansetron, a selective 5-HT3 antagonist</article-title><source>Methods Find Exp Clin Pharmacol</source><year>1996</year><volume>18</volume><fpage>677</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">9121224</pub-id></element-citation></ref><ref id="R255"><label>255.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Pinelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Trivulzio</surname><given-names>S</given-names></name><name name-style="western"><surname>Tomasoni</surname><given-names>L</given-names></name></person-group><article-title>Effects of ondansetron administration on opioid withdrawal syndrome observed in rats</article-title><source>Eur J Pharmacol</source><year>1997</year><volume>340</volume><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">9537805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0014-2999(97)01349-6</pub-id></element-citation></ref><ref id="R256"><label>256.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Peltz</surname><given-names>G</given-names></name><name name-style="western"><surname>Jansson</surname><given-names>LM</given-names></name><name name-style="western"><surname>Adeniyi-Jones</surname><given-names>S</given-names></name><etal/></person-group><article-title>Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial</article-title><source>J Perinatol</source><year>2023</year><volume>43</volume><fpage>271</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">36030327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41372-022-01487-2</pub-id><pub-id pub-id-type="pmcid">PMC9968817</pub-id></element-citation></ref><ref id="R257"><label>257.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>LF</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Clemenson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Ondansetron does not reduce withdrawal in patients with physical dependence on chronic opioid therapy</article-title><source>J Addict Med</source><year>2017</year><volume>11</volume><fpage>342</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">28514235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ADM.0000000000000321</pub-id><pub-id pub-id-type="pmcid">PMC5610060</pub-id></element-citation></ref><ref id="R258"><label>258.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Guiraud</surname><given-names>J</given-names></name><name name-style="western"><surname>Spanagel</surname><given-names>R</given-names></name><name name-style="western"><surname>van den Brink</surname><given-names>W</given-names></name></person-group><article-title>Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy</article-title><source>Int Rev Neurobiol</source><year>2024</year><volume>175</volume><fpage>187</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">38555116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.irn.2024.03.005</pub-id></element-citation></ref><ref id="R259"><label>259.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Siraskar</surname><given-names>B</given-names></name><name name-style="western"><surname>V&#246;lkl</surname><given-names>J</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Enhanced catecholamine release in mice expressing PKB/SGK-resistant GSK3</article-title><source>Pflugers Arch</source><year>2011</year><volume>462</volume><fpage>811</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">21922189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00424-011-1006-6</pub-id></element-citation></ref><ref id="R260"><label>260.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Buchholz</surname><given-names>B</given-names></name><name name-style="western"><surname>Donato</surname><given-names>M</given-names></name><name name-style="western"><surname>Perez</surname><given-names>V</given-names></name><etal/></person-group><article-title>Changes in the loading conditions induced by vagal stimulation modify the myocardial infarct size through sympathetic-parasympathetic interactions</article-title><source>Pflugers Arch</source><year>2015</year><volume>467</volume><fpage>1509</fpage><lpage>1522</lpage><pub-id pub-id-type="pmid">25127674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00424-014-1591-2</pub-id></element-citation></ref><ref id="R261"><label>261.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Fajol</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Umbach</surname><given-names>AT</given-names></name><name name-style="western"><surname>Quarles</surname><given-names>LD</given-names></name><name name-style="western"><surname>Lang</surname><given-names>F</given-names></name><name name-style="western"><surname>F&#246;ller</surname><given-names>M</given-names></name></person-group><article-title>Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by &#946;-blocker treatment</article-title><source>FASEB J</source><year>2016</year><volume>30</volume><fpage>994</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">26527066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.15-279943</pub-id><pub-id pub-id-type="pmcid">PMC6994240</pub-id></element-citation></ref><ref id="R262"><label>262.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Welzig</surname><given-names>CM</given-names></name><name name-style="western"><surname>Haburcak</surname><given-names>M</given-names></name><etal/></person-group><article-title>Targeted disruption of glycogen synthase kinase-3&#946; in cardiomyocytes attenuates cardiac parasympathetic dysfunction in type 1 diabetic Akita mice</article-title><source>PLoS One</source><year>2019</year><volume>14</volume><fpage>e0215213</fpage><pub-id pub-id-type="pmid">30978208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0215213</pub-id><pub-id pub-id-type="pmcid">PMC6461277</pub-id></element-citation></ref><ref id="R263"><label>263.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jope</surname><given-names>RS</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lowell</surname><given-names>JA</given-names></name><name name-style="western"><surname>Worthen</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Sitbon</surname><given-names>YH</given-names></name><name name-style="western"><surname>Beurel</surname><given-names>E</given-names></name></person-group><article-title>Stressed and inflamed, can GSK3 be blamed?</article-title><source>Trends Biochem Sci</source><year>2017</year><volume>42</volume><fpage>180</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">27876551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibs.2016.10.009</pub-id><pub-id pub-id-type="pmcid">PMC5336482</pub-id></element-citation></ref><ref id="R264"><label>264.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmeister</surname><given-names>L</given-names></name><name name-style="western"><surname>Diekmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Brand</surname><given-names>K</given-names></name><name name-style="western"><surname>Huber</surname><given-names>R</given-names></name></person-group><article-title>GSK3: a kinase balancing promotion and resolution of inflammation</article-title><source>Cells</source><year>2020</year><volume>9</volume><fpage>820</fpage><pub-id pub-id-type="pmid">32231133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9040820</pub-id><pub-id pub-id-type="pmcid">PMC7226814</pub-id></element-citation></ref><ref id="R265"><label>265.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dehpour</surname><given-names>AR</given-names></name><name name-style="western"><surname>Farsam</surname><given-names>H</given-names></name><name name-style="western"><surname>Azizabadi-Farahani</surname><given-names>M</given-names></name></person-group><article-title>Inhibition of the morphine withdrawal syndrome and the development of physical dependence by lithium in mice</article-title><source>Neuropharmacology</source><year>1995</year><volume>34</volume><fpage>115</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">7623960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0028-3908(94)00121-8</pub-id></element-citation></ref><ref id="R266"><label>266.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>WW</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>SY</given-names></name><name name-style="western"><surname>Liao</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Coadministration of glycogen-synthase kinase 3 inhibitor with morphine attenuates chronic morphine-induced analgesic tolerance and withdrawal syndrome</article-title><source>J Chin Med Assoc</source><year>2014</year><volume>77</volume><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">24176578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcma.2013.09.008</pub-id></element-citation></ref><ref id="R267"><label>267.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>P</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>B</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>BM</given-names></name></person-group><article-title>In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator</article-title><source>Psychopharmacology (Berl)</source><year>2015</year><volume>232</volume><fpage>465</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">25059539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-014-3680-5</pub-id></element-citation></ref><ref id="R268"><label>268.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Sellers</surname><given-names>EM</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>SD</given-names></name><name name-style="western"><surname>Zilm</surname><given-names>DH</given-names></name><name name-style="western"><surname>Shanks</surname><given-names>C</given-names></name></person-group><article-title>Lithium treatment during alcoholic withdrawal</article-title><source>Clin Pharmacol Ther</source><year>1976</year><volume>20</volume><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">181193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt1976202199</pub-id></element-citation></ref><ref id="R269"><label>269.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Seth</surname><given-names>V</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>M</given-names></name><name name-style="western"><surname>Upadhyaya</surname><given-names>P</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>M</given-names></name><name name-style="western"><surname>Moghe</surname><given-names>V</given-names></name></person-group><article-title>Effect of potassium channel modulators on morphine withdrawal in mice</article-title><source>Subst Abuse</source><year>2010</year><volume>4</volume><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">22879744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4137/SART.S6211</pub-id><pub-id pub-id-type="pmcid">PMC3411524</pub-id></element-citation></ref><ref id="R270"><label>270.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>C</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K</given-names></name><name name-style="western"><surname>Okerman</surname><given-names>T</given-names></name><etal/></person-group><article-title>Morphine efficacy, tolerance, and hypersensitivity are altered after modulation of SUR1 subtype K(ATP) channel activity in mice</article-title><source>Front Neurosci</source><year>2019</year><volume>13</volume><fpage>1122</fpage><pub-id pub-id-type="pmid">31695594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2019.01122</pub-id><pub-id pub-id-type="pmcid">PMC6817471</pub-id></element-citation></ref><ref id="R271"><label>271.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bedair</surname><given-names>AF</given-names></name><name name-style="western"><surname>Wahid</surname><given-names>A</given-names></name><name name-style="western"><surname>El-Mezayen</surname><given-names>NS</given-names></name><name name-style="western"><surname>Afify</surname><given-names>EA</given-names></name></person-group><article-title>Nicorandil reduces morphine withdrawal symptoms, potentiates morphine antinociception, and ameliorates liver fibrosis in rats</article-title><source>Life Sci</source><year>2023</year><volume>319</volume><fpage>121522</fpage><pub-id pub-id-type="pmid">36822314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2023.121522</pub-id></element-citation></ref><ref id="R272"><label>272.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Doucette</surname><given-names>A</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K</given-names></name><name name-style="western"><surname>Hulke</surname><given-names>S</given-names></name><etal/></person-group><article-title>K(ATP) channel prodrugs reduce inflammatory and neuropathic hypersensitivity, morphine-induced hypersensitivity, and precipitated withdrawal in mice</article-title><source>J Pharmacol Exp Ther</source><year>2023</year><volume>387</volume><fpage>18</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">36931644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.122.001522</pub-id><pub-id pub-id-type="pmcid">PMC10519579</pub-id></element-citation></ref><ref id="R273"><label>273.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Spahn</surname><given-names>V</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>O</given-names></name><name name-style="western"><surname>Endres-Becker</surname><given-names>J</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>M</given-names></name><name name-style="western"><surname>Stein</surname><given-names>C</given-names></name><name name-style="western"><surname>Z&#246;llner</surname><given-names>C</given-names></name></person-group><article-title>Opioid withdrawal increases transient receptor potential vanilloid 1 activity in a protein kinase A-dependent manner</article-title><source>Pain</source><year>2013</year><volume>154</volume><fpage>598</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">23398938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pain.2012.12.026</pub-id></element-citation></ref><ref id="R274"><label>274.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Fatemi</surname><given-names>I</given-names></name><name name-style="western"><surname>Hadadianpour</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fatehi</surname><given-names>F</given-names></name><etal/></person-group><article-title>The role of locus coeruleus nucleus TRPV1 receptors in the development and expression of morphine dependence</article-title><source>Iran J Basic Med Sci</source><year>2019</year><volume>22</volume><fpage>1186</fpage><lpage>1191</lpage><pub-id pub-id-type="pmid">31998461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.22038/ijbms.2019.35055.8338</pub-id><pub-id pub-id-type="pmcid">PMC6885386</pub-id></element-citation></ref><ref id="R275"><label>275.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dandekar</surname><given-names>MP</given-names></name><name name-style="western"><surname>Yin</surname><given-names>X</given-names></name><name name-style="western"><surname>Peng</surname><given-names>T</given-names></name><etal/></person-group><article-title>Repetitive xenon treatment improves post-stroke sensorimotor and neuropsychiatric dysfunction</article-title><source>J Affect Disord</source><year>2022</year><volume>301</volume><fpage>315</fpage><lpage>330</lpage><pub-id pub-id-type="pmid">34990636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2022.01.025</pub-id></element-citation></ref><ref id="R276"><label>276.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Azzopardi</surname><given-names>D</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Kapetanakis</surname><given-names>A</given-names></name><etal/></person-group><article-title>Anticonvulsant effect of xenon on neonatal asphyxial seizures</article-title><source>Arch Dis Child Fetal Neonatal Ed</source><year>2013</year><volume>98</volume><fpage>F437</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">23572341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/archdischild-2013-303786</pub-id></element-citation></ref><ref id="R277"><label>277.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Xenon exerts anti-seizure and neuroprotective effects in kainic acid-induced status epilepticus and neonatal hypoxia-induced seizure</article-title><source>Exp Neurol</source><year>2019</year><volume>322</volume><fpage>113054</fpage><pub-id pub-id-type="pmid">31499063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2019.113054</pub-id></element-citation></ref><ref id="R278"><label>278.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mode-dependent effect of xenon inhalation on kainic acid-induced status epilepticus in rats</article-title><source>Front Cell Neurosci</source><year>2019</year><volume>13</volume><fpage>375</fpage><pub-id pub-id-type="pmid">31474835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2019.00375</pub-id><pub-id pub-id-type="pmcid">PMC6702968</pub-id></element-citation></ref><ref id="R279"><label>279.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Attenuation of the mutual elevation of iron accumulation and oxidative stress may contribute to the neuroprotective and anti-seizure effects of xenon in neonatal hypoxia-induced seizures</article-title><source>Free Radic Biol Med</source><year>2020</year><volume>161</volume><fpage>212</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">33075502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2020.09.030</pub-id></element-citation></ref><ref id="R280"><label>280.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><etal/></person-group><article-title>Xenon exerts neuroprotective effects on kainic acid-induced acute generalized seizures in rats via increased autophagy</article-title><source>Front Cell Neurosci</source><year>2020</year><volume>14</volume><fpage>582872</fpage><pub-id pub-id-type="pmid">33132850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2020.582872</pub-id><pub-id pub-id-type="pmcid">PMC7573545</pub-id></element-citation></ref><ref id="R281"><label>281.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Attenuated iron stress and oxidative stress may participate in anti-seizure and neuroprotective roles of xenon in pentylenetetrazole-induced epileptogenesis</article-title><source>Front Cell Neurosci</source><year>2022</year><volume>16</volume><fpage>1007458</fpage><pub-id pub-id-type="pmid">36467611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2022.1007458</pub-id><pub-id pub-id-type="pmcid">PMC9712733</pub-id></element-citation></ref><ref id="R282"><label>282.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Xenon inhalation attenuates neuronal injury and prevents epilepsy in febrile seizure Sprague-Dawley pups</article-title><source>Front Cell Neurosci</source><year>2023</year><volume>17</volume><fpage>1155303</fpage><pub-id pub-id-type="pmid">37645594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2023.1155303</pub-id><pub-id pub-id-type="pmcid">PMC10461106</pub-id></element-citation></ref><ref id="R283"><label>283.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>K</given-names></name><name name-style="western"><surname>Ji</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure</article-title><source>Science</source><year>2001</year><volume>292</volume><fpage>1543</fpage><lpage>1546</lpage><pub-id pub-id-type="pmid">11375491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1059829</pub-id></element-citation></ref><ref id="R284"><label>284.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Rubaj</surname><given-names>A</given-names></name><name name-style="western"><surname>Zgodzi&#324;ski</surname><given-names>W</given-names></name><name name-style="western"><surname>Sieklucka-Dziuba</surname><given-names>M</given-names></name></person-group><article-title>The epileptogenic effect of seizures induced by hypoxia: the role of NMDA and AMPA/KA antagonists</article-title><source>Pharmacol Biochem Behav</source><year>2003</year><volume>74</volume><fpage>303</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">12479949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0091-3057(02)00998-x</pub-id></element-citation></ref><ref id="R285"><label>285.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Blednov</surname><given-names>YA</given-names></name><name name-style="western"><surname>Benavidez</surname><given-names>JM</given-names></name><name name-style="western"><surname>Homanics</surname><given-names>GE</given-names></name><name name-style="western"><surname>Harris</surname><given-names>RA</given-names></name></person-group><article-title>Behavioral characterization of knockin mice with mutations M287L and Q266I in the glycine receptor &#945;1 subunit</article-title><source>J Pharmacol Exp Ther</source><year>2012</year><volume>340</volume><fpage>317</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">22037202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.111.185124</pub-id><pub-id pub-id-type="pmcid">PMC3263963</pub-id></element-citation></ref><ref id="R286"><label>286.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Rogawski</surname><given-names>MA</given-names></name></person-group><article-title>AMPA receptors as a molecular target in epilepsy therapy</article-title><source>Acta Neurol Scand Suppl.</source><volume>2013</volume><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ane.12099</pub-id><pub-id pub-id-type="pmcid">PMC4506648</pub-id><pub-id pub-id-type="pmid">23480151</pub-id></element-citation></ref><ref id="R287"><label>287.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>K</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Z</given-names></name><etal/></person-group><article-title>2-Deoxy-d-glucose exhibits anti-seizure effects by mediating the netrin-G1-KATP signaling pathway in epilepsy</article-title><source>Neurochem Res</source><year>2019</year><volume>44</volume><fpage>994</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">30805800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-019-02734-3</pub-id></element-citation></ref><ref id="R288"><label>288.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Fukushima</surname><given-names>K</given-names></name><name name-style="western"><surname>Hatanaka</surname><given-names>K</given-names></name><name name-style="western"><surname>Sagane</surname><given-names>K</given-names></name><name name-style="western"><surname>Ido</surname><given-names>K</given-names></name></person-group><article-title>Inhibitory effect of anti-seizure medications on ionotropic glutamate receptors: special focus on AMPA receptor subunits</article-title><source>Epilepsy Res</source><year>2020</year><volume>167</volume><fpage>106452</fpage><pub-id pub-id-type="pmid">32911258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eplepsyres.2020.106452</pub-id></element-citation></ref><ref id="R289"><label>289.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name></person-group><article-title>Roles of N-methyl-D-aspartate receptors (NMDARs) in epilepsy</article-title><source>Front Mol Neurosci</source><year>2021</year><volume>14</volume><fpage>797253</fpage><pub-id pub-id-type="pmid">35069111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnmol.2021.797253</pub-id><pub-id pub-id-type="pmcid">PMC8780133</pub-id></element-citation></ref><ref id="R290"><label>290.</label><element-citation publication-type="webpage" publication-format="web"><person-group person-group-type="author"><collab>National Institute on Drug Abuse</collab></person-group><article-title>Commonly used drugs charts</article-title><comment><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nida.nih.gov/research-topics/commonly-used-drugs-charts#TobaccoNicotineandVaping">https://nida.nih.gov/research-topics/commonly-used-drugs-charts#TobaccoNicotineandVaping</uri>. Accessed June 15, 2024</comment></element-citation></ref><ref id="R291"><label>291.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dobrovolsky</surname><given-names>A</given-names></name><name name-style="western"><surname>Ichim</surname><given-names>TE</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name><name name-style="western"><surname>Kesari</surname><given-names>S</given-names></name><name name-style="western"><surname>Bogin</surname><given-names>V</given-names></name></person-group><article-title>Xenon in the treatment of panic disorder: an open label study</article-title><source>J Transl Med</source><year>2017</year><volume>15</volume><fpage>137</fpage><pub-id pub-id-type="pmid">28610592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-017-1237-1</pub-id><pub-id pub-id-type="pmcid">PMC5470223</pub-id></element-citation></ref><ref id="R292"><label>292.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Aftanas</surname><given-names>LI</given-names></name><name name-style="western"><surname>Bazanova</surname><given-names>OM</given-names></name><name name-style="western"><surname>Khabarov</surname><given-names>AN</given-names></name><name name-style="western"><surname>Pustovoyt</surname><given-names>SM</given-names></name></person-group><article-title>Psychophysiological analysis of thymoleptic effects of xenon in humans</article-title><source>Bull Exp Biol Med</source><year>2020</year><volume>169</volume><fpage>183</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">32651812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10517-020-04846-1</pub-id></element-citation></ref><ref id="R293"><label>293.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dobrovolsky</surname><given-names>AP</given-names></name><name name-style="western"><surname>Gedzun</surname><given-names>VR</given-names></name><name name-style="western"><surname>Bogin</surname><given-names>VI</given-names></name><etal/></person-group><article-title>Beneficial effects of xenon inhalation on behavioral changes in a valproic acid-induced model of autism in rats</article-title><source>J Transl Med</source><year>2019</year><volume>17</volume><fpage>400</fpage><pub-id pub-id-type="pmid">31796043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-019-02161-6</pub-id><pub-id pub-id-type="pmcid">PMC6891980</pub-id></element-citation></ref><ref id="R294"><label>294.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yagi</surname><given-names>M</given-names></name><name name-style="western"><surname>Mashimo</surname><given-names>T</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Yoshiya</surname><given-names>I</given-names></name></person-group><article-title>Analgesic and hypnotic effects of subanaesthetic concentrations of xenon in human volunteers: comparison with nitrous oxide</article-title><source>Br J Anaesth</source><year>1995</year><volume>74</volume><fpage>670</fpage><lpage>673</lpage><pub-id pub-id-type="pmid">7640122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/74.6.670</pub-id></element-citation></ref><ref id="R295"><label>295.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ohara</surname><given-names>A</given-names></name><name name-style="western"><surname>Mashimo</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Inagaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shibuta</surname><given-names>S</given-names></name><name name-style="western"><surname>Yoshiya</surname><given-names>I</given-names></name></person-group><article-title>A comparative study of the antinociceptive action of xenon and nitrous oxide in rats</article-title><source>Anesth Analg</source><year>1997</year><volume>85</volume><fpage>931</fpage><lpage>936</lpage><pub-id pub-id-type="pmid">9322482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000539-199710000-00039</pub-id></element-citation></ref><ref id="R296"><label>296.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Benrath</surname><given-names>J</given-names></name><name name-style="western"><surname>Kempf</surname><given-names>C</given-names></name><name name-style="western"><surname>Georgieff</surname><given-names>M</given-names></name><name name-style="western"><surname>Sandk&#252;hler</surname><given-names>J</given-names></name></person-group><article-title>Xenon blocks the induction of synaptic long-term potentiation in pain pathways in the rat spinal cord in vivo</article-title><source>Anesth Analg</source><year>2007</year><volume>104</volume><fpage>106</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">17179253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/01.ane.0000250368.27822.31</pub-id></element-citation></ref><ref id="R297"><label>297.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Holstr&#228;ter</surname><given-names>TF</given-names></name><name name-style="western"><surname>Georgieff</surname><given-names>M</given-names></name><name name-style="western"><surname>F&#246;hr</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Intranasal application of xenon reduces opioid requirement and postoperative pain in patients undergoing major abdominal surgery: a randomized controlled trial</article-title><source>Anesthesiology</source><year>2011</year><volume>115</volume><fpage>398</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">21753726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0b013e318225cee5</pub-id></element-citation></ref><ref id="R298"><label>298.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Abuzarova</surname><given-names>GR</given-names></name><name name-style="western"><surname>Khoronenko</surname><given-names>VE</given-names></name><name name-style="western"><surname>Sarmanayeva</surname><given-names>RR</given-names></name><name name-style="western"><surname>Kuznetcov</surname><given-names>SV</given-names></name></person-group><article-title>Double-blind, randomized, placebo-controlled study of Xenon in cancer pain therapy</article-title><source>Ann Crit Care.</source><volume>2020</volume><fpage>48</fpage><lpage>57</lpage></element-citation></ref><ref id="R299"><label>299.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>Xenon ameliorates chronic post-surgical pain by regulating mitophagy in microglia and rats mediated by PINK1/Parkin pathway</article-title><source>PeerJ</source><year>2024</year><volume>12</volume><fpage>e16855</fpage><pub-id pub-id-type="pmid">38390390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7717/peerj.16855</pub-id><pub-id pub-id-type="pmcid">PMC10883148</pub-id></element-citation></ref><ref id="R300"><label>300.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Popova</surname><given-names>NN</given-names></name><name name-style="western"><surname>Zinkovich</surname><given-names>MS</given-names></name><name name-style="western"><surname>Shikhlyarova</surname><given-names>AI</given-names></name><etal/></person-group><article-title>Effect of xenon on pain severity and adaptational status of neuro-oncological and oncogynecological patients</article-title><source>Med Akad Z</source><year>2019</year><volume>19</volume><fpage>228</fpage><lpage>230</lpage></element-citation></ref><ref id="R301"><label>301.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Barkus</surname><given-names>C</given-names></name><name name-style="western"><surname>McHugh</surname><given-names>SB</given-names></name><name name-style="western"><surname>Sprengel</surname><given-names>R</given-names></name><name name-style="western"><surname>Seeburg</surname><given-names>PH</given-names></name><name name-style="western"><surname>Rawlins</surname><given-names>JN</given-names></name><name name-style="western"><surname>Bannerman</surname><given-names>DM</given-names></name></person-group><article-title>Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion</article-title><source>Eur J Pharmacol</source><year>2010</year><volume>626</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">19836379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2009.10.014</pub-id><pub-id pub-id-type="pmcid">PMC2824088</pub-id></element-citation></ref><ref id="R302"><label>302.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>WL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Glycine site N-methyl-D-aspartate receptor antagonist 7-CTKA produces rapid antidepressant-like effects in male rats</article-title><source>J Psychiatry Neurosci</source><year>2013</year><volume>38</volume><fpage>306</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">23611177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1503/jpn.120228</pub-id><pub-id pub-id-type="pmcid">PMC3756114</pub-id></element-citation></ref><ref id="R303"><label>303.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Niciu</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Henter</surname><given-names>ID</given-names></name><name name-style="western"><surname>Luckenbaugh</surname><given-names>DA</given-names></name><name name-style="western"><surname>Zarate</surname><given-names>CA</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Charney</surname><given-names>DS</given-names></name></person-group><article-title>Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds</article-title><source>Annu Rev Pharmacol Toxicol</source><year>2014</year><volume>54</volume><fpage>119</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">24392693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-pharmtox-011613-135950</pub-id><pub-id pub-id-type="pmcid">PMC4089991</pub-id></element-citation></ref><ref id="R304"><label>304.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Scala</surname><given-names>M</given-names></name><name name-style="western"><surname>Fanelli</surname><given-names>G</given-names></name><name name-style="western"><surname>De Ronchi</surname><given-names>D</given-names></name><name name-style="western"><surname>Serretti</surname><given-names>A</given-names></name><name name-style="western"><surname>Fabbri</surname><given-names>C</given-names></name></person-group><article-title>Clinical specificity profile for novel rapid acting antidepressant drugs</article-title><source>Int Clin Psychopharmacol</source><year>2023</year><volume>38</volume><fpage>297</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">37381161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/YIC.0000000000000488</pub-id><pub-id pub-id-type="pmcid">PMC10373854</pub-id></element-citation></ref><ref id="R305"><label>305.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>M</given-names></name><name name-style="western"><surname>White</surname><given-names>A</given-names></name><name name-style="western"><surname>Grako</surname><given-names>KA</given-names></name><name name-style="western"><surname>Lane</surname><given-names>R</given-names></name><name name-style="western"><surname>Cato</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Snodgrass</surname><given-names>HR</given-names></name></person-group><article-title>Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy volunteers</article-title><source>Scand J Pain</source><year>2017</year><volume>17</volume><fpage>243</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">29229209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.sjpain.2017.05.004</pub-id></element-citation></ref><ref id="R306"><label>306.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>A</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YS</given-names></name></person-group><article-title>Insight into pain modulation: nociceptors sensitization and therapeutic targets</article-title><source>Curr Drug Targets</source><year>2019</year><volume>20</volume><fpage>775</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">30706780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389450120666190131114244</pub-id></element-citation></ref><ref id="R307"><label>307.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>T</given-names></name><name name-style="western"><surname>Whiter</surname><given-names>F</given-names></name><name name-style="western"><surname>Gallop</surname><given-names>K</given-names></name><etal/></person-group><article-title>NMDA receptor antagonists and pain relief: A meta-analysis of experimental trials</article-title><source>Neurology</source><year>2019</year><volume>92</volume><fpage>e1652</fpage><lpage>e1662</lpage><pub-id pub-id-type="pmid">30842296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000007238</pub-id></element-citation></ref><ref id="R308"><label>308.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Andreasen</surname><given-names>JT</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>CM</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action</article-title><source>Brain Res</source><year>2015</year><volume>1601</volume><fpage>117</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">25578259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2015.01.001</pub-id></element-citation></ref><ref id="R309"><label>309.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Goffer</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><name name-style="western"><surname>Eberle</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Calcium-permeable AMPA receptors in the nucleus accumbens regulate depression-like behaviors in the chronic neuropathic pain state</article-title><source>J Neurosci</source><year>2013</year><volume>33</volume><fpage>19034</fpage><lpage>19044</lpage><pub-id pub-id-type="pmid">24285907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2454-13.2013</pub-id><pub-id pub-id-type="pmcid">PMC3841460</pub-id></element-citation></ref><ref id="R310"><label>310.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>A</given-names></name><name name-style="western"><surname>Hara</surname><given-names>H</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>H</given-names></name></person-group><article-title>Role of the AMPA receptor in antidepressant effects of ketamine and potential of AMPA receptor potentiators as a novel antidepressant</article-title><source>Neuropharmacology</source><year>2023</year><volume>222</volume><fpage>109308</fpage><pub-id pub-id-type="pmid">36341809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2022.109308</pub-id></element-citation></ref><ref id="R311"><label>311.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Negrete-D&#237;az</surname><given-names>JV</given-names></name><name name-style="western"><surname>Falc&#243;n-Moya</surname><given-names>R</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Moreno</surname><given-names>A</given-names></name></person-group><article-title>Kainate receptors: from synaptic activity to disease</article-title><source>FEBS J</source><year>2022</year><volume>289</volume><fpage>5074</fpage><lpage>5088</lpage><pub-id pub-id-type="pmid">34143566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/febs.16081</pub-id></element-citation></ref><ref id="R312"><label>312.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Shamabadi</surname><given-names>A</given-names></name></person-group><article-title>Topiramate and other kainate receptor antagonists for depression: A systematic review of randomized controlled trials</article-title><source>Neuropsychopharmacol Rep</source><year>2022</year><volume>42</volume><fpage>421</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">35912516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/npr2.12284</pub-id><pub-id pub-id-type="pmcid">PMC9773746</pub-id></element-citation></ref><ref id="R313"><label>313.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhuo</surname><given-names>M</given-names></name></person-group><article-title>Cortical kainate receptors and behavioral anxiety</article-title><source>Mol Brain</source><year>2017</year><volume>10</volume><fpage>16</fpage><pub-id pub-id-type="pmid">28521778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13041-017-0297-8</pub-id><pub-id pub-id-type="pmcid">PMC5437545</pub-id></element-citation></ref><ref id="R314"><label>314.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>W</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Activation of glycine receptors in the lateral habenula rescues anxiety- and depression-like behaviors associated with alcohol withdrawal and reduces alcohol intake in rats</article-title><source>Neuropharmacology</source><year>2019</year><volume>157</volume><fpage>107688</fpage><pub-id pub-id-type="pmid">31254534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2019.107688</pub-id><pub-id pub-id-type="pmcid">PMC6677595</pub-id></element-citation></ref><ref id="R315"><label>315.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zeilhofer</surname><given-names>HU</given-names></name><name name-style="western"><surname>Werynska</surname><given-names>K</given-names></name><name name-style="western"><surname>Gingras</surname><given-names>J</given-names></name><name name-style="western"><surname>Y&#233;venes</surname><given-names>GE</given-names></name></person-group><article-title>Glycine receptors in spinal nociceptive control-an update</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><fpage>846</fpage><pub-id pub-id-type="pmid">34204137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom11060846</pub-id><pub-id pub-id-type="pmcid">PMC8228028</pub-id></element-citation></ref><ref id="R316"><label>316.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Naz&#305;ro&#287;lu</surname><given-names>M</given-names></name><name name-style="western"><surname>Demirda&#351;</surname><given-names>A</given-names></name></person-group><article-title>Psychiatric disorders and TRP channels: focus on psychotropic drugs</article-title><source>Curr Neuropharmacol</source><year>2015</year><volume>13</volume><fpage>248</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">26411768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1570159X13666150304001606</pub-id><pub-id pub-id-type="pmcid">PMC4598437</pub-id></element-citation></ref><ref id="R317"><label>317.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Gregor</surname><given-names>DM</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>W</given-names></name><name name-style="western"><surname>Fu</surname><given-names>R</given-names></name><name name-style="western"><surname>Bekker</surname><given-names>A</given-names></name><name name-style="western"><surname>Ye</surname><given-names>JH</given-names></name></person-group><article-title>Elevation of transient receptor potential vanilloid 1 function in the lateral habenula mediates aversive behaviors in alcohol-withdrawn rats</article-title><source>Anesthesiology</source><year>2019</year><volume>130</volume><fpage>592</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">30676422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0000000000002615</pub-id><pub-id pub-id-type="pmcid">PMC6417946</pub-id></element-citation></ref><ref id="R318"><label>318.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ram&#237;rez</surname><given-names>D</given-names></name><name name-style="western"><surname>Z&#250;&#241;iga</surname><given-names>R</given-names></name><name name-style="western"><surname>Concha</surname><given-names>G</given-names></name><name name-style="western"><surname>Z&#250;&#241;iga</surname><given-names>L</given-names></name></person-group><article-title>HCN channels: new therapeutic targets for pain treatment</article-title><source>Molecules</source><year>2018</year><volume>23</volume><fpage>2094</fpage><pub-id pub-id-type="pmid">30134541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules23092094</pub-id><pub-id pub-id-type="pmcid">PMC6225464</pub-id></element-citation></ref><ref id="R319"><label>319.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Ye</surname><given-names>S</given-names></name><name name-style="western"><surname>Luo</surname><given-names>R</given-names></name><name name-style="western"><surname>Wu</surname><given-names>LM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>Inhibition of acid-sensing ion channels reduces the hypothalamus-pituitary-adrenal axis activity and ameliorates depression-like behavior in rats</article-title><source>RSC Adv</source><year>2019</year><volume>9</volume><fpage>8707</fpage><lpage>8713</lpage><pub-id pub-id-type="pmid">35517700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c9ra00020h</pub-id><pub-id pub-id-type="pmcid">PMC9061884</pub-id></element-citation></ref><ref id="R320"><label>320.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>WG</given-names></name><name name-style="western"><surname>Xu</surname><given-names>TL</given-names></name></person-group><article-title>Acid-sensing ion channels: a novel therapeutic target for pain and anxiety</article-title><source>Curr Pharm Des</source><year>2015</year><volume>21</volume><fpage>885</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">25345607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1381612820666141027124506</pub-id></element-citation></ref><ref id="R321"><label>321.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Khariv</surname><given-names>V</given-names></name><name name-style="western"><surname>Elkabes</surname><given-names>S</given-names></name></person-group><article-title>Contribution of plasma membrane calcium ATPases to neuronal maladaptive responses: Focus on spinal nociceptive mechanisms and neurodegeneration</article-title><source>Neurosci Lett</source><year>2018</year><volume>663</volume><fpage>60</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">28780172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2017.08.003</pub-id></element-citation></ref><ref id="R322"><label>322.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Djillani</surname><given-names>A</given-names></name><name name-style="western"><surname>Mazella</surname><given-names>J</given-names></name><name name-style="western"><surname>Heurteaux</surname><given-names>C</given-names></name><name name-style="western"><surname>Borsotto</surname><given-names>M</given-names></name></person-group><article-title>Role of TREK-1 in health and disease, focus on the central nervous system</article-title><source>Front Pharmacol</source><year>2019</year><volume>10</volume><fpage>379</fpage><pub-id pub-id-type="pmid">31031627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2019.00379</pub-id><pub-id pub-id-type="pmcid">PMC6470294</pub-id></element-citation></ref><ref id="R323"><label>323.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Beurel</surname><given-names>E</given-names></name><name name-style="western"><surname>Song</surname><given-names>L</given-names></name><name name-style="western"><surname>Jope</surname><given-names>RS</given-names></name></person-group><article-title>Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice</article-title><source>Mol Psychiatry</source><year>2011</year><volume>16</volume><fpage>1068</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">21502951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mp.2011.47</pub-id><pub-id pub-id-type="pmcid">PMC3200424</pub-id></element-citation></ref><ref id="R324"><label>324.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Duda</surname><given-names>P</given-names></name><name name-style="western"><surname>Hajka</surname><given-names>D</given-names></name><name name-style="western"><surname>W&#243;jcicka</surname><given-names>O</given-names></name><name name-style="western"><surname>Rakus</surname><given-names>D</given-names></name><name name-style="western"><surname>Gizak</surname><given-names>A</given-names></name></person-group><article-title>GSK3&#946;: a master player in depressive disorder pathogenesis and treatment responsiveness</article-title><source>Cells</source><year>2020</year><volume>9</volume><fpage>727</fpage><pub-id pub-id-type="pmid">32188010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9030727</pub-id><pub-id pub-id-type="pmcid">PMC7140610</pub-id></element-citation></ref><ref id="R325"><label>325.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Crofton</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Nenov</surname><given-names>MN</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Glycogen synthase kinase 3 beta alters anxiety-, depression-, and addiction-related behaviors and neuronal activity in the nucleus accumbens shell</article-title><source>Neuropharmacology</source><year>2017</year><volume>117</volume><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">28126496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2017.01.020</pub-id><pub-id pub-id-type="pmcid">PMC5386787</pub-id></element-citation></ref><ref id="R326"><label>326.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Maixner</surname><given-names>DW</given-names></name><name name-style="western"><surname>Weng</surname><given-names>HR</given-names></name></person-group><article-title>The role of glycogen synthase kinase 3 beta in neuroinflammation and pain</article-title><source>J Pharm Pharmacol (Los Angel)</source><year>2013</year><volume>1</volume><fpage>001</fpage><pub-id pub-id-type="pmid">25309941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.13188/2327-204X.1000001</pub-id><pub-id pub-id-type="pmcid">PMC4193379</pub-id></element-citation></ref><ref id="R327"><label>327.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Giraud</surname><given-names>F</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>E</given-names></name><name name-style="western"><surname>Anizon</surname><given-names>F</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>P</given-names></name></person-group><article-title>Recent advances in pain management: relevant protein kinases and their inhibitors</article-title><source>Molecules</source><year>2021</year><volume>26</volume><fpage>2696</fpage><pub-id pub-id-type="pmid">34064521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules26092696</pub-id><pub-id pub-id-type="pmcid">PMC8124620</pub-id></element-citation></ref><ref id="R328"><label>328.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>F</given-names></name><name name-style="western"><surname>Xie</surname><given-names>KL</given-names></name><name name-style="western"><surname>Yu</surname><given-names>YH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>GL</given-names></name></person-group><article-title>Glycogen synthase kinase-3&#946; contributes to remifentanil-induced postoperative hyperalgesia via regulating N-methyl-D-aspartate receptor trafficking</article-title><source>Anesth Analg</source><year>2013</year><volume>116</volume><fpage>473</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">23267003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0b013e318274e3f1</pub-id></element-citation></ref><ref id="R329"><label>329.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Tang</surname><given-names>XH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Glycogen synthase kinase-3&#946; inhibition prevents remifentanil-induced postoperative hyperalgesia via regulating the expression and function of AMPA receptors</article-title><source>Anesth Analg</source><year>2014</year><volume>119</volume><fpage>978</fpage><lpage>987</lpage><pub-id pub-id-type="pmid">25126703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0000000000000365</pub-id></element-citation></ref><ref id="R330"><label>330.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><name name-style="western"><surname>Yin</surname><given-names>M</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L</given-names></name><etal/></person-group><article-title>Reduction of depression-like behavior in rat model induced by ShRNA targeting norepinephrine transporter in locus coeruleus</article-title><source>Transl Psychiatry</source><year>2020</year><volume>10</volume><fpage>130</fpage><pub-id pub-id-type="pmid">32366842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-020-0808-8</pub-id><pub-id pub-id-type="pmcid">PMC7198598</pub-id></element-citation></ref><ref id="R331"><label>331.</label><element-citation publication-type="book" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Merwar</surname><given-names>G</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>JR</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>SA</given-names></name><name name-style="western"><surname>Saadabadi</surname><given-names>A</given-names></name></person-group><article-title>Nortriptyline</article-title><source>StatPearls</source><publisher-loc>Treasure Island (FL)</publisher-loc><publisher-name>StatPearls Publishing</publisher-name><year>2024</year><pub-id pub-id-type="pmid">29489270</pub-id></element-citation></ref><ref id="R332"><label>332.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Montoya</surname><given-names>A</given-names></name><name name-style="western"><surname>Bruins</surname><given-names>R</given-names></name><name name-style="western"><surname>Katzman</surname><given-names>MA</given-names></name><name name-style="western"><surname>Blier</surname><given-names>P</given-names></name></person-group><article-title>The noradrenergic paradox: implications in the management of depression and anxiety</article-title><source>Neuropsychiatr Dis Treat</source><year>2016</year><volume>12</volume><fpage>541</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">27042068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/NDT.S91311</pub-id><pub-id pub-id-type="pmcid">PMC4780187</pub-id></element-citation></ref><ref id="R333"><label>333.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Moncrieff</surname><given-names>J</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>RE</given-names></name><name name-style="western"><surname>Stockmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Amendola</surname><given-names>S</given-names></name><name name-style="western"><surname>Hengartner</surname><given-names>MP</given-names></name><name name-style="western"><surname>Horowitz</surname><given-names>MA</given-names></name></person-group><article-title>The serotonin theory of depression: a systematic umbrella review of the evidence</article-title><source>Mol Psychiatry</source><year>2023</year><volume>28</volume><fpage>3243</fpage><lpage>3256</lpage><pub-id pub-id-type="pmid">35854107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-022-01661-0</pub-id><pub-id pub-id-type="pmcid">PMC10618090</pub-id></element-citation></ref><ref id="R334"><label>334.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Koch</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kell</surname><given-names>S</given-names></name><name name-style="western"><surname>Hinze-Selch</surname><given-names>D</given-names></name><name name-style="western"><surname>Aldenhoff</surname><given-names>JB</given-names></name></person-group><article-title>Changes in CREB-phosphorylation during recovery from major depression</article-title><source>J Psychiatr Res</source><year>2002</year><volume>36</volume><fpage>369</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">12393305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-3956(02)00056-0</pub-id></element-citation></ref><ref id="R335"><label>335.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>XM</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>ZQ</given-names></name><name name-style="western"><surname>Yang</surname><given-names>JJ</given-names></name></person-group><article-title>Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex</article-title><source>Eur Psychiatry</source><year>2014</year><volume>29</volume><fpage>419</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">24321772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eurpsy.2013.10.005</pub-id></element-citation></ref><ref id="R336"><label>336.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Duman</surname><given-names>RS</given-names></name><name name-style="western"><surname>Shinohara</surname><given-names>R</given-names></name><name name-style="western"><surname>Foga&#231;a</surname><given-names>MV</given-names></name><name name-style="western"><surname>Hare</surname><given-names>B</given-names></name></person-group><article-title>Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function</article-title><source>Mol Psychiatry</source><year>2019</year><volume>24</volume><fpage>1816</fpage><lpage>1832</lpage><pub-id pub-id-type="pmid">30894661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-019-0400-x</pub-id><pub-id pub-id-type="pmcid">PMC6754322</pub-id></element-citation></ref><ref id="R337"><label>337.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Pandey</surname><given-names>SC</given-names></name><name name-style="western"><surname>Roy</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name></person-group><article-title>The decreased phosphorylation of cyclic adenosine monophosphate (cAMP) response element binding (CREB) protein in the central amygdala acts as a molecular substrate for anxiety related to ethanol withdrawal in rats</article-title><source>Alcohol Clin Exp Res</source><year>2003</year><volume>27</volume><fpage>396</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">12658105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.ALC.0000056616.81971.49</pub-id></element-citation></ref><ref id="R338"><label>338.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Suliman</surname><given-names>S</given-names></name><name name-style="western"><surname>Hemmings</surname><given-names>SM</given-names></name><name name-style="western"><surname>Seedat</surname><given-names>S</given-names></name></person-group><article-title>Brain-Derived Neurotrophic Factor (BDNF) protein levels in anxiety disorders: systematic review and meta-regression analysis</article-title><source>Front Integr Neurosci</source><year>2013</year><volume>7</volume><fpage>55</fpage><pub-id pub-id-type="pmid">23908608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnint.2013.00055</pub-id><pub-id pub-id-type="pmcid">PMC3725410</pub-id></element-citation></ref><ref id="R339"><label>339.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>I</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>D</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group><article-title>Elevating the level of hypoxia inducible factor may be a new potential target for the treatment of depression</article-title><source>Med Hypotheses</source><year>2021</year><volume>146</volume><fpage>110398</fpage><pub-id pub-id-type="pmid">33246695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mehy.2020.110398</pub-id></element-citation></ref><ref id="R340"><label>340.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kanngiesser</surname><given-names>M</given-names></name><name name-style="western"><surname>Mair</surname><given-names>N</given-names></name><name name-style="western"><surname>Lim</surname><given-names>HY</given-names></name><etal/></person-group><article-title>Hypoxia-inducible factor 1 regulates heat and cold pain sensitivity and persistence</article-title><source>Antioxid Redox Signal</source><year>2014</year><volume>20</volume><fpage>2555</fpage><lpage>2571</lpage><pub-id pub-id-type="pmid">24144405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/ars.2013.5494</pub-id></element-citation></ref><ref id="R341"><label>341.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>YY</given-names></name><name name-style="western"><surname>Chou</surname><given-names>CK</given-names></name><name name-style="western"><surname>Yang</surname><given-names>YC</given-names></name><name name-style="western"><surname>Fu</surname><given-names>HC</given-names></name><name name-style="western"><surname>Loh</surname><given-names>EW</given-names></name><name name-style="western"><surname>Kang</surname><given-names>HY</given-names></name></person-group><article-title>Exosomal let-7e, miR-21-5p, miR-145, miR-146a and miR-155 in predicting antidepressants response in patients with major depressive disorder</article-title><source>Biomedicines</source><year>2021</year><volume>9</volume><fpage>1428</fpage><pub-id pub-id-type="pmid">34680545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines9101428</pub-id><pub-id pub-id-type="pmcid">PMC8533438</pub-id></element-citation></ref><ref id="R342"><label>342.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>L</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>LJ</given-names></name></person-group><article-title>miR-21-5p inhibits neuropathic pain development via directly targeting C-C motif ligand 1 and tissue inhibitor of metalloproteinase-3</article-title><source>J Cell Biochem</source><year>2019</year><volume>120</volume><fpage>16614</fpage><lpage>16623</lpage><pub-id pub-id-type="pmid">31161659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.28920</pub-id></element-citation></ref><ref id="R343"><label>343.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>The involvement of caspases in neuroinflammation and neuronal apoptosis in chronic pain and potential therapeutic targets</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><fpage>898574</fpage><pub-id pub-id-type="pmid">35592413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.898574</pub-id><pub-id pub-id-type="pmcid">PMC9110832</pub-id></element-citation></ref><ref id="R344"><label>344.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>JR</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Cryan</surname><given-names>JF</given-names></name><name name-style="western"><surname>Dinan</surname><given-names>TG</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>G</given-names></name><name name-style="western"><surname>Hyland</surname><given-names>NP</given-names></name></person-group><article-title>Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders</article-title><source>Front Cell Neurosci</source><year>2015</year><volume>9</volume><fpage>392</fpage><pub-id pub-id-type="pmid">26528128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2015.00392</pub-id><pub-id pub-id-type="pmcid">PMC4604320</pub-id></element-citation></ref><ref id="R345"><label>345.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Qamar</surname><given-names>N</given-names></name><name name-style="western"><surname>Castano</surname><given-names>D</given-names></name><name name-style="western"><surname>Patt</surname><given-names>C</given-names></name><name name-style="western"><surname>Chu</surname><given-names>T</given-names></name><name name-style="western"><surname>Cottrell</surname><given-names>J</given-names></name><name name-style="western"><surname>Chang</surname><given-names>SL</given-names></name></person-group><article-title>Meta-analysis of alcohol induced gut dysbiosis and the resulting behavioral impact</article-title><source>Behav Brain Res</source><year>2019</year><volume>376</volume><fpage>112196</fpage><pub-id pub-id-type="pmid">31476330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2019.112196</pub-id></element-citation></ref><ref id="R346"><label>346.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Eitan</surname><given-names>S</given-names></name><name name-style="western"><surname>Madison</surname><given-names>CA</given-names></name><name name-style="western"><surname>Kuempel</surname><given-names>J</given-names></name></person-group><article-title>The self-serving benefits of being a good host: A role for our micro-inhabitants in shaping opioids&#8217; function</article-title><source>Neurosci Biobehav Rev</source><year>2021</year><volume>127</volume><fpage>284</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">33894242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2021.04.019</pub-id></element-citation></ref><ref id="R347"><label>347.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hayhurst</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Durieux</surname><given-names>ME</given-names></name></person-group><article-title>Differential opioid tolerance and opioid-induced hyperalgesia: a clinical reality</article-title><source>Anesthesiology</source><year>2016</year><volume>124</volume><fpage>483</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">26594912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0000000000000963</pub-id></element-citation></ref><ref id="R348"><label>348.</label><element-citation publication-type="webpage" publication-format="web"><person-group person-group-type="author"><collab>Substance Abuse and Mental Health Services Administration</collab></person-group><article-title>2021 NSDUH Annual National Report</article-title><comment><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report">https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report</uri>. Accessed July 22, 2024</comment></element-citation></ref><ref id="R349"><label>349.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Nakata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Goto</surname><given-names>T</given-names></name><name name-style="western"><surname>Saito</surname><given-names>H</given-names></name><etal/></person-group><article-title>Plasma concentration of fentanyl with xenon to block somatic and hemodynamic responses to surgical incision</article-title><source>Anesthesiology</source><year>2000</year><volume>92</volume><fpage>1043</fpage><lpage>1048</lpage><pub-id pub-id-type="pmid">10754624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200004000-00022</pub-id></element-citation></ref><ref id="R350"><label>350.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Klimas</surname><given-names>J</given-names></name><name name-style="western"><surname>Gorfinkel</surname><given-names>L</given-names></name><name name-style="western"><surname>Fairbairn</surname><given-names>N</given-names></name><etal/></person-group><article-title>Strategies to identify patient risks of prescription opioid addiction when initiating opioids for pain: a systematic review</article-title><source>JAMA Netw Open</source><year>2019</year><volume>2</volume><fpage>e193365</fpage><pub-id pub-id-type="pmid">31050783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2019.3365</pub-id><pub-id pub-id-type="pmcid">PMC6503484</pub-id></element-citation></ref><ref id="R351"><label>351.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>McLemore</surname><given-names>GL</given-names></name><name name-style="western"><surname>Kest</surname><given-names>B</given-names></name><name name-style="western"><surname>Inturrisi</surname><given-names>CE</given-names></name></person-group><article-title>The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence</article-title><source>Brain Res</source><year>1997</year><volume>778</volume><fpage>120</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">9462883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-8993(97)00985-2</pub-id></element-citation></ref><ref id="R352"><label>352.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Lutfy</surname><given-names>K</given-names></name><name name-style="western"><surname>Doan</surname><given-names>P</given-names></name><name name-style="western"><surname>Weber</surname><given-names>E</given-names></name></person-group><article-title>ACEA-1328, a NMDA receptor/glycine site antagonist, acutely potentiates antinociception and chronically attenuates tolerance induced by morphine</article-title><source>Pharmacol Res</source><year>1999</year><volume>40</volume><fpage>435</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">10527659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/phrs.1999.0538</pub-id></element-citation></ref><ref id="R353"><label>353.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Quartaroli</surname><given-names>M</given-names></name><name name-style="western"><surname>Fasdelli</surname><given-names>N</given-names></name><name name-style="western"><surname>Bettelini</surname><given-names>L</given-names></name><name name-style="western"><surname>Maraia</surname><given-names>G</given-names></name><name name-style="western"><surname>Corsi</surname><given-names>M</given-names></name></person-group><article-title>GV196771A, an NMDA receptor/glycine site antagonist, attenuates mechanical allodynia in neuropathic rats and reduces tolerance induced by morphine in mice</article-title><source>Eur J Pharmacol</source><year>2001</year><volume>430</volume><fpage>219</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">11711034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0014-2999(01)01278-x</pub-id></element-citation></ref><ref id="R354"><label>354.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Danysz</surname><given-names>W</given-names></name><name name-style="western"><surname>Kozela</surname><given-names>E</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>CG</given-names></name><name name-style="western"><surname>Sladek</surname><given-names>M</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>T</given-names></name><name name-style="western"><surname>Popik</surname><given-names>P</given-names></name></person-group><article-title>Peripherally acting NMDA receptor/glycineB site receptor antagonists inhibit morphine tolerance</article-title><source>Neuropharmacology</source><year>2005</year><volume>48</volume><fpage>360</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">15721168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2004.11.005</pub-id></element-citation></ref><ref id="R355"><label>355.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Adam</surname><given-names>F</given-names></name><name name-style="western"><surname>Dufour</surname><given-names>E</given-names></name><name name-style="western"><surname>Le Bars</surname><given-names>D</given-names></name></person-group><article-title>The glycine site-specific NMDA antagonist (+)-HA966 enhances the effect of morphine and reverses morphine tolerance via a spinal mechanism</article-title><source>Neuropharmacology</source><year>2008</year><volume>54</volume><fpage>588</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">18177675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2007.11.013</pub-id></element-citation></ref><ref id="R356"><label>356.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Hydrogen enriched saline alleviates morphine tolerance via inhibiting neuroinflammation, GLT&#8211;1, GS nitration and NMDA receptor trafficking and functioning in the spinal cord of rats</article-title><source>Neurosci Lett</source><year>2021</year><volume>755</volume><fpage>135847</fpage><pub-id pub-id-type="pmid">33774150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2021.135847</pub-id></element-citation></ref><ref id="R357"><label>357.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kest</surname><given-names>B</given-names></name><name name-style="western"><surname>McLemore</surname><given-names>G</given-names></name><name name-style="western"><surname>Kao</surname><given-names>B</given-names></name><name name-style="western"><surname>Inturrisi</surname><given-names>CE</given-names></name></person-group><article-title>The competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist LY293558 attenuates and reverses analgesic tolerance to morphine but not to delta or kappa opioids</article-title><source>J Pharmacol Exp Ther</source><year>1997</year><volume>283</volume><fpage>1249</fpage><lpage>1255</lpage><pub-id pub-id-type="pmid">9400000</pub-id></element-citation></ref><ref id="R358"><label>358.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ozsoy</surname><given-names>S</given-names></name><name name-style="western"><surname>Ozdemir</surname><given-names>E</given-names></name><name name-style="western"><surname>Gunes</surname><given-names>H</given-names></name><name name-style="western"><surname>Gevrek</surname><given-names>F</given-names></name><name name-style="western"><surname>Gulmez</surname><given-names>K</given-names></name></person-group><article-title>Ondansetron and AS19 attenuate morphine tolerance by modulating serotonin 5-HT3 and 5-HT7 receptor expressions in rat dorsal root ganglia</article-title><source>J Radiat Res Appl Sci</source><year>2023</year><volume>16</volume><fpage>100682</fpage></element-citation></ref><ref id="R359"><label>359.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Alborzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Mehr</surname><given-names>SE</given-names></name><name name-style="western"><surname>Rezania</surname><given-names>F</given-names></name><etal/></person-group><article-title>The effect of lithium chloride on morphine-induced tolerance and dependence in isolated guinea pig ileum</article-title><source>Eur J Pharmacol</source><year>2006</year><volume>545</volume><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">16904101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2006.06.061</pub-id></element-citation></ref><ref id="R360"><label>360.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Parkitna</surname><given-names>JR</given-names></name><name name-style="western"><surname>Obara</surname><given-names>I</given-names></name><name name-style="western"><surname>Wawrzczak-Bargiela</surname><given-names>A</given-names></name><name name-style="western"><surname>Makuch</surname><given-names>W</given-names></name><name name-style="western"><surname>Przewlocka</surname><given-names>B</given-names></name><name name-style="western"><surname>Przewlocki</surname><given-names>R</given-names></name></person-group><article-title>Effects of glycogen synthase kinase 3beta and cyclin-dependent kinase 5 inhibitors on morphine-induced analgesia and tolerance in rats</article-title><source>J Pharmacol Exp Ther</source><year>2006</year><volume>319</volume><fpage>832</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">16902054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.106.107581</pub-id></element-citation></ref><ref id="R361"><label>361.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dobashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Tanabe</surname><given-names>S</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H</given-names></name><name name-style="western"><surname>Nishino</surname><given-names>T</given-names></name><name name-style="western"><surname>Aoe</surname><given-names>T</given-names></name></person-group><article-title>Valproate attenuates the development of morphine antinociceptive tolerance</article-title><source>Neurosci Lett</source><year>2010</year><volume>485</volume><fpage>125</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">20816918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2010.08.084</pub-id></element-citation></ref><ref id="R362"><label>362.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Okuyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H</given-names></name><name name-style="western"><surname>Kokubun</surname><given-names>H</given-names></name><name name-style="western"><surname>Aoe</surname><given-names>T</given-names></name></person-group><article-title>Pharmacological chaperones attenuate the development of opioid tolerance</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>7536</fpage><pub-id pub-id-type="pmid">33066035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21207536</pub-id><pub-id pub-id-type="pmcid">PMC7593907</pub-id></element-citation></ref><ref id="R363"><label>363.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Geis</surname><given-names>C</given-names></name><name name-style="western"><surname>Sommer</surname><given-names>C</given-names></name></person-group><article-title>Activation of TRPV1 contributes to morphine tolerance: involvement of the mitogen-activated protein kinase signaling pathway</article-title><source>J Neurosci</source><year>2008</year><volume>28</volume><fpage>5836</fpage><lpage>5845</lpage><pub-id pub-id-type="pmid">18509045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.4170-07.2008</pub-id><pub-id pub-id-type="pmcid">PMC6670790</pub-id></element-citation></ref><ref id="R364"><label>364.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>TL</given-names></name><name name-style="western"><surname>Nam</surname><given-names>YS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HC</given-names></name><name name-style="western"><surname>Jang</surname><given-names>CG</given-names></name></person-group><article-title>Effects of capsazepine, a transient receptor potential vanilloid type 1 antagonist, on morphine-induced antinociception, tolerance, and dependence in mice</article-title><source>Br J Anaesth</source><year>2010</year><volume>105</volume><fpage>668</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">20719804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/aeq212</pub-id></element-citation></ref><ref id="R365"><label>365.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Meng</surname><given-names>J</given-names></name><name name-style="western"><surname>Ban</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Morphine tolerance is attenuated in germfree mice and reversed by probiotics, implicating the role of gut microbiome</article-title><source>Proc Natl Acad Sci U S A</source><year>2019</year><volume>116</volume><fpage>13523</fpage><lpage>13532</lpage><pub-id pub-id-type="pmid">31209039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1901182116</pub-id><pub-id pub-id-type="pmcid">PMC6613141</pub-id></element-citation></ref><ref id="R366"><label>366.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Devilliers</surname><given-names>M</given-names></name><name name-style="western"><surname>Busserolles</surname><given-names>J</given-names></name><name name-style="western"><surname>Lolignier</surname><given-names>S</given-names></name><etal/></person-group><article-title>Activation of TREK-1 by morphine results in analgesia without adverse side effects</article-title><source>Nat Commun</source><year>2013</year><volume>4</volume><fpage>2941</fpage><pub-id pub-id-type="pmid">24346231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms3941</pub-id></element-citation></ref><ref id="R367"><label>367.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bali</surname><given-names>A</given-names></name><name name-style="western"><surname>Randhawa</surname><given-names>PK</given-names></name><name name-style="western"><surname>Jaggi</surname><given-names>AS</given-names></name></person-group><article-title>Stress and opioids: role of opioids in modulating stress-related behavior and effect of stress on morphine conditioned place preference</article-title><source>Neurosci Biobehav Rev</source><year>2015</year><volume>51</volume><fpage>138</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">25636946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2014.12.018</pub-id></element-citation></ref><ref id="R368"><label>368.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Valentino</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Van Bockstaele</surname><given-names>E</given-names></name></person-group><article-title>Endogenous opioids: the downside of opposing stress</article-title><source>Neurobiol Stress</source><year>2015</year><volume>1</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">25506603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ynstr.2014.09.006</pub-id><pub-id pub-id-type="pmcid">PMC4260408</pub-id></element-citation></ref><ref id="R369"><label>369.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>DI</given-names></name><name name-style="western"><surname>Park</surname><given-names>S</given-names></name><name name-style="western"><surname>Park</surname><given-names>S</given-names></name><etal/></person-group><article-title>Presynaptic sensor and silencer of peptidergic transmission reveal neuropeptides as primary transmitters in pontine fear circuit</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>5102</fpage><lpage>5117.e5116</lpage><pub-id pub-id-type="pmid">39043179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2024.06.035</pub-id><pub-id pub-id-type="pmcid">PMC11380597</pub-id></element-citation></ref><ref id="R370"><label>370.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Shaham</surname><given-names>Y</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>J</given-names></name></person-group><article-title>Exposure to mild stress enhances the reinforcing efficacy of intravenous heroin self-administration in rats</article-title><source>Psychopharmacology (Berl)</source><year>1994</year><volume>114</volume><fpage>523</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">7855213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02249346</pub-id></element-citation></ref><ref id="R371"><label>371.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Der-Avakian</surname><given-names>A</given-names></name><name name-style="western"><surname>Will</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Bland</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Surgical and pharmacological suppression of glucocorticoids prevents the enhancement of morphine conditioned place preference by uncontrollable stress in rats</article-title><source>Psychopharmacology (Berl)</source><year>2005</year><volume>179</volume><fpage>409</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">15821955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-004-2041-1</pub-id></element-citation></ref><ref id="R372"><label>372.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Der-Avakian</surname><given-names>A</given-names></name><name name-style="western"><surname>Bland</surname><given-names>ST</given-names></name><name name-style="western"><surname>Rozeske</surname><given-names>RR</given-names></name><etal/></person-group><article-title>The effects of a single exposure to uncontrollable stress on the subsequent conditioned place preference responses to oxycodone, cocaine, and ethanol in rats</article-title><source>Psychopharmacology (Berl)</source><year>2007</year><volume>191</volume><fpage>909</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">17211647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-006-0678-7</pub-id></element-citation></ref><ref id="R373"><label>373.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jing Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Szkudlarek</surname><given-names>H</given-names></name><name name-style="western"><surname>Renard</surname><given-names>J</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>R</given-names></name><name name-style="western"><surname>Rushlow</surname><given-names>W</given-names></name><name name-style="western"><surname>Laviolette</surname><given-names>SR</given-names></name></person-group><article-title>Fear memory recall potentiates opiate reward sensitivity through dissociable dopamine D1 versus D4 receptor-dependent memory mechanisms in the prefrontal cortex</article-title><source>J Neurosci</source><year>2018</year><volume>38</volume><fpage>4543</fpage><lpage>4555</lpage><pub-id pub-id-type="pmid">29686048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.3113-17.2018</pub-id><pub-id pub-id-type="pmcid">PMC6705931</pub-id></element-citation></ref><ref id="R374"><label>374.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kearns</surname><given-names>AM</given-names></name><name name-style="western"><surname>Vollmer</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Long-term impact of acute restraint stress on heroin self-administration, reinstatement, and stress reactivity</article-title><source>Psychopharmacology (Berl)</source><year>2020</year><volume>237</volume><fpage>1709</fpage><lpage>1721</lpage><pub-id pub-id-type="pmid">32125483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-020-05486-z</pub-id><pub-id pub-id-type="pmcid">PMC7857092</pub-id></element-citation></ref><ref id="R375"><label>375.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Tull</surname><given-names>MT</given-names></name><name name-style="western"><surname>Gratz</surname><given-names>KL</given-names></name><name name-style="western"><surname>Aklin</surname><given-names>WM</given-names></name><name name-style="western"><surname>Lejuez</surname><given-names>CW</given-names></name></person-group><article-title>A preliminary examination of the relationships between posttraumatic stress symptoms and crack/cocaine, heroin, and alcohol dependence</article-title><source>J Anxiety Disord</source><year>2010</year><volume>24</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">19767174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.janxdis.2009.08.006</pub-id><pub-id pub-id-type="pmcid">PMC2808189</pub-id></element-citation></ref><ref id="R376"><label>376.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Shorter</surname><given-names>D</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>J</given-names></name><name name-style="western"><surname>Kosten</surname><given-names>TR</given-names></name></person-group><article-title>Pharmacologic management of comorbid post-traumatic stress disorder and addictions</article-title><source>Am J Addict</source><year>2015</year><volume>24</volume><fpage>705</fpage><lpage>712</lpage><pub-id pub-id-type="pmid">26587796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajad.12306</pub-id></element-citation></ref><ref id="R377"><label>377.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bernardy</surname><given-names>N</given-names></name><name name-style="western"><surname>Monta&#241;o</surname><given-names>M</given-names></name></person-group><article-title>Opioid use among individuals with posttraumatic stress disorder</article-title><source>PTSD Res Q</source><year>2019</year><volume>30</volume><fpage>1</fpage><lpage>8</lpage></element-citation></ref><ref id="R378"><label>378.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>AN</given-names></name><name name-style="western"><surname>Le Foll</surname><given-names>B</given-names></name><name name-style="western"><surname>Imtiaz</surname><given-names>S</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>J</given-names></name></person-group><article-title>The effect of post-traumatic stress disorder on the risk of developing prescription opioid use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III</article-title><source>Drug Alcohol Depend</source><year>2017</year><volume>179</volume><fpage>260</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">28818717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2017.07.012</pub-id></element-citation></ref><ref id="R379"><label>379.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Pennington</surname><given-names>ZT</given-names></name><name name-style="western"><surname>Trott</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rajbhandari</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Chronic opioid pretreatment potentiates the sensitization of fear learning by trauma</article-title><source>Neuropsychopharmacology</source><year>2020</year><volume>45</volume><fpage>482</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">31787748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41386-019-0559-5</pub-id><pub-id pub-id-type="pmcid">PMC6968993</pub-id></element-citation></ref><ref id="R380"><label>380.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Michalscheck</surname><given-names>RML</given-names></name><name name-style="western"><surname>Leidl</surname><given-names>DM</given-names></name><name name-style="western"><surname>Westbrook</surname><given-names>RF</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>NM</given-names></name></person-group><article-title>The opioid receptor antagonist naloxone enhances first-order fear conditioning, second-order fear conditioning and sensory preconditioning in rats</article-title><source>Front Behav Neurosci</source><year>2021</year><volume>15</volume><fpage>771767</fpage><pub-id pub-id-type="pmid">34938166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnbeh.2021.771767</pub-id><pub-id pub-id-type="pmcid">PMC8685270</pub-id></element-citation></ref><ref id="R381"><label>381.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Eippert</surname><given-names>F</given-names></name><name name-style="western"><surname>Bingel</surname><given-names>U</given-names></name><name name-style="western"><surname>Schoell</surname><given-names>E</given-names></name><name name-style="western"><surname>Yacubian</surname><given-names>J</given-names></name><name name-style="western"><surname>B&#252;chel</surname><given-names>C</given-names></name></person-group><article-title>Blockade of endogenous opioid neurotransmission enhances acquisition of conditioned fear in humans</article-title><source>J Neurosci</source><year>2008</year><volume>28</volume><fpage>5465</fpage><lpage>5472</lpage><pub-id pub-id-type="pmid">18495880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5336-07.2008</pub-id><pub-id pub-id-type="pmcid">PMC6670627</pub-id></element-citation></ref><ref id="R382"><label>382.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Haaker</surname><given-names>J</given-names></name><name name-style="western"><surname>Yi</surname><given-names>J</given-names></name><name name-style="western"><surname>Petrovic</surname><given-names>P</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>A</given-names></name></person-group><article-title>Endogenous opioids regulate social threat learning in humans</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>15495</fpage><pub-id pub-id-type="pmid">28541285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms15495</pub-id><pub-id pub-id-type="pmcid">PMC5458514</pub-id></element-citation></ref><ref id="R383"><label>383.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dunn</surname><given-names>KE</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>FS</given-names></name><name name-style="western"><surname>Yepez-Laubach</surname><given-names>C</given-names></name><etal/></person-group><article-title>Brief Opioid Overdose Knowledge (BOOK): a questionnaire to assess overdose knowledge in individuals who use illicit or prescribed opioids</article-title><source>J Addict Med</source><year>2016</year><volume>10</volume><fpage>314</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">27504923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ADM.0000000000000235</pub-id><pub-id pub-id-type="pmcid">PMC5042823</pub-id></element-citation></ref><ref id="R384"><label>384.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>KE</given-names></name><name name-style="western"><surname>Tomko</surname><given-names>C</given-names></name><name name-style="western"><surname>Nestadt</surname><given-names>DF</given-names></name><name name-style="western"><surname>Silberzahn</surname><given-names>BE</given-names></name><name name-style="western"><surname>White</surname><given-names>RH</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>SG</given-names></name></person-group><article-title>Conceptualizing overdose trauma: The relationships between experiencing and witnessing overdoses with PTSD symptoms among street-recruited female sex workers in Baltimore, Maryland</article-title><source>Int J Drug Policy</source><year>2021</year><volume>92</volume><fpage>102859</fpage><pub-id pub-id-type="pmid">32712164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugpo.2020.102859</pub-id><pub-id pub-id-type="pmcid">PMC7854789</pub-id></element-citation></ref><ref id="R385"><label>385.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Cottler</surname><given-names>LB</given-names></name><name name-style="western"><surname>Compton</surname><given-names>WM</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Mager</surname><given-names>D</given-names></name><name name-style="western"><surname>Spitznagel</surname><given-names>EL</given-names></name><name name-style="western"><surname>Janca</surname><given-names>A</given-names></name></person-group><article-title>Posttraumatic stress disorder among substance users from the general population</article-title><source>Am J Psychiatry</source><year>1992</year><volume>149</volume><fpage>664</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">1575258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/ajp.149.5.664</pub-id></element-citation></ref><ref id="R386"><label>386.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jacobsen</surname><given-names>LK</given-names></name><name name-style="western"><surname>Southwick</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kosten</surname><given-names>TR</given-names></name></person-group><article-title>Substance use disorders in patients with posttraumatic stress disorder: a review of the literature</article-title><source>Am J Psychiatry</source><year>2001</year><volume>158</volume><fpage>1184</fpage><lpage>1190</lpage><pub-id pub-id-type="pmid">11481147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.158.8.1184</pub-id></element-citation></ref><ref id="R387"><label>387.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>KL</given-names></name><name name-style="western"><surname>Teesson</surname><given-names>M</given-names></name><name name-style="western"><surname>Ross</surname><given-names>J</given-names></name><name name-style="western"><surname>Peters</surname><given-names>L</given-names></name></person-group><article-title>Trauma, PTSD, and substance use disorders: findings from the Australian National Survey of Mental Health and Well-Being</article-title><source>Am J Psychiatry</source><year>2006</year><volume>163</volume><fpage>652</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">16585440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/ajp.2006.163.4.652</pub-id></element-citation></ref><ref id="R388"><label>388.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Meshberg-Cohen</surname><given-names>S</given-names></name><name name-style="western"><surname>Ross MacLean</surname><given-names>R</given-names></name><name name-style="western"><surname>Schnakenberg Martin</surname><given-names>AM</given-names></name><name name-style="western"><surname>Sofuoglu</surname><given-names>M</given-names></name><name name-style="western"><surname>Petrakis</surname><given-names>IL</given-names></name></person-group><article-title>Treatment outcomes in individuals diagnosed with comorbid opioid use disorder and Posttraumatic stress disorder: A review</article-title><source>Addict Behav</source><year>2021</year><volume>122</volume><fpage>107026</fpage><pub-id pub-id-type="pmid">34182307</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addbeh.2021.107026</pub-id></element-citation></ref><ref id="R389"><label>389.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></name><name name-style="western"><surname>Michaelides</surname><given-names>M</given-names></name><name name-style="western"><surname>Baler</surname><given-names>R</given-names></name></person-group><article-title>The neuroscience of drug reward and addiction</article-title><source>Physiol Rev</source><year>2019</year><volume>99</volume><fpage>2115</fpage><lpage>2140</lpage><pub-id pub-id-type="pmid">31507244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00014.2018</pub-id><pub-id pub-id-type="pmcid">PMC6890985</pub-id></element-citation></ref><ref id="R390"><label>390.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Carlezon</surname><given-names>WA</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Nestler</surname><given-names>EJ</given-names></name></person-group><article-title>Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse?</article-title><source>Trends Neurosci</source><year>2002</year><volume>25</volume><fpage>610</fpage><lpage>615</lpage><pub-id pub-id-type="pmid">12446127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0166-2236(02)02289-0</pub-id></element-citation></ref><ref id="R391"><label>391.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Picciotto</surname><given-names>MR</given-names></name><name name-style="western"><surname>Addy</surname><given-names>NA</given-names></name><name name-style="western"><surname>Mineur</surname><given-names>YS</given-names></name><name name-style="western"><surname>Brunzell</surname><given-names>DH</given-names></name></person-group><article-title>It is not &#8220;either/or&#8221;: activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood</article-title><source>Prog Neurobiol</source><year>2008</year><volume>84</volume><fpage>329</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">18242816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2007.12.005</pub-id><pub-id pub-id-type="pmcid">PMC2390914</pub-id></element-citation></ref><ref id="R392"><label>392.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bia&#322;a</surname><given-names>G</given-names></name><name name-style="western"><surname>Kotli&#324;ska</surname><given-names>J</given-names></name></person-group><article-title>Blockade of the acquisition of ethanol-induced conditioned place preference by N-methyl-D-aspartate receptor antagonists</article-title><source>Alcohol Alcohol</source><year>1999</year><volume>34</volume><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">10344778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/alcalc/34.2.175</pub-id></element-citation></ref><ref id="R393"><label>393.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>MT</given-names></name><name name-style="western"><surname>Bellone</surname><given-names>C</given-names></name><name name-style="western"><surname>Mameli</surname><given-names>M</given-names></name><etal/></person-group><article-title>Drug-driven AMPA receptor redistribution mimicked by selective dopamine neuron stimulation</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e15870</fpage><pub-id pub-id-type="pmid">21209835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0015870</pub-id><pub-id pub-id-type="pmcid">PMC3013137</pub-id></element-citation></ref><ref id="R394"><label>394.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hsiao</surname><given-names>YC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MY</given-names></name><name name-style="western"><surname>Chan</surname><given-names>MH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>HH</given-names></name></person-group><article-title>NMDA receptor glycine binding site modulators for prevention and treatment of ketamine use disorder</article-title><source>Pharmaceuticals (Basel)</source><year>2023</year><volume>16</volume><fpage>812</fpage><pub-id pub-id-type="pmid">37375760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph16060812</pub-id><pub-id pub-id-type="pmcid">PMC10305354</pub-id></element-citation></ref><ref id="R395"><label>395.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>SI</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>TL</given-names></name><name name-style="western"><surname>Ma</surname><given-names>SX</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SY</given-names></name><name name-style="western"><surname>Jang</surname><given-names>CG</given-names></name></person-group><article-title>TRPV1 modulates morphine-induced conditioned place preference via p38 MAPK in the nucleus accumbens</article-title><source>Behav Brain Res</source><year>2017</year><volume>334</volume><fpage>26</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">28734766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2017.07.017</pub-id></element-citation></ref><ref id="R396"><label>396.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ahmadian Salami</surname><given-names>A</given-names></name><name name-style="western"><surname>Alavi</surname><given-names>MS</given-names></name><name name-style="western"><surname>Souri</surname><given-names>MS</given-names></name><name name-style="western"><surname>Roohbakhsh</surname><given-names>A</given-names></name></person-group><article-title>Involvement of the transient receptor potential A1 in morphine-induced conditioned place preference and physical dependence in mice</article-title><source>Can J Physiol Pharmacol</source><year>2022</year><volume>100</volume><fpage>1135</fpage><lpage>1142</lpage><pub-id pub-id-type="pmid">36223654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1139/cjpp-2022-0333</pub-id></element-citation></ref><ref id="R397"><label>397.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Beaulieu</surname><given-names>JM</given-names></name><name name-style="western"><surname>Sotnikova</surname><given-names>TD</given-names></name><name name-style="western"><surname>Yao</surname><given-names>WD</given-names></name><etal/></person-group><article-title>Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>5099</fpage><lpage>5104</lpage><pub-id pub-id-type="pmid">15044694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0307921101</pub-id><pub-id pub-id-type="pmcid">PMC387380</pub-id></element-citation></ref><ref id="R398"><label>398.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Itzhak</surname><given-names>Y</given-names></name></person-group><article-title>Role of the NMDA receptor and nitric oxide in memory reconsolidation of cocaine-induced conditioned place preference in mice</article-title><source>Ann N Y Acad Sci</source><year>2008</year><volume>1139</volume><fpage>350</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">18991881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1196/annals.1432.051</pub-id></element-citation></ref><ref id="R399"><label>399.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>YC</given-names></name><name name-style="western"><surname>Gao</surname><given-names>WJ</given-names></name></person-group><article-title>GSK-3&#946; activity and hyperdopamine-dependent behaviors</article-title><source>Neurosci Biobehav Rev</source><year>2011</year><volume>35</volume><fpage>645</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">20727368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2010.08.001</pub-id><pub-id pub-id-type="pmcid">PMC2997336</pub-id></element-citation></ref><ref id="R400"><label>400.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Xue</surname><given-names>YX</given-names></name><name name-style="western"><surname>Ding</surname><given-names>ZB</given-names></name><name name-style="western"><surname>Xue</surname><given-names>LF</given-names></name><name name-style="western"><surname>Xu</surname><given-names>CM</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name></person-group><article-title>Glycogen synthase kinase 3&#946; in the basolateral amygdala is critical for the reconsolidation of cocaine reward memory</article-title><source>J Neurochem</source><year>2011</year><volume>118</volume><fpage>113</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">21592120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1471-4159.2011.07277.x</pub-id></element-citation></ref><ref id="R401"><label>401.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Enman</surname><given-names>NM</given-names></name><name name-style="western"><surname>Unterwald</surname><given-names>EM</given-names></name></person-group><article-title>Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse</article-title><source>Behav Brain Res</source><year>2012</year><volume>231</volume><fpage>217</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">22649795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2012.03.027</pub-id><pub-id pub-id-type="pmcid">PMC3566781</pub-id></element-citation></ref><ref id="R402"><label>402.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>JS</given-names></name><name name-style="western"><surname>Barr</surname><given-names>JL</given-names></name><name name-style="western"><surname>Harper</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Poole</surname><given-names>RL</given-names></name><name name-style="western"><surname>Gould</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Unterwald</surname><given-names>EM</given-names></name></person-group><article-title>The GSK3 signaling pathway is activated by cocaine and is critical for cocaine conditioned reward in mice</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e88026</fpage><pub-id pub-id-type="pmid">24505362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0088026</pub-id><pub-id pub-id-type="pmcid">PMC3913742</pub-id></element-citation></ref><ref id="R403"><label>403.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>X</given-names></name><name name-style="western"><surname>Miller</surname><given-names>JS</given-names></name><name name-style="western"><surname>Harper</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Poole</surname><given-names>RL</given-names></name><name name-style="western"><surname>Gould</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Unterwald</surname><given-names>EM</given-names></name></person-group><article-title>Reactivation of cocaine reward memory engages the Akt/GSK3/mTOR signaling pathway and can be disrupted by GSK3 inhibition</article-title><source>Psychopharmacology (Berl)</source><year>2014</year><volume>231</volume><fpage>3109</fpage><lpage>3118</lpage><pub-id pub-id-type="pmid">24595501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-014-3491-8</pub-id><pub-id pub-id-type="pmcid">PMC4110417</pub-id></element-citation></ref><ref id="R404"><label>404.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>X</given-names></name><name name-style="western"><surname>von Weltin</surname><given-names>E</given-names></name><name name-style="western"><surname>Barr</surname><given-names>JL</given-names></name><name name-style="western"><surname>Unterwald</surname><given-names>EM</given-names></name></person-group><article-title>Activation of GSK3&#946; induced by recall of cocaine reward memories is dependent on GluN2A/B NMDA receptor signaling</article-title><source>J Neurochem</source><year>2019</year><volume>151</volume><fpage>91</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">31361029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.14842</pub-id><pub-id pub-id-type="pmcid">PMC6788955</pub-id></element-citation></ref><ref id="R405"><label>405.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Barr</surname><given-names>JL</given-names></name><name name-style="western"><surname>Unterwald</surname><given-names>EM</given-names></name></person-group><article-title>Glycogen synthase kinase-3 signaling in cellular and behavioral responses to psychostimulant drugs</article-title><source>Biochim Biophys Acta Mol Cell Res</source><year>2020</year><volume>1867</volume><fpage>118746</fpage><pub-id pub-id-type="pmid">32454064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbamcr.2020.118746</pub-id><pub-id pub-id-type="pmcid">PMC7313643</pub-id></element-citation></ref><ref id="R406"><label>406.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cannabidiol attenuates methamphetamine-induced conditioned place preference in male rats and viability in PC12 cells through the Sigma1R/AKT/GSK3&#946;/CREB signaling pathway</article-title><source>Am J Drug Alcohol Abuse</source><year>2022</year><volume>48</volume><fpage>548</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">35881880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00952990.2022.2073450</pub-id></element-citation></ref><ref id="R407"><label>407.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name><name name-style="western"><surname>Vuong</surname><given-names>HE</given-names></name><name name-style="western"><surname>Nusbaum</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>EY</given-names></name><name name-style="western"><surname>Evans</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>AMW</given-names></name></person-group><article-title>The gut microbiota mediates reward and sensory responses associated with regimen-selective morphine dependence</article-title><source>Neuropsychopharmacology</source><year>2018</year><volume>43</volume><fpage>2606</fpage><lpage>2614</lpage><pub-id pub-id-type="pmid">30258112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41386-018-0211-9</pub-id><pub-id pub-id-type="pmcid">PMC6224506</pub-id></element-citation></ref><ref id="R408"><label>408.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S</given-names></name></person-group><article-title>Opioid modulation of the gut-brain axis in opioid-associated comorbidities</article-title><source>Cold Spring Harb Perspect Med</source><year>2021</year><volume>11</volume><fpage>a040485</fpage><pub-id pub-id-type="pmid">32816876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a040485</pub-id><pub-id pub-id-type="pmcid">PMC8415294</pub-id></element-citation></ref><ref id="R409"><label>409.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Cabrerizo</surname><given-names>R</given-names></name><name name-style="western"><surname>Carbia</surname><given-names>C</given-names></name><name name-style="western"><surname>KJ</surname><given-names>OR</given-names></name><name name-style="western"><surname>Schellekens</surname><given-names>H</given-names></name><name name-style="western"><surname>Cryan</surname><given-names>JF</given-names></name></person-group><article-title>Microbiota-gut-brain axis as a regulator of reward processes</article-title><source>J Neurochem</source><year>2021</year><volume>157</volume><fpage>1495</fpage><lpage>1524</lpage><pub-id pub-id-type="pmid">33368280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.15284</pub-id></element-citation></ref><ref id="R410"><label>410.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hodder</surname><given-names>SL</given-names></name><name name-style="western"><surname>Feinberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Strathdee</surname><given-names>SA</given-names></name><etal/></person-group><article-title>The opioid crisis and HIV in the USA: deadly synergies</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>1139</fpage><lpage>1150</lpage><pub-id pub-id-type="pmid">33617769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00391-3</pub-id></element-citation></ref><ref id="R411"><label>411.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Garner</surname><given-names>BR</given-names></name><name name-style="western"><surname>Gotham</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Knudsen</surname><given-names>HK</given-names></name><etal/></person-group><article-title>The prevalence and negative impacts of substance use disorders among people with HIV in the United States: a real-time Delphi survey of key stakeholders</article-title><source>AIDS Behav</source><year>2022</year><volume>26</volume><fpage>1183</fpage><lpage>1196</lpage><pub-id pub-id-type="pmid">34586532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10461-021-03473-9</pub-id><pub-id pub-id-type="pmcid">PMC8940836</pub-id></element-citation></ref><ref id="R412"><label>412.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Denis</surname><given-names>CM</given-names></name><name name-style="western"><surname>Dominique</surname><given-names>T</given-names></name><name name-style="western"><surname>Smith</surname><given-names>P</given-names></name><etal/></person-group><article-title>HIV infection and depression among opiate users in a US epicenter of the opioid epidemic</article-title><source>AIDS Behav</source><year>2021</year><volume>25</volume><fpage>2230</fpage><lpage>2239</lpage><pub-id pub-id-type="pmid">33449236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10461-020-03151-2</pub-id><pub-id pub-id-type="pmcid">PMC7809894</pub-id></element-citation></ref><ref id="R413"><label>413.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>A</given-names></name><name name-style="western"><surname>Barbaro</surname><given-names>J</given-names></name><name name-style="western"><surname>Mart&#237;nez-Aguado</surname><given-names>P</given-names></name><name name-style="western"><surname>Chilunda</surname><given-names>V</given-names></name><name name-style="western"><surname>Jaureguiberry-Bravo</surname><given-names>M</given-names></name><name name-style="western"><surname>Berman</surname><given-names>JW</given-names></name></person-group><article-title>The effects of opioids on HIV neuropathogenesis</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>2445</fpage><pub-id pub-id-type="pmid">31681322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.02445</pub-id><pub-id pub-id-type="pmcid">PMC6813247</pub-id></element-citation></ref><ref id="R414"><label>414.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Buch</surname><given-names>S</given-names></name><name name-style="western"><surname>Periyasamy</surname><given-names>P</given-names></name><name name-style="western"><surname>Thangaraj</surname><given-names>A</given-names></name><name name-style="western"><surname>Sil</surname><given-names>S</given-names></name><name name-style="western"><surname>Chivero</surname><given-names>ET</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>A</given-names></name></person-group><article-title>Opioid-mediated HIV-1 immunopathogenesis</article-title><source>J Neuroimmune Pharmacol</source><year>2020</year><volume>15</volume><fpage>628</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">33029670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11481-020-09960-5</pub-id><pub-id pub-id-type="pmcid">PMC7872067</pub-id></element-citation></ref><ref id="R415"><label>415.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Fitting</surname><given-names>S</given-names></name><name name-style="western"><surname>McRae</surname><given-names>M</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>KF</given-names></name></person-group><article-title>Opioid and neuroHIV comorbidity - current and future perspectives</article-title><source>J Neuroimmune Pharmacol</source><year>2020</year><volume>15</volume><fpage>584</fpage><lpage>627</lpage><pub-id pub-id-type="pmid">32876803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11481-020-09941-8</pub-id><pub-id pub-id-type="pmcid">PMC7463108</pub-id></element-citation></ref><ref id="R416"><label>416.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>MH</given-names></name><name name-style="western"><surname>Benning</surname><given-names>L</given-names></name><name name-style="western"><surname>Weber</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Predictors and consequences of prescription opioid use in women living with and without HIV: 20-year follow-up</article-title><source>J Womens Health (Larchmt)</source><year>2022</year><volume>31</volume><fpage>1188</fpage><lpage>1196</lpage><pub-id pub-id-type="pmid">35230165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/jwh.2021.0231</pub-id><pub-id pub-id-type="pmcid">PMC9419927</pub-id></element-citation></ref><ref id="R417"><label>417.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Goodkin</surname><given-names>K</given-names></name><name name-style="western"><surname>Evering</surname><given-names>TH</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>AM</given-names></name><etal/></person-group><article-title>The comorbidity of depression and neurocognitive disorder in persons with HIV infection: call for investigation and treatment</article-title><source>Front Cell Neurosci</source><year>2023</year><volume>17</volume><fpage>1130938</fpage><pub-id pub-id-type="pmid">37206666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2023.1130938</pub-id><pub-id pub-id-type="pmcid">PMC10190964</pub-id></element-citation></ref><ref id="R418"><label>418.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Maggirwar</surname><given-names>SB</given-names></name><name name-style="western"><surname>Tong</surname><given-names>N</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>S</given-names></name><name name-style="western"><surname>Gelbard</surname><given-names>HA</given-names></name><name name-style="western"><surname>Dewhurst</surname><given-names>S</given-names></name></person-group><article-title>HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity</article-title><source>J Neurochem</source><year>1999</year><volume>73</volume><fpage>578</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">10428053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1471-4159.1999.0730578.x</pub-id></element-citation></ref><ref id="R419"><label>419.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dou</surname><given-names>H</given-names></name><name name-style="western"><surname>Birusingh</surname><given-names>K</given-names></name><name name-style="western"><surname>Faraci</surname><given-names>J</given-names></name><etal/></person-group><article-title>Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis</article-title><source>J Neurosci</source><year>2003</year><volume>23</volume><fpage>9162</fpage><lpage>9170</lpage><pub-id pub-id-type="pmid">14534250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.23-27-09162.2003</pub-id><pub-id pub-id-type="pmcid">PMC6740824</pub-id></element-citation></ref><ref id="R420"><label>420.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dou</surname><given-names>H</given-names></name><name name-style="western"><surname>Ellison</surname><given-names>B</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>J</given-names></name><etal/></person-group><article-title>Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><fpage>8375</fpage><lpage>8385</lpage><pub-id pub-id-type="pmid">16162919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2164-05.2005</pub-id><pub-id pub-id-type="pmcid">PMC6725659</pub-id></element-citation></ref><ref id="R421"><label>421.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Everall</surname><given-names>IP</given-names></name><name name-style="western"><surname>Bell</surname><given-names>C</given-names></name><name name-style="western"><surname>Mallory</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lithium ameliorates HIV-gp120-mediated neurotoxicity</article-title><source>Mol Cell Neurosci</source><year>2002</year><volume>21</volume><fpage>493</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">12498789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/mcne.2002.1196</pub-id></element-citation></ref><ref id="R422"><label>422.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Sui</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sniderhan</surname><given-names>LF</given-names></name><name name-style="western"><surname>Fan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3beta to antagonize nuclear factor-kappaB survival pathway in neurons</article-title><source>Eur J Neurosci</source><year>2006</year><volume>23</volume><fpage>2623</fpage><lpage>2634</lpage><pub-id pub-id-type="pmid">16817865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1460-9568.2006.04813.x</pub-id></element-citation></ref><ref id="R423"><label>423.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Fitting</surname><given-names>S</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>PE</given-names></name><name name-style="western"><surname>Zou</surname><given-names>S</given-names></name><etal/></person-group><article-title>Interactive HIV-1 Tat and morphine-induced synaptodendritic injury is triggered through focal disruptions in Na&#8314; influx, mitochondrial instability, and Ca&#178;&#8314; overload</article-title><source>J Neurosci</source><year>2014</year><volume>34</volume><fpage>12850</fpage><lpage>12864</lpage><pub-id pub-id-type="pmid">25232120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5351-13.2014</pub-id><pub-id pub-id-type="pmcid">PMC4166164</pub-id></element-citation></ref><ref id="R424"><label>424.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Masvekar</surname><given-names>RR</given-names></name><name name-style="western"><surname>El-Hage</surname><given-names>N</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>KF</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>PE</given-names></name></person-group><article-title>Morphine enhances HIV-1SF162-mediated neuron death and delays recovery of injured neurites</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e100196</fpage><pub-id pub-id-type="pmid">24949623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0100196</pub-id><pub-id pub-id-type="pmcid">PMC4064991</pub-id></element-citation></ref><ref id="R425"><label>425.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>S</given-names></name><name name-style="western"><surname>Balinang</surname><given-names>JM</given-names></name><name name-style="western"><surname>Paris</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>KF</given-names></name><name name-style="western"><surname>Fuss</surname><given-names>B</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>PE</given-names></name></person-group><article-title>Effects of HIV-1 Tat on oligodendrocyte viability are mediated by CaMKII&#946;-GSK3&#946; interactions</article-title><source>J Neurochem</source><year>2019</year><volume>149</volume><fpage>98</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">30674062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.14668</pub-id><pub-id pub-id-type="pmcid">PMC6438763</pub-id></element-citation></ref><ref id="R426"><label>426.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><name name-style="western"><surname>Phan</surname><given-names>T</given-names></name><name name-style="western"><surname>Lin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Morphine exposure exacerbates HIV-1 Tat driven changes to neuroinflammatory factors in cultured astrocytes</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><fpage>e0230563</fpage><pub-id pub-id-type="pmid">32210470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0230563</pub-id><pub-id pub-id-type="pmcid">PMC7094849</pub-id></element-citation></ref><ref id="R427"><label>427.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Mediouni</surname><given-names>S</given-names></name><name name-style="western"><surname>Darque</surname><given-names>A</given-names></name><name name-style="western"><surname>Baillat</surname><given-names>G</given-names></name><etal/></person-group><article-title>Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein</article-title><source>Infect Disord Drug Targets</source><year>2012</year><volume>12</volume><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">22280310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/187152612798994939</pub-id></element-citation></ref><ref id="R428"><label>428.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>TP</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>13588</fpage><lpage>13593</lpage><pub-id pub-id-type="pmid">23898208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1308673110</pub-id><pub-id pub-id-type="pmcid">PMC3746932</pub-id></element-citation></ref><ref id="R429"><label>429.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Henderson</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>TP</given-names></name><name name-style="western"><surname>Smith</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Presence of Tat and transactivation response element in spinal fluid despite antiretroviral therapy</article-title><source>AIDS</source><year>2019</year><volume>33</volume><issue>Suppl 2</issue><fpage>S145</fpage><lpage>S157</lpage><pub-id pub-id-type="pmid">31789815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAD.0000000000002268</pub-id><pub-id pub-id-type="pmcid">PMC11032747</pub-id></element-citation></ref><ref id="R430"><label>430.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>ST</given-names></name><name name-style="western"><surname>Matsushita</surname><given-names>M</given-names></name><name name-style="western"><surname>Moriwaki</surname><given-names>A</given-names></name><etal/></person-group><article-title>HIV-1 Tat inhibits long-term potentiation and attenuates spatial learning [corrected]</article-title><source>Ann Neurol</source><year>2004</year><volume>55</volume><fpage>362</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">14991814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.10844</pub-id></element-citation></ref><ref id="R431"><label>431.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Carey</surname><given-names>AN</given-names></name><name name-style="western"><surname>Sypek</surname><given-names>EI</given-names></name><name name-style="western"><surname>Singh</surname><given-names>HD</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>MJ</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>JP</given-names></name></person-group><article-title>Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse</article-title><source>Behav Brain Res</source><year>2012</year><volume>229</volume><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">22197678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2011.12.019</pub-id><pub-id pub-id-type="pmcid">PMC3580389</pub-id></element-citation></ref><ref id="R432"><label>432.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Vitaliano</surname><given-names>GD</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JK</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Clathrin-nanoparticles deliver BDNF to hippocampus and enhance neurogenesis, synaptogenesis and cognition in HIV/neuroAIDS mouse model</article-title><source>Commun Biol</source><year>2022</year><volume>5</volume><fpage>236</fpage><pub-id pub-id-type="pmid">35301411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-022-03177-3</pub-id><pub-id pub-id-type="pmcid">PMC8931075</pub-id></element-citation></ref><ref id="R433"><label>433.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Fitting</surname><given-names>S</given-names></name><name name-style="western"><surname>Ignatowska-Jankowska</surname><given-names>BM</given-names></name><name name-style="western"><surname>Bull</surname><given-names>C</given-names></name><etal/></person-group><article-title>Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice</article-title><source>Biol Psychiatry</source><year>2013</year><volume>73</volume><fpage>443</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">23218253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2012.09.026</pub-id><pub-id pub-id-type="pmcid">PMC3570635</pub-id></element-citation></ref><ref id="R434"><label>434.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kesby</surname><given-names>JP</given-names></name><name name-style="western"><surname>Markou</surname><given-names>A</given-names></name><name name-style="western"><surname>Semenova</surname><given-names>S</given-names></name></person-group><article-title>The effects of HIV-1 regulatory TAT protein expression on brain reward function, response to psychostimulants and delay-dependent memory in mice</article-title><source>Neuropharmacology</source><year>2016</year><volume>109</volume><fpage>205</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">27316905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2016.06.011</pub-id><pub-id pub-id-type="pmcid">PMC4970920</pub-id></element-citation></ref><ref id="R435"><label>435.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Marks</surname><given-names>WD</given-names></name><name name-style="western"><surname>Paris</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Schier</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>HIV-1 Tat causes cognitive deficits and selective loss of parvalbumin, somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron subpopulations</article-title><source>J Neurovirol</source><year>2016</year><volume>22</volume><fpage>747</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">27178324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13365-016-0447-2</pub-id><pub-id pub-id-type="pmcid">PMC5107352</pub-id></element-citation></ref><ref id="R436"><label>436.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Marks</surname><given-names>WD</given-names></name><name name-style="western"><surname>Paris</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Barbour</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>HIV-1 tat and morphine differentially disrupt pyramidal cell structure and function and spatial learning in hippocampal area CA1: continuous versus interrupted morphine exposure</article-title><source>eNeuro</source><year>2021</year><volume>8</volume><comment>ENEURO.0547-20.2021</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/ENEURO.0547-20.2021</pub-id><pub-id pub-id-type="pmcid">PMC8146490</pub-id><pub-id pub-id-type="pmid">33782102</pub-id></element-citation></ref><ref id="R437"><label>437.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Paris</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Singh</surname><given-names>HD</given-names></name><name name-style="western"><surname>Ganno</surname><given-names>ML</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>P</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>JP</given-names></name></person-group><article-title>Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat</article-title><source>Psychopharmacology (Berl)</source><year>2014</year><volume>231</volume><fpage>2349</fpage><lpage>2360</lpage><pub-id pub-id-type="pmid">24352568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-013-3385-1</pub-id><pub-id pub-id-type="pmcid">PMC4020990</pub-id></element-citation></ref><ref id="R438"><label>438.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>McLaughlin</surname><given-names>JP</given-names></name><name name-style="western"><surname>Paris</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Mintzopoulos</surname><given-names>D</given-names></name><etal/></person-group><article-title>Conditional human immunodeficiency virus transactivator of transcription protein expression induces depression-like effects and oxidative stress</article-title><source>Biol Psychiatry Cogn Neurosci Neuroimaging</source><year>2017</year><volume>2</volume><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">29057370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bpsc.2017.04.002</pub-id><pub-id pub-id-type="pmcid">PMC5648358</pub-id></element-citation></ref><ref id="R439"><label>439.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Salahuddin</surname><given-names>MF</given-names></name><name name-style="western"><surname>Mahdi</surname><given-names>F</given-names></name><name name-style="western"><surname>Paris</surname><given-names>JJ</given-names></name></person-group><article-title>HIV-1 tat dysregulates the hypothalamic-pituitary-adrenal stress axis and potentiates oxycodone-mediated psychomotor and anxiety-like behavior of male mice</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>8212</fpage><pub-id pub-id-type="pmid">33153023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21218212</pub-id><pub-id pub-id-type="pmcid">PMC7662349</pub-id></element-citation></ref><ref id="R440"><label>440.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Salahuddin</surname><given-names>MF</given-names></name><name name-style="western"><surname>Qrareya</surname><given-names>AN</given-names></name><name name-style="western"><surname>Mahdi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Combined HIV-1 Tat and oxycodone activate the hypothalamic-pituitary-adrenal and -gonadal axes and promote psychomotor, affective, and cognitive dysfunction in female mice</article-title><source>Horm Behav</source><year>2020</year><volume>119</volume><fpage>104649</fpage><pub-id pub-id-type="pmid">31821792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yhbeh.2019.104649</pub-id><pub-id pub-id-type="pmcid">PMC7071558</pub-id></element-citation></ref><ref id="R441"><label>441.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Qrareya</surname><given-names>AN</given-names></name><name name-style="western"><surname>Mahdi</surname><given-names>F</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Ashpole</surname><given-names>NM</given-names></name><name name-style="western"><surname>Paris</surname><given-names>JJ</given-names></name></person-group><article-title>HIV-1 Tat promotes age-related cognitive, anxiety-like, and antinociceptive impairments in female mice that are moderated by aging and endocrine status</article-title><source>Geroscience</source><year>2021</year><volume>43</volume><fpage>309</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">32940828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11357-020-00268-z</pub-id><pub-id pub-id-type="pmcid">PMC8050151</pub-id></element-citation></ref><ref id="R442"><label>442.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wodarski</surname><given-names>R</given-names></name><name name-style="western"><surname>Bagdas</surname><given-names>D</given-names></name><name name-style="western"><surname>Paris</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Reduced intraepidermal nerve fibre density, glial activation, and sensory changes in HIV type-1 Tat-expressing female mice: involvement of Tat during early stages of HIV-associated painful sensory neuropathy</article-title><source>Pain Rep</source><year>2018</year><volume>3</volume><fpage>e654</fpage><pub-id pub-id-type="pmid">29922746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PR9.0000000000000654</pub-id><pub-id pub-id-type="pmcid">PMC5999412</pub-id></element-citation></ref><ref id="R443"><label>443.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bagdas</surname><given-names>D</given-names></name><name name-style="western"><surname>Paris</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Carper</surname><given-names>M</given-names></name><etal/></person-group><article-title>Conditional expression of HIV-1 tat in the mouse alters the onset and progression of tonic, inflammatory and neuropathic hypersensitivity in a sex-dependent manner</article-title><source>Eur J Pain</source><year>2020</year><volume>24</volume><fpage>1609</fpage><lpage>1623</lpage><pub-id pub-id-type="pmid">32533878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ejp.1618</pub-id><pub-id pub-id-type="pmcid">PMC7856573</pub-id></element-citation></ref><ref id="R444"><label>444.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Cirino</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Alleyne</surname><given-names>AR</given-names></name><name name-style="western"><surname>Duarte</surname><given-names>V</given-names></name><etal/></person-group><article-title>Expression of human immunodeficiency virus transactivator of transcription (HIV-Tat(1-86)) protein alters nociceptive processing that is sensitive to anti-oxidant and anti-inflammatory interventions</article-title><source>J Neuroimmune Pharmacol</source><year>2022</year><volume>17</volume><fpage>152</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">33619645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11481-021-09985-4</pub-id><pub-id pub-id-type="pmcid">PMC8380260</pub-id></element-citation></ref><ref id="R445"><label>445.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Fitting</surname><given-names>S</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>DL</given-names></name><name name-style="western"><surname>Khan</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Morphine tolerance and physical dependence are altered in conditional HIV-1 tat transgenic mice</article-title><source>J Pharmacol Exp Ther</source><year>2016</year><volume>356</volume><fpage>96</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">26542403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.115.226407</pub-id><pub-id pub-id-type="pmcid">PMC4702077</pub-id></element-citation></ref><ref id="R446"><label>446.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hermes</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>IR</given-names></name><name name-style="western"><surname>Key</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Escalating morphine dosing in HIV-1 Tat transgenic mice with sustained Tat exposure reveals an allostatic shift in neuroinflammatory regulation accompanied by increased neuroprotective non-endocannabinoid lipid signaling molecules and amino acids</article-title><source>J Neuroinflammation</source><year>2020</year><volume>17</volume><fpage>345</fpage><pub-id pub-id-type="pmid">33208151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-020-01971-6</pub-id><pub-id pub-id-type="pmcid">PMC7672881</pub-id></element-citation></ref><ref id="R447"><label>447.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Paris</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Carey</surname><given-names>AN</given-names></name><name name-style="western"><surname>Shay</surname><given-names>CF</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>SM</given-names></name><name name-style="western"><surname>He</surname><given-names>JJ</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>JP</given-names></name></person-group><article-title>Effects of conditional central expression of HIV-1 tat protein to potentiate cocaine-mediated psychostimulation and reward among male mice</article-title><source>Neuropsychopharmacology</source><year>2014</year><volume>39</volume><fpage>380</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">23945478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npp.2013.201</pub-id><pub-id pub-id-type="pmcid">PMC3870789</pub-id></element-citation></ref><ref id="R448"><label>448.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Mediouni</surname><given-names>S</given-names></name><name name-style="western"><surname>Jablonski</surname><given-names>J</given-names></name><name name-style="western"><surname>Paris</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Didehydro-cortistatin A inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in Tat transgenic mice</article-title><source>Curr HIV Res</source><year>2015</year><volume>13</volume><fpage>64</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">25613133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1570162x13666150121111548</pub-id><pub-id pub-id-type="pmcid">PMC4416414</pub-id></element-citation></ref><ref id="R449"><label>449.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Schier</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Marks</surname><given-names>WD</given-names></name><name name-style="western"><surname>Paris</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Selective vulnerability of striatal D2 versus D1 dopamine receptor-expressing medium spiny neurons in HIV-1 tat transgenic male mice</article-title><source>J Neurosci</source><year>2017</year><volume>37</volume><fpage>5758</fpage><lpage>5769</lpage><pub-id pub-id-type="pmid">28473642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0622-17.2017</pub-id><pub-id pub-id-type="pmcid">PMC5469310</pub-id></element-citation></ref><ref id="R450"><label>450.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Strauss</surname><given-names>M</given-names></name><name name-style="western"><surname>O&#8217;Donovan</surname><given-names>B</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><etal/></person-group><article-title>[(3)H]Dopamine uptake through the dopamine and norepinephrine transporters is decreased in the prefrontal cortex of transgenic mice expressing HIV-1 transactivator of transcription protein</article-title><source>J Pharmacol Exp Ther</source><year>2020</year><volume>374</volume><fpage>241</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">32461322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.120.266023</pub-id><pub-id pub-id-type="pmcid">PMC7366287</pub-id></element-citation></ref><ref id="R451"><label>451.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>McLaughlin</surname><given-names>JP</given-names></name><name name-style="western"><surname>Ganno</surname><given-names>ML</given-names></name><name name-style="western"><surname>Eans</surname><given-names>SO</given-names></name><name name-style="western"><surname>Mizrachi</surname><given-names>E</given-names></name><name name-style="western"><surname>Paris</surname><given-names>JJ</given-names></name></person-group><article-title>HIV-1 Tat protein exposure potentiates ethanol reward and reinstates extinguished ethanol-conditioned place preference</article-title><source>Curr HIV Res</source><year>2014</year><volume>12</volume><fpage>415</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">25760047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1570162x1206150311160133</pub-id></element-citation></ref><ref id="R452"><label>452.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dewhurst</surname><given-names>S</given-names></name><name name-style="western"><surname>Maggirwar</surname><given-names>SB</given-names></name><name name-style="western"><surname>Schifitto</surname><given-names>G</given-names></name><name name-style="western"><surname>Gendelman</surname><given-names>HE</given-names></name><name name-style="western"><surname>Gelbard</surname><given-names>HA</given-names></name></person-group><article-title>Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS</article-title><source>J Neuroimmune Pharmacol</source><year>2007</year><volume>2</volume><fpage>93</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">18040831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11481-006-9051-1</pub-id></element-citation></ref><ref id="R453"><label>453.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kehn-Hall</surname><given-names>K</given-names></name><name name-style="western"><surname>Guendel</surname><given-names>I</given-names></name><name name-style="western"><surname>Carpio</surname><given-names>L</given-names></name><etal/></person-group><article-title>Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors</article-title><source>Virology</source><year>2011</year><volume>415</volume><fpage>56</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">21514616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2011.03.025</pub-id><pub-id pub-id-type="pmcid">PMC3677548</pub-id></element-citation></ref><ref id="R454"><label>454.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>H&#246;hne</surname><given-names>K</given-names></name><name name-style="western"><surname>Businger</surname><given-names>R</given-names></name><name name-style="western"><surname>van Nuffel</surname><given-names>A</given-names></name><etal/></person-group><article-title>Virion encapsidated HIV-1 Vpr induces NFAT to prime non-activated T cells for productive infection</article-title><source>Open Biol</source><year>2016</year><volume>6</volume><fpage>160046</fpage><pub-id pub-id-type="pmid">27383627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rsob.160046</pub-id><pub-id pub-id-type="pmcid">PMC4967821</pub-id></element-citation></ref><ref id="R455"><label>455.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Gramatica</surname><given-names>A</given-names></name><name name-style="western"><surname>Schwarzer</surname><given-names>R</given-names></name><name name-style="western"><surname>Brantley</surname><given-names>W</given-names></name><etal/></person-group><article-title>Evaluating a new class of akt/mtor activators for hiv latency reversing activity ex vivo and in vivo</article-title><source>J Virol</source><year>2021</year><volume>95</volume><fpage>e02393</fpage><lpage>02320</lpage><pub-id pub-id-type="pmid">33536176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02393-20</pub-id><pub-id pub-id-type="pmcid">PMC8103695</pub-id></element-citation></ref><ref id="R456"><label>456.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Barbian</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Seaton</surname><given-names>MS</given-names></name><name name-style="western"><surname>Narasipura</surname><given-names>SD</given-names></name><etal/></person-group><article-title>&#946;-Catenin regulates HIV latency and modulates HIV reactivation</article-title><source>PLoS Pathog</source><year>2022</year><volume>18</volume><fpage>e1010354</fpage><pub-id pub-id-type="pmid">35255110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1010354</pub-id><pub-id pub-id-type="pmcid">PMC8939789</pub-id></element-citation></ref><ref id="R457"><label>457.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>QX</given-names></name><etal/></person-group><article-title>Pharmacological suppression of glycogen synthase kinase-3 reactivates HIV-1 from latency via activating Wnt/&#946;-catenin/TCF1 axis in CD4(+) T cells</article-title><source>Emerg Microbes Infect</source><year>2022</year><volume>11</volume><fpage>391</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">34985411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/22221751.2022.2026198</pub-id><pub-id pub-id-type="pmcid">PMC8812804</pub-id></element-citation></ref><ref id="R458"><label>458.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Armani-Tourret</surname><given-names>M</given-names></name><name name-style="western"><surname>Bone</surname><given-names>B</given-names></name><name name-style="western"><surname>Tan</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure</article-title><source>Nat Rev Microbiol</source><year>2024</year><volume>22</volume><fpage>328</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">38337034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-024-01010-8</pub-id><pub-id pub-id-type="pmcid">PMC11131351</pub-id></element-citation></ref><ref id="R459"><label>459.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>McCubrey</surname><given-names>JA</given-names></name><name name-style="western"><surname>Steelman</surname><given-names>LS</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>FE</given-names></name><etal/></person-group><article-title>GSK-3 as potential target for therapeutic intervention in cancer</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>2881</fpage><lpage>2911</lpage><pub-id pub-id-type="pmid">24931005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.2037</pub-id><pub-id pub-id-type="pmcid">PMC4102778</pub-id></element-citation></ref><ref id="R460"><label>460.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>McConnell</surname><given-names>DD</given-names></name><name name-style="western"><surname>Carr</surname><given-names>SB</given-names></name><name name-style="western"><surname>Litofsky</surname><given-names>NS</given-names></name></person-group><article-title>Potential effects of nicotine on glioblastoma and chemoradiotherapy: a review</article-title><source>Expert Rev Neurother</source><year>2019</year><volume>19</volume><fpage>545</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">31092064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14737175.2019.1617701</pub-id></element-citation></ref><ref id="R461"><label>461.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Pucci</surname><given-names>S</given-names></name><name name-style="western"><surname>Fasoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Choline and nicotine increase glioblastoma cell proliferation by binding and activating &#945;7- and &#945;9- containing nicotinic receptors</article-title><source>Pharmacol Res</source><year>2021</year><volume>163</volume><fpage>105336</fpage><pub-id pub-id-type="pmid">33276105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2020.105336</pub-id></element-citation></ref><ref id="R462"><label>462.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Gallo</surname><given-names>S</given-names></name><name name-style="western"><surname>Vitacolonna</surname><given-names>A</given-names></name><name name-style="western"><surname>Crepaldi</surname><given-names>T</given-names></name></person-group><article-title>NMDA receptor and its emerging role in cancer</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><fpage>2540</fpage><pub-id pub-id-type="pmid">36768862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24032540</pub-id><pub-id pub-id-type="pmcid">PMC9917092</pub-id></element-citation></ref><ref id="R463"><label>463.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Evangelisti</surname><given-names>C</given-names></name><name name-style="western"><surname>Chiarini</surname><given-names>F</given-names></name><name name-style="western"><surname>Paganelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Marmiroli</surname><given-names>S</given-names></name><name name-style="western"><surname>Martelli</surname><given-names>AM</given-names></name></person-group><article-title>Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer</article-title><source>Biochim Biophys Acta Mol Cell Res</source><year>2020</year><volume>1867</volume><fpage>118635</fpage><pub-id pub-id-type="pmid">31884070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbamcr.2019.118635</pub-id></element-citation></ref><ref id="R464"><label>464.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>BM</given-names></name><name name-style="western"><surname>Cloughesy</surname><given-names>TF</given-names></name></person-group><article-title>Adult glioblastoma</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><fpage>2402</fpage><lpage>2409</lpage><pub-id pub-id-type="pmid">28640706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2017.73.0119</pub-id></element-citation></ref><ref id="R465"><label>465.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>AC</given-names></name><name name-style="western"><surname>Ashley</surname><given-names>DM</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>GY</given-names></name><name name-style="western"><surname>Malinzak</surname><given-names>M</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>HS</given-names></name><name name-style="western"><surname>Khasraw</surname><given-names>M</given-names></name></person-group><article-title>Management of glioblastoma: state of the art and future directions</article-title><source>CA Cancer J Clin</source><year>2020</year><volume>70</volume><fpage>299</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">32478924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21613</pub-id></element-citation></ref><ref id="R466"><label>466.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Takano</surname><given-names>T</given-names></name><name name-style="western"><surname>Lin</surname><given-names>JH</given-names></name><name name-style="western"><surname>Arcuino</surname><given-names>G</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>M</given-names></name></person-group><article-title>Glutamate release promotes growth of malignant gliomas</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><fpage>1010</fpage><lpage>1015</lpage><pub-id pub-id-type="pmid">11533703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm0901-1010</pub-id></element-citation></ref><ref id="R467"><label>467.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Venkataramani</surname><given-names>V</given-names></name><name name-style="western"><surname>Tanev</surname><given-names>DI</given-names></name><name name-style="western"><surname>Strahle</surname><given-names>C</given-names></name><etal/></person-group><article-title>Glutamatergic synaptic input to glioma cells drives brain tumour progression</article-title><source>Nature</source><year>2019</year><volume>573</volume><fpage>532</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">31534219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1564-x</pub-id></element-citation></ref><ref id="R468"><label>468.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>ZC</given-names></name><name name-style="western"><surname>Sontheimer</surname><given-names>H</given-names></name></person-group><article-title>Glioma cells release excitotoxic concentrations of glutamate</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>4383</fpage><lpage>4391</lpage><pub-id pub-id-type="pmid">10485487</pub-id></element-citation></ref><ref id="R469"><label>469.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller-L&#228;ngle</surname><given-names>A</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>H</given-names></name><name name-style="western"><surname>Hehlgans</surname><given-names>S</given-names></name><name name-style="western"><surname>R&#246;del</surname><given-names>F</given-names></name><name name-style="western"><surname>Rau</surname><given-names>K</given-names></name><name name-style="western"><surname>Laube</surname><given-names>B</given-names></name></person-group><article-title>NMDA receptor-mediated signaling pathways enhance radiation resistance, survival and migration in glioblastoma cells-a potential target for adjuvant radiotherapy</article-title><source>Cancers (Basel)</source><year>2019</year><volume>11</volume><fpage>503</fpage><pub-id pub-id-type="pmid">30970642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11040503</pub-id><pub-id pub-id-type="pmcid">PMC6520759</pub-id></element-citation></ref><ref id="R470"><label>470.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>B&#252;ttner</surname><given-names>T</given-names></name><name name-style="western"><surname>Maerevoet</surname><given-names>MKE</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>FA</given-names></name><name name-style="western"><surname>Veldwijk</surname><given-names>MR</given-names></name><name name-style="western"><surname>Herskind</surname><given-names>C</given-names></name><name name-style="western"><surname>Ruder</surname><given-names>AM</given-names></name></person-group><article-title>Combining a noble gas with radiotherapy: glutamate receptor antagonist xenon may act as a radiosensitizer in glioblastoma</article-title><source>Radiat Oncol</source><year>2024</year><volume>19</volume><fpage>16</fpage><pub-id pub-id-type="pmid">38291439</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13014-023-02395-1</pub-id><pub-id pub-id-type="pmcid">PMC10826195</pub-id></element-citation></ref><ref id="R471"><label>471.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Miyashita</surname><given-names>K</given-names></name><name name-style="western"><surname>Kawakami</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakada</surname><given-names>M</given-names></name><etal/></person-group><article-title>Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>887</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">19188159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-08-0760</pub-id></element-citation></ref><ref id="R472"><label>472.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kitabayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Furuta</surname><given-names>T</given-names></name><etal/></person-group><article-title>Identification of GSK3&#946; inhibitor kenpaullone as a temozolomide enhancer against glioblastoma</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><fpage>10049</fpage><pub-id pub-id-type="pmid">31296906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-46454-8</pub-id><pub-id pub-id-type="pmcid">PMC6624278</pub-id></element-citation></ref><ref id="R473"><label>473.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bou-Gharios</surname><given-names>J</given-names></name><name name-style="western"><surname>Assi</surname><given-names>S</given-names></name><name name-style="western"><surname>Bahmad</surname><given-names>HF</given-names></name><etal/></person-group><article-title>The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells</article-title><source>Pharmacol Rep</source><year>2021</year><volume>73</volume><fpage>227</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">33140310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s43440-020-00180-5</pub-id></element-citation></ref><ref id="R474"><label>474.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Aguilar-Morante</surname><given-names>D</given-names></name><name name-style="western"><surname>Morales-Garcia</surname><given-names>JA</given-names></name><name name-style="western"><surname>Sanz-SanCristobal</surname><given-names>M</given-names></name><name name-style="western"><surname>Garcia-Cabezas</surname><given-names>MA</given-names></name><name name-style="western"><surname>Santos</surname><given-names>A</given-names></name><name name-style="western"><surname>Perez-Castillo</surname><given-names>A</given-names></name></person-group><article-title>Inhibition of glioblastoma growth by the thiadiazolidinone compound TDZD-8</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e13879</fpage><pub-id pub-id-type="pmid">21079728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0013879</pub-id><pub-id pub-id-type="pmcid">PMC2975629</pub-id></element-citation></ref><ref id="R475"><label>475.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q</given-names></name></person-group><article-title>Glycogen synthase kinase-3: a potential immunotherapeutic target in tumor microenvironment</article-title><source>Biomed Pharmacother</source><year>2024</year><volume>173</volume><fpage>116377</fpage><pub-id pub-id-type="pmid">38442671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2024.116377</pub-id></element-citation></ref><ref id="R476"><label>476.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Petzelt</surname><given-names>C</given-names></name><name name-style="western"><surname>Taschenberger</surname><given-names>G</given-names></name><name name-style="western"><surname>Schmehl</surname><given-names>W</given-names></name><name name-style="western"><surname>Hafner</surname><given-names>M</given-names></name><name name-style="western"><surname>Kox</surname><given-names>WJ</given-names></name></person-group><article-title>Xenon induces metaphase arrest in rat astrocytes</article-title><source>Life Sci</source><year>1999</year><volume>65</volume><fpage>901</fpage><lpage>913</lpage><pub-id pub-id-type="pmid">10465350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0024-3205(99)00320-3</pub-id></element-citation></ref><ref id="R477"><label>477.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Cornago</surname><given-names>M</given-names></name><name name-style="western"><surname>Garcia-Alberich</surname><given-names>C</given-names></name><name name-style="western"><surname>Blasco-Angulo</surname><given-names>N</given-names></name><etal/></person-group><article-title>Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe</article-title><source>Cell Death Dis</source><year>2014</year><volume>5</volume><fpage>e1435</fpage><pub-id pub-id-type="pmid">25275596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cddis.2014.412</pub-id><pub-id pub-id-type="pmcid">PMC4237242</pub-id></element-citation></ref><ref id="R478"><label>478.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Gousias</surname><given-names>K</given-names></name><name name-style="western"><surname>Theocharous</surname><given-names>T</given-names></name><name name-style="western"><surname>Simon</surname><given-names>M</given-names></name></person-group><article-title>Mechanisms of cell cycle arrest and apoptosis in glioblastoma</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><fpage>564</fpage><pub-id pub-id-type="pmid">35327366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines10030564</pub-id><pub-id pub-id-type="pmcid">PMC8945784</pub-id></element-citation></ref><ref id="R479"><label>479.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Chronic stress accelerates glioblastoma progression via DRD2/ERK/&#946;-catenin axis and Dopamine/ERK/TH positive feedback loop</article-title><source>J Exp Clin Cancer Res</source><year>2023</year><volume>42</volume><fpage>161</fpage><pub-id pub-id-type="pmid">37415171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-023-02728-8</pub-id><pub-id pub-id-type="pmcid">PMC10327168</pub-id></element-citation></ref><ref id="R480"><label>480.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>L</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name><name name-style="western"><surname>She</surname><given-names>X</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name></person-group><article-title>Chronic stress as an emerging risk factor for the development and progression of glioma</article-title><source>Chin Med J (Engl)</source><year>2024</year><volume>137</volume><fpage>394</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">38238191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000002976</pub-id><pub-id pub-id-type="pmcid">PMC10876262</pub-id></element-citation></ref><ref id="R481"><label>481.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yonas</surname><given-names>H</given-names></name><name name-style="western"><surname>Grundy</surname><given-names>B</given-names></name><name name-style="western"><surname>Gur</surname><given-names>D</given-names></name><name name-style="western"><surname>Shabason</surname><given-names>L</given-names></name><name name-style="western"><surname>Wolfson</surname><given-names>SK</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Cook</surname><given-names>EE</given-names></name></person-group><article-title>Side effects of xenon inhalation</article-title><source>J Comput Assist Tomogr</source><year>1981</year><volume>5</volume><fpage>591</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">7264006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00004728-198108000-00029</pub-id></element-citation></ref><ref id="R482"><label>482.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bedi</surname><given-names>A</given-names></name><name name-style="western"><surname>McCarroll</surname><given-names>C</given-names></name><name name-style="western"><surname>Murray</surname><given-names>JM</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>MA</given-names></name><name name-style="western"><surname>Fee</surname><given-names>JP</given-names></name></person-group><article-title>The effects of subanaesthetic concentrations of xenon in volunteers</article-title><source>Anaesthesia</source><year>2002</year><volume>57</volume><fpage>233</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">11879212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.0003-2409.2001.02455.x</pub-id></element-citation></ref><ref id="R483"><label>483.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Beardsley</surname><given-names>PM</given-names></name><name name-style="western"><surname>Ratti</surname><given-names>E</given-names></name><name name-style="western"><surname>Balster</surname><given-names>RL</given-names></name><name name-style="western"><surname>Willetts</surname><given-names>J</given-names></name><name name-style="western"><surname>Trist</surname><given-names>D</given-names></name></person-group><article-title>The selective glycine antagonist gavestinel lacks phencyclidine-like behavioral effects</article-title><source>Behav Pharmacol</source><year>2002</year><volume>13</volume><fpage>583</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">12409996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00008877-200211000-00007</pub-id></element-citation></ref><ref id="R484"><label>484.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Nicholson</surname><given-names>KL</given-names></name><name name-style="western"><surname>Balster</surname><given-names>RL</given-names></name></person-group><article-title>The discriminative stimulus effects of N-methyl-D-aspartate glycine-site ligands in NMDA antagonist-trained rats</article-title><source>Psychopharmacology (Berl)</source><year>2009</year><volume>203</volume><fpage>441</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">19183964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-009-1469-8</pub-id><pub-id pub-id-type="pmcid">PMC2836855</pub-id></element-citation></ref><ref id="R485"><label>485.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Saitz</surname><given-names>R</given-names></name></person-group><article-title>Introduction to alcohol withdrawal</article-title><source>Alcohol Health Res World</source><year>1998</year><volume>22</volume><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">15706727</pub-id><pub-id pub-id-type="pmcid">PMC6761824</pub-id></element-citation></ref><ref id="R486"><label>486.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>Zong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Elsaidi</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Kr/Xe separation over a chabazite zeolite membrane</article-title><source>J Am Chem Soc</source><year>2016</year><volume>138</volume><fpage>9791</fpage><lpage>9794</lpage><pub-id pub-id-type="pmid">27464226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.6b06515</pub-id></element-citation></ref><ref id="R487"><label>487.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Neice</surname><given-names>AE</given-names></name><name name-style="western"><surname>Zornow</surname><given-names>MH</given-names></name></person-group><article-title>Xenon anesthesia for all, or only a select few?</article-title><source>Anaesthesia</source><year>2016</year><volume>71</volume><fpage>1267</fpage><lpage>1272</lpage><pub-id pub-id-type="pmid">27530275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/anae.13569</pub-id></element-citation></ref><ref id="R488"><label>488.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yao</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The first example of commensurate adsorption of atomic gas in a MOF and effective separation of xenon from other noble gases</article-title><source>Chem Sci</source><year>2014</year><volume>5</volume><fpage>620</fpage><lpage>624</lpage></element-citation></ref><ref id="R489"><label>489.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Reiss</surname><given-names>PS</given-names></name><name name-style="western"><surname>Chong</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Separation of rare gases and chiral molecules by selective binding in porous organic cages</article-title><source>Nat Mater</source><year>2014</year><volume>13</volume><fpage>954</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">25038731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmat4035</pub-id></element-citation></ref><ref id="R490"><label>490.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Adil</surname><given-names>K</given-names></name><name name-style="western"><surname>Belmabkhout</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pillai</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Gas/vapour separation using ultra-microporous metal-organic frameworks: insights into the structure/separation relationship</article-title><source>Chem Soc Rev</source><year>2017</year><volume>46</volume><fpage>3402</fpage><lpage>3430</lpage><pub-id pub-id-type="pmid">28555216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c7cs00153c</pub-id></element-citation></ref><ref id="R491"><label>491.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Xenon recovery by DD3R zeolite membranes: application in anaesthetics</article-title><source>Angew Chem Int Ed Engl</source><year>2019</year><volume>58</volume><fpage>15518</fpage><lpage>15525</lpage><pub-id pub-id-type="pmid">31452313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201909544</pub-id></element-citation></ref><ref id="R492"><label>492.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X</given-names></name><name name-style="western"><surname>Deng</surname><given-names>C</given-names></name><etal/></person-group><article-title>Exhaled anesthetic xenon regeneration by gas separation using a metal-organic framework with sorbent-sorbate induced-fit</article-title><source>Angew Chem Int Ed Engl</source><year>2024</year><volume>63</volume><fpage>e202407840</fpage><pub-id pub-id-type="pmid">38953248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202407840</pub-id></element-citation></ref><ref id="R493"><label>493.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>HN</given-names></name><name name-style="western"><surname>Haelewyn</surname><given-names>B</given-names></name><name name-style="western"><surname>Rouillon</surname><given-names>C</given-names></name><etal/></person-group><article-title>Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia</article-title><source>FASEB J</source><year>2008</year><volume>22</volume><fpage>1275</fpage><lpage>1286</lpage><pub-id pub-id-type="pmid">18024836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.07-9420com</pub-id></element-citation></ref><ref id="R494"><label>494.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Britton</surname><given-names>GL</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Kee</surname><given-names>PH</given-names></name><etal/></person-group><article-title>In vivo therapeutic gas delivery for neuroprotection with echogenic liposomes</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>1578</fpage><lpage>1587</lpage><pub-id pub-id-type="pmid">20921443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.109.879338</pub-id><pub-id pub-id-type="pmcid">PMC2981142</pub-id></element-citation></ref><ref id="R495"><label>495.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>YF</given-names></name><name name-style="western"><surname>Peng</surname><given-names>T</given-names></name><name name-style="western"><surname>Moody</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Delivery of xenon-containing echogenic liposomes inhibits early brain injury following subarachnoid hemorrhage</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><fpage>450</fpage><pub-id pub-id-type="pmid">29323183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-18914-6</pub-id><pub-id pub-id-type="pmcid">PMC5765033</pub-id></element-citation></ref><ref id="R496"><label>496.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>JL</given-names></name><name name-style="western"><surname>Mateus</surname><given-names>CF</given-names></name><name name-style="western"><surname>Malcolm</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Brady</surname><given-names>KT</given-names></name><name name-style="western"><surname>Back</surname><given-names>SE</given-names></name></person-group><article-title>Efficacy of ketamine in the treatment of substance use disorders: a systematic review</article-title><source>Front Psychiatry</source><year>2018</year><volume>9</volume><fpage>277</fpage><pub-id pub-id-type="pmid">30140240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2018.00277</pub-id><pub-id pub-id-type="pmcid">PMC6094990</pub-id></element-citation></ref><ref id="R497"><label>497.</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kelson</surname><given-names>M</given-names></name><name name-style="western"><surname>Burnett</surname><given-names>JM</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>A</given-names></name><name name-style="western"><surname>Juneja</surname><given-names>T</given-names></name></person-group><article-title>Ketamine treatment for alcohol use disorder: a systematic review</article-title><source>Cureus</source><year>2023</year><volume>15</volume><fpage>e38498</fpage><pub-id pub-id-type="pmid">37273364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.38498</pub-id><pub-id pub-id-type="pmcid">PMC10237681</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>